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ABSTRACT 
 
 
In the past several decades, advances in our understanding of cells that comprise 
our bodies have been remarkable. This is due in large part to the development of 
mammalian cell culture practices that allow researchers to mimic conditions in the body. 
Cell culture techniques have allowed researchers to study the behavior of cells under 
various circumstances that would be impossible to study in humans. While there are some 
drawbacks to the reductionism inherent in studying cells in a dish, many medical 
treatments have resulted from cell culture experiments. Additionally, many new 
therapeutics are only possible due to these improved cell culture techniques.   
To that end, this research has encompassed the full spectrum of cell culture 
techniques and applications. For example, DNA microarrays can be used to study 
glycosylation gene expression in mammalian cells, where glycosylation is an important 
quality attribute of recombinant human therapeutic proteins. Specifically, a method is 
described to conduct glycosylation experiments. Next, research is described where DNA 
microarrays were used to investigate the response to elevated ammonium levels for a 
mammalian cell line often used to produce human therapeutics, because it has been show 
that elevated ammonium decreases product quality for these recombinant therapeutics. 
So, understanding if gene expression controlled the response was important. It was 
determined, through DNA microarray and PCR analysis, that glycosylation genes in these 
cells are unaffected by the elevated ammonium levels commonly experienced in end-
stage cultures. Therefore, it was concluded that the effects of ammonium on protein 
quality appear to be due to translational or substrate-level effects.  
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 This research transitioned from analyzing the behavior of NS0 cell cultures to 
analyzing the behavior of stem cell cultures. For NS0 cells, the recombinant proteins are 
the product of interest. For stem cells, the products are the actual cells, which are 
anticipated to serve as starting material for future cell-based regenerative therapies. For 
NS0 cells, the goal is to produce high quality protein products. For stem cells, the goal is 
to produce robust multipotent stem cells. To that end, we developed a novel method for 
buffering the pH of mesenchymal stem cell (MSCs) cultures, such that it might be easier 
to culture the MSCs in large volumes without requiring carbon dioxide sparging. 
Through the use of PCR and histological staining, it was demonstrated that MSCs were 
capable of growth in the absence of an elevated CO2 environment and differentiation into 
adipogenic, chondrogenic, and osteogenic lineages. These results provide a route for 
simplifying bioreactor control and paving the way for efficient, large-scale generation of 
high-quality multipotent stem cells.  
Just as elevated ammonium affects the protein quality for NS0 cells and pH 
governs the behavior of stem cells, metabolites within tumors affect the behavior of 
cancer cells. One such metabolite – lactate – accumulates in tumors and adversely affects 
patient outcomes. Interestingly, lactate accumulation is also a major challenge in 
therapeutic protein production and cell-based therapy cell production. Thus, gaining a 
better understanding of elevated extracellular lactate’s effects on the metabolic behavior 
of breast cancer cells was examined. Three breast cancer cell lines were used. A 
comprehensive technique called 13C-metabolic flux analysis (MFA) was used to estimate 
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intracellular fluxes. All three cell lines has decreased glucose consumption and decreased 
lactate production under the elevated lactate compared to the control condition. Under the 
elevated lactate conditions, all three cell lines also consumed lactate, an effect seen in 
stage late cultures of cells used for recombinant protein production, which might 
represent a general cellular mechanism used by a variety of cell lines to deal with 
extracellular lactate accumulation. At the same time, all three cell lines increased 
reductive carboxylation in the TCA cycle under elevated lactate compared to control, and 
this effect has also been observed in cells – both normal and cancerous - under hypoxia. 
These results suggest a previously unreported link between hypoxia and lactate, which 
demands further investigation. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Motivation 
Cell culture technology provides an indispensible tool for advancements in the 
biomedical and bioengineering fields. Performing studies on cells outside of the complex 
environment in the human body allows researchers to derive insights into cell biology 
and disease progression that might otherwise be hard to uncover. Additionally, we can 
harness the unique attributes of mammalian cells to create complex therapeutics and 
hopefully improved cell-based therapies. Ultimately, cell culture experiments allow 
researchers to simplify the situation, so that links between environmental factors and cell 
behavior can be more clearly discerned. As the scientific and medical communities gather 
more knowledge about the causes and effects of phenomena surrounding us, this 
knowledge can be used to develop solutions to the problems that we face. Above all, the 
motivation for all of my projects – from NS0 cells to stem cells to cancer – stemmed 
from the basic desire to contribute to this enterprise: to expand scientific knowledge in 
order to improve patients’ lives.  
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1.2 Organization 
This dissertation contains six chapters. Chapter 1 outlines and explains the motivation 
for this research. Chapter 2 is a published methods paper that describes DNA microarray 
technology and its application in studying mammalian cell gene expression. My co-
authors were Mary Caldwell and Dr. Sarah W. Harcum (Brodsky et al., 2012). Chapter 3 
is a published research paper, which follows thematically from the methods paper and 
describes the application of this method to NS0 cells and how elevated ammonium levels 
affects the expression of key glycosylation genes. My co-authors were Mary Caldwell, 
Sooneon Bae, and Dr. Sarah W. Harcum (Brodsky et al., 2014). Chapter 4 is a published 
research paper that describes a novel method to expand mesenchymal stem cells (MSCs) 
in atmospheric carbon dioxide. My co-authors were Dr. Jing Zhang, Dr. Richard P. 
Visconti, and Dr. Sarah W. Harcum (Brodsky et al., 2013). Chapter 5 describes ongoing 
research that examines the effects of high extracellular lactate on the metabolism of three 
different breast cancer cell lines using 13C-metabolic flux analysis (MFA). My co-
investigators are Daniel Odenwelder and Dr. Sarah W. Harcum. Chapter 6 describes 
future work, mostly related to the 13C-MFA studies. 
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CHAPTER TWO: GLYCOSYLATION AND POST-TRANSLATIONAL 
MODIFICATION GENE EXPRESSION ANALYSIS BY DNA MICROARRAYS  
FOR CULTURED MAMMALIAN CELLS 
 
2.1 Abstract 
DNA microarray analysis of gene expression has become a valuable tool for 
bioprocessing research aimed at improving therapeutic protein yields. The highly parallel 
nature of DNA microarray technology allows researchers to assess hundreds of gene 
simultaneously, essentially enabling genome-wide snapshots. The quality and amount of 
therapeutic proteins produced by cultured mammalian cells rely heavily on the culture 
environment. In order to implement beneficial changes to the culture environment, a 
better understanding of the relationship between the product quality and culture 
environment must be developed. By analyzing gene expression levels under various 
environmental conditions, light can be shed on the underlying mechanisms. This paper 
describes a method for evaluating gene expression changes for cultured NS0 cells, a 
mouse-derived myeloma cell line, under culture environment conditions, such as 
ammonia buildup, known to affect product quality. These procedures can be easily 
adapted to other environmental conditions and any mammalian cell lines cultured in 
suspension, so long as a sufficient number of gene sequences are publicly available.
 4 
2.2 Introduction 
 Production of therapeutic proteins in cultured mammalian cells has advanced 
significantly over the last few decades. Yields during this time have increased from less 
than ten milligrams per liter to over five grams per liter of product mainly due to 
improved cell numbers (Hacker et al., 2009). However, there has not been the same level 
of improvement in protein quality, specifically with respect to glycosylation and other 
post-translational modifications that directly impact a therapeutic protein’s efficacy 
(Jenkins et al., 2008; Lim et al., 2010). Much research has examined how culture variants 
– including substrate and precursor- feeding, oxygen and carbon dioxide levels, amino 
acid additions, and osmolarity – influence protein quality (Ozturk et al., 1990; Patel et al., 
1992; Maiorella et al, 1993; Hayter et al., 1993; Chotigeat et al., 1994; Gawlitzek et al., 
1995; Castro et al., 1995; Gu et al., 1997; Chuppa et al, 1997; Etchevarry et al., 1998; 
Kunkel et al., 1998; Hooker et al., 1999; Valley et al., 1999; Kaufmann et al., 1999; 
deZengotita et al., 2002; Chung et al., 2001; Baker et al., 2001; Yang and Butler, 2002; 
Sung and Lee, 2005), but currently no robust, reliable means to positively influence 
protein quality are known (Jenkins et al., 2009). 
Many studies have investigated gene expression in mammalian cell culture under 
bioreactor conditions designed to improve protein productivity. Earlier work used real-
time quantitative reverse transcription polymerase chain reaction (real-time qRT-PCR) to 
assess the expression levels of a few particular genes in response to induced culture 
variants (Kim et al., 2005; Yoon et al., 2003; Clark et al., 2005; Clark et al., 2004; Chen 
and Harcum, 2006; Chen and Harcum, 2007; Wong et al., 2010a; Wong et al., 2010b). 
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However, these narrow depictions of gene expression did not provide the global analysis 
necessary to formulate comprehensive models of glycosylation and other post-
translational modifications, whereas DNA microarray analysis is beginning to provide 
adequate levels of detail (Jaluria et al., 2007). 
DNA microarray technology, with its ability to take genome-wide snapshots, 
provides a comprehensive tool for gene expression analysis (Jaluria et al., 2007) that 
when combined with proteomic and metabolic data will finally provide the inputs needed 
to design predictive models for control of post-translational modification, especially 
glycosylation (Jenkins et al., 2009; Jaluria et al., 2007; Redestig and Costa, 2011). 
However, DNA microarrays are still most effective for genetically sequenced species, 
such as mouse cell lines. Thus, the lack of a complete genome prior to July 2011 (Xu et 
al., 2011) has limited Chinese hamster ovary (CHO) cell applications, though analysis 
using private DNA microarrays has yielded insightful results (Korke et al., 2004; 
Wlaschin et al., 2006; Nissom et al., 2006; Gatti et al., 2007; Kumar at al., 2007; Yee et 
al., 2009; Kantardjieff et al., 2010; Shen et al., 2010; Qian et al., 2011; Clarke et al., 
2011). Studies have revealed that genes for vesicle trafficking, endocytosis and 
cytoskeletal elements critically influenced antibody production (Yee et al., 2009) and that 
death receptor- and mitochondria-mediated pathways, not endoplasmic reticulum-
mediated pathways, signaled apoptosis (Nissom et al., 2006). Studies with sodium 
butyrate have linked its positive effect on protein productivity and improved 
glycosylation to histone modifications, chaperones, lipid metabolism, and protein 
processing (Gatti et al., 2007). When sodium butyrate was combined with lower culture 
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temperatures, genes associated with the Golgi apparatus, cytoskeleton, and signal 
transduction contributed to the improved protein quality, despite diminished growth rates 
Kantardjieff et al., 2010). Additionally, hyperosmolarity has been investigated in 
hybridoma cells (a mouse-derived cell line) using DNA microarrays and it has been 
observed that differential expression of genes associated with catabolism, cell-cycle 
regulation, apoptosis, regulation of transcription and translation, and transport and 
signaling pathways play a significant part in cell survival. Surprisingly, hyperosmolarity 
affected few genes involved in stress response (Shen et al., 2010). The positive affects of 
copper sulfate on protein productivity and aggregation have been examined via DNA 
microarrays. The down-regulation of the transferrin receptor and lactate dehydrogenase 
genes, and the up-regulation of cytochrome P450 family genes were determined to 
mediate the positive metabolic responses (Qian et al., 2011). A weighted gene expression 
network analysis has been used to identify patterns in gene expression due to relevant 
bioprocess conditions from 295 DNA microarrays. As expected, genes associated with 
cell cycle, nucleic acid metabolism, and DNA replication were enriched in the clusters 
that had positive effects on cell growth and protein production. These clusters may prove 
useful in identifying biomarkers indicative of high producing CHO cell lines (Clarke et 
al., 2011). As these previous results demonstrate, the parallel, high throughput 
capabilities of DNA microarray technology makes it an ideal tool for evaluating a larger 
scope of transcriptomic responses to design strategies for improving protein yields and 
quality. 
This article covers step-by-step protocols for mimicking the elevated ammonium 
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stress associated with late-stage bioreactor cultures (Gawlitzek et al., 2000) and using 
DNA microarrays to analyze the effect of these culture conditions on glycosylation gene 
expression. While the analysis will focus on NS0 cells (a mouse myeloma cell line used 
commonly for monoclonal antibody production), these procedures are, in principle, easily 
adaptable to CHO cells and other relevant suspension cell lines. Additionally, the 
glycosylation and housekeeping gene sequences that are publicly available could be used 
with any DNA microarray platform and could be extended to include other post-
translational modification genes. 
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2.3 Materials 
Cell Lines  
1. NS0 cells (ECACC#85110503) from the European Collection of Cell Culture 
(a mouse myeloma cell line with lymphoblast morphology, non-secreting clone, 
and cholesterol auxotroph). 
2. (Alternative) Chinese hamster ovary (CHO) cells from the American Tissue 
Culture Collection (ATCC). 
Cell Culture Media 
1. ADCF-MAb™ media without L-glutamine (HyClone) plus Lglutamine (200 
mM) with LS-250 or LS-1000 lipid supplement (HyClone), or (Alternative) 
SyntheChol™ cholesterol supplement (Sigma) and fatty acid supplement (Sigma). 
2. (Alternative) EX-CELL® NS0 Serum-Free Medium (Sigma) plus L-glutamine 
(200 mM). 
3. (Alternative) CDM4NS0® Medium (Hyclone). 
Cell culture reagents, plasticware, and glassware 
1. T-75 (75 cm2) Flasks (e.g. Nunc). 
2. One or two 250 mL spinner flask (Kontes Cytostir or similar). 
3. Four or five 1 L spinner flasks (Kontes Cytostir or similar). 
4. Orbital Shaker Platform/Multiple Purpose Rotator (e.g. Barnstead Lab-Line). 
5. Stir Plate with at least 4 places for 1L spinner flasks  
6. 5 M NH4Cl stock (in Milli-Q water) (e.g. Sigma). 
7. 5 M NaCl stock (in Milli-Q water) (e.g. Sigma). 
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8. 5 M Proline stock (in Milli-Q water) (e.g. Sigma). 
9. (Alternative/Additional) Computer-controlled fermenter system (e.g. Sartorius 
BiostatB Plus). 
Cell counting 
1. Scepter™ 2.0 Handheld Automated Cell Counter (Millipore). 
2. (Alternative) Trypan Blue (e.g. Invitrogen), Microscope (e.g. Olympia), and 
Hemocytometer. 
3. (Alternative) Coulter counter (e.g. Beckman). 
Glucose analysis 
1. HemoCue® B-Glucose Analyzer (HemoCue). 
2. (Alternative) YSI 2300 STAT Plus™ Glucose & Lactate Analyzer 
(Yellow Springs Instruments). 
3. (Alternative) NOVA BioProfile® Basic analyzer (NOVA Biomedical). 
RNA stabilization 
1. Ice bath to quickly cool cells. 
2. (Optional) RNAlater® (Ambion). 
3. (Optional) RNAProtect® (Qiagen). 
RNA isolation and purification 
1. RNAqueous-Midi®kits (Ambion). 
2. (Alternative) PureYield™ RNA Midiprep System (Promega). 
3. (Alternative) RNeasy® Midi Kit (Qiagen). 
RNA clean-up (optional) 
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1. RNeasy® Mini Kit (Qiagen). 
2. RiboPure™ Kit (Ambion). 
3. (Optional) RNase-Free DNase Set (Qiagen). 
RNA quantification 
1. Agilent 2100 Bioanalyzer (Agilent Technologies). 
2. (Alternative) Ribogreen® RNA Quantification kit (e.g. Molecular Probes). 
3. (Alternative) Spectrophotometer with 280 and 260 nm filters (e.g. TECAN). 
4. (Alternative) Gel electrophoresis apparatus (e.g. Nunc). 
DNA microarray 
1. GLYCOv4 GeneChip® (Affymetrix), not available for commercial use. 
2. (Alternative) Custom Nimblegen DNA microarray. 
3. (Altenative) Custom spotted DNA microarray. 
Gene expression analysis 
1. GeneSpring® (Agilent). 
2. (Alternative) ArrayStar® (DNASTAR). 
3. (Alternative) ORIOGEN v3, not for commercial use 
.(http://www.niehs.nih.gov/research/resources/software/oriogen/index.cfm),  
Real-time qRT-PCR validation 
1. Access RT-PCR kit (Promega, WI). 
2. SYBR®Green I dye chemistry (Molecular Probes, Eugene, OR). 
3. Primer Express® (Applied Biosystems, Foster City, CA). 
4. Smart Cycler® (Cepheid, Sunnyvale, CA). 
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 2.4 Methods 
Overview 
This article will cover the key elements of the procedures needed to assess gene 
expression changes under bioreactor conditions with particular focus on protein 
glycosylation and other posttranslational modification genes. The factors that should be 
considered when planning such experiments will be discussed. Although DNA 
microarrays are central to assessing gene expression levels, much of the experimental 
procedures described here – including experimental setup and sampling procedures – are 
independent of the selected DNA microarray platform. Additionally, most DNA 
microarray scanning software can generate multiple types of specialized files (such as 
CEL for Affymetrix) as well as tab-delimited text files, and gene expression software 
programs can read a variety of file types. Due to this flexibility, the experimental 
procedures mentioned here can be performed fairly independent of the DNA microarray 
platform to be used. A flow diagram outlining the basic procedure can be found in Figure 
2.1. The details of the experimental design and set up will be discussed in more detail and 
the reader will be informed of potential options. 
 
Experimental design and set-up 
As a means to demonstrate how to set up and run an experiment focused on 
quantifying expression changes in genes associated with glycosylation and post- 
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 Figure 2.1 Flow diagram for the collection and analysis of gene expression data. The 
process begins with the experimental design.  Next, the experiments are conducted in 
triplicate for each condition.  From each condition, the samples are harvested and the 
cells obtained.  In order to analyze gene expression, the total RNA is separated from the 
cells and purified.  Depending on the DNA microarray platform, the researcher will 
convert the mRNA to cDNA, or send the total RNA to the DNA microarray contract 
facility for processing.  The cDNA is then hybridized with DNA microarray, the DNA 
microarray is scanned and the data is processed.  At this point the process data will be 
returned to the researcher for analysis.  The processed data is usually imported into a 
DNA microarray analysis software tool, where the data is normalized. Once the data is 
normalized, statistical analysis is conducted to identify genes with differential expression 
between the replicates.  A variety of tools can be used to determine underlying gene 
regulation principles.  In order to publish the research results, the data is then submitted 
to a public database. 
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translation modification, a step-by-step procedure will be described for a model system. 
The model system will be NS0 cells exposed to conditions known to affect protein 
glycosylation, including elevated ammonium (Valley et al., 1999; Gawlitzek et al., 2000; 
Gawlitzek et al., 1998) as well as three other conditions. Specifically, the experimental 
procedure to set up ammonium-stressed, salt-stressed, ammonium-stressed with proline, 
and control cultures will be described. The salt-stressed will provide a control for 
osmolarity. The ammonium-stressed with proline will examine the ability of proline to 
mitigate the negative effects of ammonium (Chen and Harcum, 2006). Additionally, a 
control will normalize volumes, nutrients, and osmolarity. Biological triplicates for each 
condition will be needed, thus requiring 12 individual culture vessels. 
Since the anticipated gene expression changes are likely to be small, relative to 
the large magnitude changes observed due to a heat-shock, it is important to synchronize 
the control and ‘‘stressed’’ cultures as much as possible to reduce the growth-associated 
differences. The use of a common inoculum for the control and stressed conditions 
synchronizes the culture behavior, which should reduce the noise-to-signal ratio. In 
Figure 2.2, a scale-up plan is shown for using a common inoculum to seed four 1 L 
spinner flasks. These four spinner flasks represent only one-third of the experiment and 
one complete set of the conditions. This process would need to be repeated two more 
times to generate the biological triplicates (12 experimental vessels total). Since most 
CO2 incubators can only hold one multi-place stirrer with four 1 L spinner positions, the 
procedure outlined in this article runs biological triplicates from three separate inocula, 
sequentially. It is possible to reduce the overall time by staggering the T-75 flasks and  
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 Figure 2.2  Expansion timeline for NS0 cells to be used in parallel 1 L spinner flasks.  
NS0 cells are inoculated into a T-75 flask and allowed to expand to 1.5 x 105 cells/mL, 
which takes 4 to 5 days.  The T-75 flask cells (25 mL) are used to inoculate one 250 mL 
spinner flask with 225 mL fresh media added.  If the desired volume in the four 1 L 
spinners is only 500 mL each, the cells from one 250 mL spinner flask can be used to 
inoculate all four 1 L spinners.  However, if a higher volume is required in the 1 L 
spinners, an additional 1 L spinner can be used.  Inoculate the extra 1 L spinner with the 
entire contents of the 250 mL spinner flask and add up to 750 mL fresh media.  Inoculate 
the Control and Condition spinner flasks with the same volume of cells from either the 
250 mL spinner or the extra 1 L spinner flasks (50 mL to 250 mL depending on desired 
timeframe).     
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recycling the 250 mL spinner with a one-day delay. This would stagger the four 
experimental 1 L spinner flasks by one day, allowing sufficient time to harvest, wash, and 
sterilize the spinner flasks. 
For stresses sufficiently mild as to not alter the growth significantly, inoculating 
the cells directly into the vessels containing the control and ‘‘stressed’’ media allows for 
synchronization. An example set of growth profiles are shown in Figure 2.3A where the 
stresses were mild, as indicated by the parallel growth profiles. An alternative approach is 
required if the stresses to be investigated cause significant growth rate changes. In this 
case, it is best to inoculate all the vessels with cells in control media. This will allow the 
cells to grow sufficiently to obtain a baseline growth rate and confirm that cultures are 
not different, and then the stresses can be applied. An example set of growth profiles are 
shown in Figure 2.3B that highlights this approach, where the stresses were added at 40-
h. The growth profiles were similar prior to the stress at 40-h, and divergent after 40-h. 
The sampling frequency and types needed for analysis will directly determine the 
minimum volumes needed in the experimental vessels. In the model system, 500 mL 
media was used in 1 L spinner flasks to assure sufficient material throughout the entire 
experiment. The volume reduction due to sampling should not significantly alter the 
culture characteristics, such as the mixing dynamics. For the model case, samples would 
be taken for cell density, cell viability, glucose, lactate, osmolarity, and total RNA. If the 
cell line of interest expressed a therapeutic recombinant protein, samples analyzing the 
product quality should be taken periodically. The cell density, cell viability, glucose, and 
lactate samples would be taken approximately every 12-h (see Figure 2.3A). For  
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Figure 2.3 Example growth profiles for biological triplicate conditions.  A) The 
conditions being examined did not significantly affect the growth rate; however, the final 
cell densities were significantly different.  In this case, obtaining gene expression analysis 
data from one time point, late in culture (around 90 hours) would not have high noise in 
the data due to a growth effect.  B) The conditions being examined significantly affect the 
growth rate.  In this case, the stress was applied at 40 hours.  Sampling throughout the 
culture’s growth (before and after the stress) would be desirable, such that gene 
expression changes due to growth effect could be identified.   
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mammalian cells, the sampling frequency can vary from 10 to 16-h without missing the 
culture dynamics; however, it is important that the time intervals used be the same for all 
replicates such that error bars in time are not needed. In the model case, the sample 
interval was initially 16-h, and then alternated between 10 and 14-h to accommodate 
more user-friendly work hours (see Figure 2.3). The volumes withdrawn for these 
samples should be 5 mL per time point with 10 time points (50 mL total). The frequency 
of these sample types would be the same for the growth inhibitory stress conditions (see 
Figure 2.3B). 
For DNA microarrays, a minimum of 10 µg total RNA is usually required. Thus, 
it is critical that the cell pellet samples for total RNA to be sufficiently large enough to 
assure sufficient material is obtained. Cultured cells typically have much lower total 
RNA levels than tissue sample, consequently 1 x 107 cells are a minimum target of cells 
to assure that 10 µg total RNA is obtained at the necessary concentration (1 µg/µL). For 
beginning cultures with cell densities in the 2 x 105 cell/mL range, harvesting 50 mL 
culture media per sample is sufficient. Once the cell densities are greater than 3 x 105 
cell/mL, the harvest volumes can be decreased to 15 mL. The recommended RNA 
isolation kits can handle up to 100 µg total RNA and associated cell debris, so it is 
unlikely that a kit will be saturated with cell debris. For the non-growth altering stresses, 
a single, late-stage exponential-phase total RNA sample from each condition would be 
sufficient to capture gene expression changes due to the stress, which was indicated by 
the vertical line in Figure 2.3A. Taken together with the other sample volumes (50 mL), 
the total anticipated volume change in the vessel is only approximately 65 mL out of 500 
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mL. For the growth altering stresses, multiple total RNA samples from each condition 
would be needed to capture gene expression changes due to the stress. For the model 
experiment shown in Figure 2.3B as vertical lines, total RNA samples should be taken at 
40, 45, 50, 60, 70, 90, and 110-h to fully capture the potential culture gene expression 
dynamics. Taken together with the other sample volumes (50 mL), the total anticipated 
volume change in the vessel would be 155 mL. The similarity of mixing dynamics can be 
assessed using culture media and tracer dyes at the various anticipated volumes to 
confirm minimal effects. So, depending on the placement of the stirring paddles, the 
initial culture volume for the growth altering stressed cultures may need to be increased 
to between 750 and 1000 mL. 
 
Culturing NS0 cells 
Standard cell culture techniques should be used to thaw and expand the NS0 cells. 
 
Standard media preparation 
The ADCF-MAb media requires a cholesterol supplement, since NS0 cells are 
cholesterol auxotrophs. ADCF-MAb media was designed to be used with the LS 250 
lipid supplement (4 mL per liter media; Hyclone) or LS 1000 (1 mL per liter media; 
HyClone). Alternatively, the cholesterol supplement SyntheChol™ (2 mL per liter, 
Sigma) and the fatty acid supplement (0.5 mL per liter, Sigma) can be used as well. As 
needed, add L-glutamine (25 mL of 200 mM L-glutamine stock per liter) to the ADCF-
MAb media. If other cell lines or media are used, prepare media appropriately. 
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The NS0 cells will be inoculated into fresh media at approximately 2 x 105 
cells/mL and allowed to reach 1.5 x 106 cells/mL prior to subsequent inoculation. 
Preparation of the first spinner flask requires a cell density in the T-75 flask greater than 
1.0 x 106 cells/mL. For example, 25 mL of 1.0 x 106 cells/mL added to 225 mL of fresh 
media will result in an initial cell density of 1 x 105 cells/mL in the 250 mL spinner flask. 
The 250 mL spinner flask will reach approximately 1.0 x 106 cells/mL in about 3– 
4 days. Since the complete ADCF-MAb media supports cell densities of approximately 2 
x 106 cells/mL, the cells should be transferred to fresh media in the exponential phase 
(<1.5 x 106 cells/mL) to reduce the potential of a growth lag. For NS0 cells, a lead-time 
of 8–12 days is needed for each replicate set. These lead-times can be shortened if the 
cell line to be examined has faster doubling times than NS0 cells. For example, the higher 
growth rate of CHO cells compared to NS0 cells results in less time required to expand 
the cells. 
If the phenomenon to be investigated requires high cell density cultures, 
computer-controlled fermenters operated in a fed-batch manner will be required. The 
description of fed-batch operation of mammalian cell cultures will not be described; 
however, there are several research papers that describe fed-batch operation (Zhou et al., 
1997; Lee et al., 2003; Wong et al., 2005). The inoculum for the fermenters will be 
generated in spinner flasks, as described above. Depending on the number of fermenters 
available, the conditions to be examined may need to be run sequentially. If sequential 
operation is required, it is very important to have standardized expansion trains. 
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Media preparation 
For the model case, three stressed conditions were compared to the control, 
representing cells cultured in the standard media. In order to minimize osmolarity and 
nutrient concentration differences, the final volumes in the experimental spinner flasks 
were kept constant by water additions to the control and other stressed conditions as 
required (see Table 2.1). For example, for the ammonium- stressed condition (Condition 
1), 2 mL of the 5 M NH4Cl stock was added to the media and 4 mL of Milli-Q water. For 
the salt-stressed condition (Condition 2), 2 mL of the 5 M NaCl stock was added and 4 
mL of Milli-Q water. For the ammonium-stressed plus proline condition (Condition 3), 2 
mL of the 5 M NH4Cl stock was added and 4 mL of the 5 M proline stock. For the 
control culture (Control), 6 mL of Milli-Q water was added. To reduce any potential 
osmolarity shocks, the salts, proline, ammonia, and water should be added to the medias 
prior to the addition of cells. If the stresses significantly affect growth after the stress is 
added, the control culture should have a water addition of equal volume to any chemical 
addition. 
 
Initial sampling 
Once the vessels are inoculated, the initial cell density should be determined. A 
Scepter™ 2.0 Handheld Automated Cell Counter or a similar device can be used to 
obtain the initial cell densities and if cell viability is desired, the Trypan Blue exclusion 
method can be used. Additionally, samples should be taken for glucose and lactate 
analysis using a NOVA BioProfile Basic analyzer or the YSI 2300 STAT Plus™  
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Table 2.1. Experimental media formulations. Media additions to induce the stressful 
condition, while normalizing the nutrient concentrations and osmolality.  Amounts listed 
are per liter of the final media. 
 
 
 
 
 
 
 
 
 
 
 
 
Additions Control 
Condition 1 
(10 mM 
Ammonium) 
Condition 2 
(10 mM 
Salt) 
Condition 3 
(10 mM Ammonium  
+ 20 mM Proline) 
 5 M NH4Cl 0 2 mL 0 2 mL 
5 M NaCl 0 0 2 mL 0 
5 M Proline 0 0 0 4 mL 
Milli-Q 
Water 
6 mL 4 mL 4 mL 0 
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Glucose & Lactate Analyzer. Procedures for the NOVA BioProfile Basic analyzer or 
the YSI 2300 STAT Plus™ Glucose & Lactate Analyzer can be found from the 
manufacturers. 
 
Sampling 
The cultures should be monitored periodically for 110 h with sampling every 10–
14 h. Samples for every time point should minimally include cell density and glucose 
concentrations. Cell viability and lactate may provide additionally information on cell 
health. The cell pellets for total RNA samples should be taken as per the experimental 
design. Protein quality assessment samples should also be taken for systems that express 
a therapeutic recombinant protein. 
 
RNA isolation and purification 
Sampling for total RNA isolation requires some type of stabilization. One method 
simply rapidly cools the cell broth on ice water (4°C), then centrifuges at 4°C. The cell 
pellet is then stored at -80° C. Alternatively, a stabilization agent can be added directly to 
the cell broth for storage. Usually an equal volume of the stabilization agent is needed. 
Commercially available stabilization agents include RNAlater Stabilization Solution 
(Ambion) and RNAprotect cell reagent (Qiagen). The stabilized cell broth is then either 
stored at -20 or -80°C depending on the manufacturer  
Although the RNA extraction kits are designed to inactivate RNAses and other 
degradative compounds, it is essential that proper sterile practices be used, and that no 
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part of the kits be touched with bare hands, as RNAses are especially abundant on human 
skin, and could affect reagents and samples. Also, all water and pipette tips used in 
conjunction with these kits must be nuclease-free. It is best to process all the RNA from 
all samples together. 
 
RNA isolation 
The RNAqueous Midi Kit can be used to extract and isolate the total RNA, 
although many other kits, such as RNeasy Mini Kits, are also effective. These 
procedures can be found at http://www.ambion.com and http://www.qiagen.com. Also, 
the phenol–chloroform extraction method can be utilized. It is sold under the name TRI 
Reagent (Sigma) and TRIzol (Invitrogen). Essentially, these procedures all have steps 
to lyse the cells, remove cellular debris including lipids, proteins and DNA, followed by 
binding and eluting the total RNA in nuclease-free water. 
 
RNA purification 
Many DNA microarray contract facilities require an additional RNA purification. 
The RNeasy Mini Kits can be used for all RNA purifications procedures. Other 
companies, such as Norgen Biotek offer alternatives; however, one should confirm the 
compatibility with the DNA microarray contract facility beforehand. Normally, RNA 
purification kits efficiently remove the majority of DNA without DNAse treatment; 
however, if any of the mRNA transcripts of interest are in low abundance, an additional 
DNAse digestion step should be performed. An RNase-Free DNAse Set should be used. 
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The procedure for Qiagen’s DNAse digestion can be found at 
www.qiagen.com/hb/rnasefreednaseset. In the model case, the DNAse digestion step was 
not needed; however, the additional Qiagen RNA clean-up was required by the 
Consortium for Function Genomics DNA microarray facility. 
 
RNA quantification 
The Ribogreen RNA Quantification Kit (Molecular Probes) was used to 
quantify the concentration of all RNA samples, although other alternatives include the 
Agilent 2100 Bioanalyzer, UV/VIS spectrophotometer, or gel electrophoresis apparatus. 
The Ribogreen® Quantification Kit procedure can be found at 
http://hcgs.unh.edu/protocol/realtime/RiboGreen.pdf. 
 
DNA microarray 
There are several existing DNA microarray technologies; however, for this article, 
the descriptions will focus on the usage of a high-density oligonucleotide DNA 
microarray synthesized in situ using photolithography, a method developed by 
Affymetrix. Other DNA microarray platforms that could be used with the glycosylation 
and post-translational modification genes include pin-based fluid transfer systems, piezo-
based inkjet dispenser systems, and electronic-based addressing systems (Heller et al., 
2002). Selection of a DNA microarray platform depends on the experimental design, 
gene sequences available, processing facility availability, and cost. Muyal et al. provides 
a good review of the different platform technologies (Muyal et al., 2008). Further, Larkin 
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et al. demonstrated that results obtained obtain from Affymetrix and two-color DNA 
microarray platforms agreed, as long as reliable and consistent methods of identifying 
genes were used. This makes sense when one considers that the biological and procedural 
variation exerts a greater effect than platform variation (Larkin et al., 2005). 
The specific DNA microarray that will be described is the GLYCOv4 GeneChip 
DNA microarrays. The GLYCOv4 GeneChips are Affymetrix-manufactured DNA 
microarrays that contain the known glycosylation-related genes for human and mouse. 
The GLYCOv4 DNA microarrays were constructed for the Consortium for Functional 
Glycomics with funding from the National Institutes of Health (NIH). The GLYCOv4 
GeneChips are only available through a proposal process to academic researchers from 
the Consortium for Function Genomics. Alternatively, a researcher could have a custom 
DNA microarray manufactured containing these glycosylation genes using any platform 
technology, as all the gene sequences are publicly available. 
The GLYCOv4 GeneChip DNA microarray contains 25 perfect match and 
mismatch (PM-MM) probes for each of the 1127 mouse glycosylation-related genes and 
the 119 housekeeping genes. The list of all the included genes and probe sequences can 
be found at 
http://www.functionalglycomics.org/static/consortium/resources/resourcecoree.shtml. 
The gene types include: 
• Glycosyltransferases 
• Glycan degradation proteins 
• Intercellular protein transport proteins 
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• Nucleotide sugar synthesis and transporter proteins 
• N-glycan biosynthesis-related proteins 
• Interleukins and receptors 
• Growth factors and receptors 
• Cytokines 
Affymetrix DNA microarrays also include numerous control probes on the array. 
Details of the Affymetrix Eukaryotic Hybridization Controls can be found at 
http://www.affymetrix.com. Briefly, the GeneChip_ Eukaryotic Hybridization Controls 
contains a mixture of four biotin-labeled cRNA controls with staggered concentrations. 
The controls provides alignment signals used by the scanning software to provide 
calibrated intensities that determine ‘‘present’’ and ‘‘absent’’ calls for a gene as well as 
confirm hybridization and chip integrity. 
 
RNA sample preparation for DNA microarray 
The total RNA samples need to be very concentrated (1 µg/µL) for DNA 
microarray analysis. Therefore, it may be necessary to precipitate the total RNA after the 
purification step. For the model case, a vacuum concentrator was used to dry the 10 µg 
samples, which then were re-suspended in 10 µL. Theses samples were sent to the 
Consortium for Function Genomics. As typical of contract DNA microarray facilities, the 
total RNA quality and concentration were determined upon arrival with an Agilent 2100 
Bioanalyzer. This quality assurance step, allows the contractor to avoid expense of 
labeling total RNA that has degraded in transit. Alternatively, some contract DNA 
 27 
microarray facilities require the researcher to reverse transcribe the RNA to cDNA, as 
shipping the more stable cDNA is less problematic. If required to reverse transcribe the 
RNA on-site, make sure to budget the cost of the reserve transcriptase (~$100 per 
sample). 
At the contract DNA microarray facilities, the RNA will be reverse transcribed in 
the presence of the fluorescently-labeled dNTP analogues to obtain biotinylated cRNA. 
The labeled RNA will be hybridized to a DNA microarray, such as the GLYCOv4 
GeneChip, including Affymetrix’s GeneChip Eukaryotic Hybridization Controls. The 
GLYCOv4 GeneChips will be scanned using the Hewlett– Packard GeneArray Scanner 
G2500A and a processed image file with calculated signal intensities assigned to each 
oligonucleotide spot on the GLYCOv4 GeneChip will be created. The data will be 
reviewed for quality control at the contract DNA microarray facilities. The data files are 
processed and returned as CEL files (for Affymetrix) to the researcher. Additionally, data 
regarding the probes is provided. An example of the probe data provide in shown in 
Table 2.2 for a GLYCOv4 GeneChip. Only data for the first 10 probes is shown in 
Table 2.2 for brevity. Muyal et al. provides a good overview description of the DNA 
microarray process from RNA sample preparation to data acquisition (imaging) (Muyal 
et al., 2008). Additionally, the GeneChip Expression Analysis Technical Manual 
provides details of the RNA preparation through imaging steps for Affymetrix DNA 
microarrays. 
 
Statistical analysis of gene expression data 
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Table 2.2 Example probe set data information for the GLYCOv4 GeneChip.  
Information for only the first 10 genes is listed.  The GLYCOv4 GeneChip contains 25 
probes per accession number.  The accession numbers are sufficient information to create 
a custom DNA microarray. 
 
 
 
 
 
 
 
 
Probeset ID Category Sub-category Common name 
Accession 
Number 
Probe 
Set 
Score 
NM_013630.
2_psr1 
CBP: C-Type 
Lectin 
10-
Polycystin 
Pkd1 [Polycystin] NM_013630 10.6 
NM_029686.
2_psr1 
CBP: C-Type 
Lectin 
10-
Polycystin 
Pkd1l2 [Polycystin 1-
like protein 2] 
NM_029686 12.6 
NM_181415.
3_psr1 
CBP: C-Type 
Lectin 11-Attractin 
Atrnl1 [Attractin 
homolog] 
NM_181415 10.5 
NM_009730.
2_psr1 
CBP: C-Type 
Lectin 11-Attractin 
Attractin NM_009730 10.8 
NM_008920.
4_psr1 
CBP: C-Type 
Lectin 
12-CTLD + 
acidic neck 
Prg2 [proteoglycan 2 
bone marrow] 
NM_008920 12.3 
NM_016914.
2_psr1 CBP: C-Type Lectin 
12-CTLD + 
acidic neck 
Prg3 [proteoglycan 3; 
Eosinophil major basic 
protein homolog] 
NM_016914 12.1 
NM_010048.
3_psr1 
CBP: C-Type 
Lectin 
12-CTLD + 
acidic neck 
DGCR2 DiGeorge 
syndrome protein C 
NM_010048 11.1 
NM_054042.
2_psr1 
CBP: C-Type 
Lectin 13-IDD 
Cd248 [CD248 antigen 
endosialin] 
NM_054042 11.7 
NM_010740.
3_psr1_s 
CBP: C-Type 
Lectin 
14-
Endosialin 
CD93 [C1q receptor; 
Cd93 antigen] 
NM_010740 10.5 
NM_009378.
2_psr1 
CBP: C-Type 
Lectin 
14-
Endosialin 
Thbd 
[Thrombomodulin] 
NM_009378 11.6 
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In order to interpret the DNA microarray data, the raw DNA microarray data files 
must be imported into a statistical analysis software program. Microsoft Excel is the  
simplest program that could be used, but has limited function. In the model case, 
GeneSpring was used; however, there are many commercial programs (e.g. 
ArrayStar) and one public domain program (ORIOGEN) available. These programs 
provide multiple statistical and post hoc tests, visualization and clustering tools, and often 
pathway mapping. GeneSpring can directly import the CEL data generated by the 
Affymetrix compatible scanner. Many gene expression analysis software tools can also 
import gene expression data from tab-delimited text files. A portion of a tab-delimited 
text file from the GLYCOv4 GeneChip is shown in Table 2.3. In this case, the data 
from three biological replicates were combined into a single file. 
The first step once the data has been imported into the software package is to 
normalize the raw data between the DNA microarrays. Normalization adjusts for the 
effects that are due to DNA microarray processing (Wit and McClure, 2004). For 
example, with two-color DNA microarrays, imbalances in the red and green dyes can 
occur due to labeling efficiency differences (Smyth and Speed, 2003). In GeneSpring, 
the researcher needs to select a normalized protocol for the data. GeneSpring also 
performs a quality check on the Affymetrix Hybridization Controls, which check for 
minimum detection levels and titration of concentrations. The default normalization is 
quartile and it is commonly normalized to the total intensity of the chip, which is often 
set to the arbitrary value of 500. This method assumes that on average the total RNA 
level in a cell is constant. Alternatively, one can normalize to the median chip intensity or  
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Table 2.3 Example gene expression data outputs for one condition.  The gene 
expression signal, call, and p-values for 10 Probesets are shown for only the first 10 
genes. Genes that are assigned as present (P) have p ≤ 0.04, whereas the genes assigned 
as absent (A) have p ≥ 0.06 and low signals. Genes with p-values in-between are assigned 
marginal (M) calls. 
 
 
 
 
 
 
 
Probeset 
ID 
Replicate 1 Replicate 2 Replicate 3  
Signal Call P-value Signal Call P-value Signal Call P-value 
NM_0136
30.2_psr1 64 P 0.00148 73.6 P 0.001049 100.4 P 0.000451 
NM_0296
86.2_psr1 37.5 A 0.160942 16.4 M 0.056885 25.1 A 0.122135 
NM_1814
15.3_psr1 7.8 A 0.493067 1.7 A 0.629375 14.9 A 0.227444 
NM_0097
30.2_psr1 566.8 P 0.00003 428.9 P 0.00003 404.8 P 0.00003 
NM_0089
20.4_psr1 32.8 A 0.129317 30.9 P 0.009484 31.9 P 0.007135 
NM_0169
14.2_psr1 6.2 A 0.728492 3 A 0.728492 6.9 A 0.58937 
NM_0100
48.3_psr1 9.5 A 0.424197 10.3 A 0.090421 1.6 A 0.655316 
NM_0540
42.2_psr1 316.8 P 0.00003 304.5 P 0.00003 308.4 P 0.00003 
NM_0107
40.3_psr1
_s 
3.3 A 0.990516 1.5 A 0.870683 11 A 0.197229 
NM_0093
78.2_psr1 5.4 A 0.728492 2 A 0.79298 3.7 A 0.772556 
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a particular set of housekeeping genes. Bahr et al. identified over 100 potential 
housekeeping genes for CHO cells after reviewing multiple DNA microarray studies 
(Bahr et al., 2009). Normalization methods also include linear models, global 
normalization, LOESS normalization, and subset quantile normalization (Khoo et al., 
2007; Wu and Aryee, 2010; Yang et al., 2002). For Affymetrix CEL files, the steps used 
are summarization, log transformation, and baseline transformation as described in the 
Gene-Spring GX Manual. 
After data normalization, differentially expressed genes can be identified from the 
replicates and between the conditions of interest. In the model case, there are three 
biological replicates for the four conditions, thus data from 12 DNA microarrays was 
analyzed. Experiment groupings are used to identify sample parameters and the 
replicates. For example, in the model case ammonium would be a parameter, as well as 
proline and salt. Also, a principle component analysis is used by GeneSpring to check 
data quality per DNA microarray. DNA microarray data that is of low quality can be 
discarded if necessary at this step; however, then all the quality control checks are 
repeated on the new experimental groupings (GeneSpring GX Manual). 
An ANOVA analysis is used to detect differential expression. The Welch 
ANOVA test using a Benjamini and Hochberg false discovery rate correction is a fairly 
robust tool for multiple comparisons (p ≤ 0.05) (Benjamini and Hochberg, 1995). Many 
software packages can also conduct numerous types of post hoc tests on the data 
(pairwise comparisons). A Tukey Honestly Significant Difference (HSD) post hoc test is 
one example that can identify genes that are significantly different between a pair of 
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conditions (GeneSpring GX Manual). Table 2.4 shows an example Tukey post hoc for 
an experiment with four conditions. Analyzing these differentially expressed genes for 
biological relevant comparisons is crucial. For example, in the model case, a direct 
comparison of the salt-stressed cultures to the ammonium with proline-stressed cultures 
may not provide any meaningful biological information. However, the other pairwise 
comparisons are more likely to result in biologically meaningful information. 
Specifically, comparing the control and ammonium-stressed cultures would provide 
information on the effects of ammonium on glycosylation genes. Comparing the control 
and salt-stressed cultures would identify glycosylation genes sensitive to a low salt 
addition (a mild osmolarity change). Comparing the ammonium-stressed and ammonium-
stressed with proline cultures would identify genes sensitive to the proline addition. 
Identifying differentially expressed genes and establishing links between these 
changes and altered biological activity in response to stressful conditions is crucial. 
Functional annotation can be used to assist with identifying underlying principles. 
Several databases can be accessed to provide functional annotation such as the Gene 
Ontology Consortium (GO), Metacyc, and the Kyoto Encyclopedia of Genes and 
Genomes (KEGG). The Gene Ontology Consortium maintains a database of controlled 
vocabularies for the description of molecular functions, biological processes and cellular 
components of gene products, which can be accessed directly from Gene-Spring_. 
Metacyc is a database of non-redundant, experimentally elucidated metabolic pathways. 
The Metacyc Pathway Tools Omics Viewers allows for gene expression data to be 
overlaid onto the metabolic pathway. KEGG is collection of manually drawn pathway  
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Table 2.4 Example pairwise comparison of the culture conditions (Tukey post-hoc) – 
hypothetical data.  The ANOVA analysis (p ≤ 0.05) identified 310 of the 952-
glycosylation genes as regulated across the four conditions. The diagonal represents self-
comparisons.  Values above the diagonal represent the genes that have significantly 
different expression levels between the two conditions. Values below the diagonal 
represent the genes that are not significantly different between the two conditions. 
 
 
 
 
 
 
 
 
Conditions Control Condition 1 Condition 2 Condition 3 
Control X 230 180 110 
Condition 1  722 X 150 165 
Condition 2  772  787 X 155 
Condition 3  842  802  797 X 
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maps representing the current knowledge of molecular interaction networks, including 
glycan biosynthesis and metabolism. Additionally, tools like the MAPPFinder software 
have been used to identify gene ontology with a higher-than-expected proportion in the 
differentially expressed data (Kantardjieff et al., 2010). 
Many different approaches can be taken to identify the biological significance for 
an observed set of gene expression changes. Cluster analysis, principle component 
analysis, heat-maps, k-means clustering, and self-organizing maps (SOM) are all 
common tools (Wit and McClure, 2004; Landgrebe at al., 2002; Kantardjieff et al., 2009). 
Hierarchical clustering was used to identify cell-cycle genes that were differentially 
expressed due to hyperosmolarity (Shen et al., 2010) and principal components analysis 
was used to condense the dimensionality for butyrate-treated culture gene expression data 
(Kantardjieff et al., 2010). Wit and McClure reviewed these various tools and provides 
examples of how each compares (Wit and McClure, 2004). 
DNA microarray gene expression data is customarily validated using an 
orthogonal method, with real-time qRT-PCR being the most commonly employed tool. In 
the recent cell culture DNA microarray literature, the number of gene expression changes 
that have been validated by real-time qRT-PCR varies from none to six genes (Gatti et 
al., 2007; Kantardjieff et al., 2010; Shen et al., 2010; Khoo et al., 2007; Wlaschin and Hu, 
2007). Work by Canales et al. demonstrated excellent concordance between real-time 
qRT-PCR and DNA microarray fold change results using the three common real-time 
qRT-PCR chemistries; calling into question the need for this validation step (Canales et 
al., 2006). However, real-time RT-qPCR does provide lower thresholds of detection and 
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larger assay ranges, which can be used to complement DNAmicroarray analysis for both 
highly and rarely expressed mRNA species (Canales et al., 2006). 
Real-time qRT-PCR uses primers to hybridize the mRNA species and amplify a 
portion of the mRNA, in which either the DNA product or probes fluoresce 
proportionally to the amount of mRNA in the sample. Gasparic et al. recently reviewed 
nine real-time qRTPCR technologies and provides a description of the mechanism of 
each (Gasparic et al., 2010). As with DNA microarrays, it is necessary to normalize the 
gene expression data. For real-time qRT-PCR, housekeeping genes are used to provide 
this normalization. Often actin, glyceraldehyde-3-phospahte dehydrogenase (GAPDH), 
and 18S rRNA are used as normalizers for mammalian mRNA (Canales et al., 2006; 
Gasparic et al., 2010). Using many DNA microarray data sets, Bahr et al. identified over 
100 housekeeping gene targets for CHO cells due to consistent expression among a 
variety of culture stresses (Bahr et al., 2009). 
To validate DNA microarray gene expression results by real-time qRT-PCR, one 
must select a real-time qRT-PCR chemistry, design primers to the target mRNA and 
housekeeping genes, run the reactions, process the data, then compare to the DNA 
microarray data. Schefe et al. provide a comprehensive guide to real-time qRT-PCR 
methods and data analysis (Schefe et al., 2006). Canales et al. provides details for 
comparing DNA microarray and real-time qRT-PCR results (Canales et al., 2006). 
In the model case, gene expression levels were quantified using SYBR Green I 
dye chemistry (Molecular Probes, Eugene, OR) (Richards et al., 2004; Hein et al., 2001). 
Primers for each of the mRNA targets were designed using Primer Express (Applied 
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Biosystems, Foster City, CA). Conventional reverse transcription polymerase chain 
reactions (RT-PCR) and 2.0% agarose gels were used to confirm primer design, after 
which visible products on the gels were sequenced to confirm primer specificity. A one 
step RT-PCR kit (Promega, WI) was used for both conventional RT-PCR and real-time 
qRT-PCR. The conventional RTPCR should be performed, as per kit instructions. The 
real-time qRT-PCR can be performed using a Smart Cycler (Cepheid, Sunnyvale, CA). 
For the model case, CT values were calculated using the Gene Expression’s CT 
Difference (GED) method (Schefe et al., 2006). Alternatively, a second derivative 
analysis CT method (Luu-The et al., 2005) outlined by Schwarz et al. and Peters et al. 
(Schwarz et al., 2004; Peters et al., 2003) and normalized as per Pfaffl (Pfaffl et al., 2001) 
can be used. The normalized gene expression levels for the control, ammonium-stressed, 
salt-stressed, and ammonium-stressed with proline cultures were assessed using 
Statistical Analysis Software (SAS). An ANOVA analysis (p ≤ 0.05) was used to identify 
gene expression differences. 
 
Data dissemination 
Researchers are often required by journals to submit gene expression data to 
public databases. Gene Expression Omnibus (GEO) at the National Institutes of Health 
(NIH) in the United States and ArrayExpress at the European Bioinformatics Institute 
(EBI) part of the European Molecular Biology Laboratory (EMBL) in the United 
Kingdom, are two well-recognized public gene expression repositories. These public 
databases offer great opportunities to compare data to other experimental results as well 
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as learn from results of other experiments. Both GEO and ArrayExpress use the 
Minimum Information About a Microarray Experiment (MIAME) guidelines that specify 
the minimum information that should be included when describing a microarray 
experiment. For GEO submission, the types of data input are categorized – including 
metadata, raw data files, matrix tables, and the platform. The metadata comprises the 
descriptive information and protocols used. The raw data files are the original, software-
generated quantitative results files. For Affymetrix DNA microarray data, the raw data is 
contained in the CEL files. The matrix table is a spreadsheet that contains the normalized 
data. The platform is a description of the DNA microarray architecture and probe 
sequences. Many commercial platforms have already been submitted to GEO; however, 
if a new platform has been used, the researcher will have to provide this information. As 
more data becomes available and accessible through these databases, existing models can 
be updated and improved. The procedure for GEO submission using MIAME can be 
found online at http://www.ncbi.nlm.nih.gov/geo/info/MIAME.html (Barrett et al., 2011). 
 
 38 
2.5 Conclusion 
DNA microarray technologies are extremely useful tools for evaluating how cells 
respond at the gene expression level to stresses in their culture environment. It is known 
that the culture environment can greatly impact protein quality, but so far, there has been 
limited research devoted to evaluating the gene expression levels in response to these 
culture conditions. While the lack of sequenced genomes hindered previous research, as 
more genomes continue to be sequenced, the potential for gene expressional analysis 
using DNA microarrays continues to grow. With DNA microarrays’ ability to look at 
many different genes at once, researchers can now evaluate a larger scope of cellular 
responses to specific stresses. This allows for the discovery of more comprehensive 
patterns, involving not only the genes responsible for the enzymes in the glycosylation 
pathway but also genes associated with other cellular functions that indirectly influence 
the protein quality. Additionally, data collections from gene expression studies are now 
publicly available online, providing researchers with even more data with which to 
formulate models. With these deeper insights, more effective strategies can be designed 
to take advantage of various culture parameters known to positively affect glycosylation 
and other post-translational modifications in an effort to develop methods to improve 
both the quality and quantity of therapeutic protein yields. 
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CHAPTER THREE: GLYCOSYLATION-RELATED GENES IN  
NS0 CELLS ARE INSENSITIVE TO MODERATELY  
ELEVATED AMMONIUM CONCENTRATIONS 
 
3.1 Abstract 
NS0 and Chinese hamster ovary (CHO) cell lines are used to produce 
recombinant proteins for human therapeutics; however, ammonium accumulation hinders 
cell growth, recombinant protein production, and protein glycosylation. To improve 
product quality and decrease costs, the link between ammonium and protein 
glycosylation must be resolved. While ammonium is known to disrupt glycosylation-
related gene expression in CHO cells, NS0 studies have not been performed. This study 
examined if NS0 cells were ammonium-sensitive at the gene expression level. The effects 
of various culture conditions – ammonium, salt, and ammonium with proline - on gene 
expression were assessed by DNA microarrays with mouse glycosylation-related and 
housekeeping genes. Surprisingly, no significant differences in gene expression levels 
were observed between the control and these conditions. Further, the elevated ammonium 
condition was analyzed using real-time quantitative reverse transcriptase PCR (qRT-
PCR) for key glycosylation genes, and the qRT-PCR results corroborated the microarray 
results, showing NS0 cells to be ammonium-insensitive at the gene expression level. 
Thus, this study suggests that for NS0 cells, the observed ammonium-induced effects on 
protein glycosylation and sugar nucleotide pools are due to translational or enzymatic 
changes rather than transcriptional changes. 
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3.2 Introduction 
Mammalian cells are increasingly being used to produce glycoproteins for human 
clinical therapies. The extent of glycosylation – or the addition of sugar groups to 
proteins – plays an important role in the effectiveness of treatments, which makes protein 
glycosylation quality a top priority (Butler, 2006; Butler and Meneses-Acosta, 2012; 
Hudak and Bertozzi; Jenkins et al., 1996; Lingg et al., 2012; Ozturk, 1992). The culture 
environment, in which ammonia and ammonium ions accumulate, plays a significant role 
in determining cell growth rates, recombinant protein production, and protein 
glycosylation quality (Berlec and Strukelj, 2013; Butler, 2006; Chen and Harcum, 2005; 
deZengotita et al., 2002; Gawlitzek et al., 1999; Hansen and Emborg, 1994; Jenkins, 
1996; Jenkins et al., 1996; Miller et al., 1988; Quek et al., 2010; Reuveny et al., 1986; 
Schneider et al., 1997; Yang and Butler, 2000a). Specifically, elevated ammonium levels 
reduce protein glycosylation quality, by decreasing terminal sialylation levels as well as 
both the tetraantennary and tetrasialylated oligosaccharide structures, while increasing 
molecular heterogeneity (Baker et al., 2001; Chen and Harcum, 2005; Yang and Butler, 
2000b, 2002). All of these factors lower the efficacy of a therapeutic glycoprotein and 
having to remove these isoforms increases costs (Jenkins et al., 1996). 
Interestingly, elevated ammonium has been shown to lead to higher intracellular 
nucleotide sugar pools, which serve as precursors for many glycosylation reactions, in 
NS0 cells (Ryll, 1994; Valley et al., 1999). Additionally, when cells are supplemented 
with glycosylation precursors, such as N-acetylmannosamine and galactose, 
glycosylation was not significantly increased, despite increased nucleotide sugar pools 
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(Baker et al., 2001; Clark et al., 2005; Gu and Wang, 1998). Furthermore, cloning 
additional copies of two genes encoding important glycosylation enzymes – 
sialyltransferase and galactosyltransferase – produced only modest improvements in 
protein glycosylation (Weikert et al., 1999).  
In this research, we sought to expand our limited understanding of protein 
glycosylation control, by investigating how elevated ammonium levels influence 
glycosylation at the gene expression level. To this end, an Affymetrix-platform DNA 
microarray was employed, that contains the known mouse glycosylation-related 
nucleotide sequences and numerous housekeeping genes for mouse, the host organism of 
the NS0 cell line. Elevated ammonium is known to significantly decrease protein 
sialylation in NS0 cells (Baker et al., 2001), and the sialyltransferase gene has been 
observed to be ammonium-sensitive in Chinese hamster ovary (CHO) cells (Chen and 
Harcum, 2006), altered gene expression was expected in NS0 cells, as well. Additionally, 
both CHO and NS0 cell lines are used to manufacture recombinant glycoproteins for 
clinical therapies and can be cultured in defined media in suspension cultures (Gatti et al., 
2007). Initially, four culture conditions were compared – control, elevated ammonium, 
elevated salt as an osmolarity control, and elevated ammonium with a proline addition, as 
proline had been observed to reduce the negative effects of ammonium on product quality 
for CHO cells. Additionally, the orthogonal gene expression quantification method real-
time qRT-PCR was used to confirm the results observed for the elevated ammonium 
culture condition using a newer media formulation. 
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3.3 Materials and Methods 
The NS0 cells (ECACC 85110503) for the DNA microarray studies were donated 
to Clemson University by Merck, Inc, and originally from the European Collection of 
Cell Cultures. The NS0 cells for the real-time qRT-PCR studies were purchased from 
Sigma (catalog no. 03061601— ECACC 85110503), where Sigma is the official US 
distributor ECACC. NS0 cells are a mouse myeloma cell line with lymphoblast 
morphology, non-secreting clone, and cholesterol auxotroph (Whitford, 2003). The NS0 
cell lines used in these studies do not express a recombinant protein and represent the 
host strain or the fusion partner for generation of hybridomas. For the DNA microarray 
studies, an animal-derived protein-free media, HyQ ADCF-Mab (Hyclone) (first-
generation media), was used and supplemented with 5 mM glutamine (Hyclone) and LS-
250 cholesterol supplement (4 mL per L media; Hyclone) in 1000 mL spinner flasks with 
100 rpm agitation. For the cultures analyzed by real-time qRT-PCR, a second-generation 
ADCF-Mab media (Thermo Hyclone) was used with a LS-1000 cholesterol supplement 
(1 mL per L media; Hyclone) in 250 mL spinner flasks with 60 rpm agitation. Both 
studies cultured the cells in humidified incubators at 37°C and 5% CO2. A common seed 
culture was used to inoculate the control and treatment cultures, which were then cultured 
in parallel. Biological triplicates were used for each condition examined. The ammonium, 
salt, and proline stock solutions (all 5000 mM) were prepared in Milli-Q water and added 
to the fresh media prior to the addition of cells. Milli-Q water was added to the control 
and treatment cultures to normalize culture volumes and media concentrations (1 to 6 mL 
per L). For initial growth studies, the culture conditions were basal media (control), and 
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basal media supplemented with either 10 mM NH4Cl (ammonium), 10 mM NaCl (salt), 
or 10 mM NH4Cl and 20 mM proline (proline). For the DNA microarray studies, the 
culture conditions were basal media (control), and basal media supplemented with either 
5 mM NH4Cl (ammonium), 5 mM NaCl (salt), or 5 mM NH4Cl and 10 mM proline 
(proline). Osmolality of the media was measured using the freezing point method 
(Schmelzer et al., 2000). The 5 mM additions increased osmolality by approximately 30 
mOsm/kg, or only approximately 10%. Cell concentrations and viabilities were 
determined by the Trypan blue exclusion method. Glucose was measured using a Blood 
Glucose Analyzer (Hemacue). For the real-time qRT-PCR studies, the control and 
elevated ammonium (5 mM) conditions were investigated. Cell concentrations were 
quantified using the Scepter 2.0 Handheld Automated Cell Counter (Millipore). Glucose 
and lactate were quantified using a Yellow Springs Instruments (Yellow Springs, OH) 
2900 Biochemistry Analyzer. 
 
RNA isolation 
Cells were harvested by centrifugation at 3000 g for 5 min at 4°C in order to 
obtain total RNA. The supernatant and pellets were saved at –20°C and –80°C, 
respectively. Total RNA was isolated from the pellet using the RNAqueous-MidiTM kits 
(Ambion), except the DNase treatment was increased to 2 μl of DNase and 1 hour. The 
total RNA was further purified using the RNeasy Qaigen kit. RNA concentrations were 
determined using a Ribogreen RNA quantification kit (Molecular Probes). 
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DNA microarray analysis 
Ten micrograms of total RNA (1 μg/μl) per sample was sent to the Consortium 
for Functional Genomics for gene expression analysis on the GLYCOv3 Chip. The 
Affymetrix-platform and data discussed in this publication have been deposited in 
NCBI's Gene Expression Omnibus (Barrett et al., 2013) and are accessible through GEO 
Platform accession GPL11096: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? 
acc=GPL11096. The GLYCOv3 Chip Mouse Gene List can also be found at 
http://www.functionalglycomics.org/static/consortium/resources/resourcecoree.shtml 
(accessed April 10, 2014). These Glyco-Gene Chips are available to academic 
researchers through a proposal process. The GLYCOv3 Chip contains 952 mouse 
glycosylation-related probes, including probes for the sialyltransferase, 
galactosyltransferase, sialidase, and fucosyltransferase genes. All 14 of the genes 
(including the two housekeeping genes), previously investigated in CHO cells under 
elevated ammonium by qRT-PCR, were on GLYCOv3 Chip (Aebi et al., 2000). 
Biological triplicates for each condition were analyzed for a total of 12 DNA 
microarrays. 
Briefly, upon arrival of the total RNA, the Consortium for Functional Genomics 
staff assessed the RNA quality using a Bioanalyzer (Agilent). Then, the RNA was reverse 
transcribed in the presence of the fluorescently-labeled dNTP analogues. The labeled 
RNA was then hybridized to the GLYCOv3 Chip, including the GeneChip Eukaryotic 
Hybridization Controls, Bacteriophage Controls, and GC Controls (Affymetrix). The 
GeneChip Eukaryotic Hybridization Controls contains a mixture of four biotin-labeled 
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cRNA controls with staggered concentrations. The Bacteriophage Controls contains four 
bacteriophage P1 oligonucleotides, and the GC Control contains 44 random and specific 
GC oligonucleotides that provide titrated fluorescent signals. These controls provide 
calibrated intensities that are used to confirm hybridization and chip integrity. These 
controls are used to determine the “Present” and “Absent” calls for a gene. Additionally, 
there are 104 housekeeping mouse gene controls on the chip as probes. The GLYCOv3 
Chips were scanned with a confocal scanner, which calculated the signal intensities 
associated with each oligonucleotide on the GLYCOv3 chip into image files viewable by 
researchers. The data was reviewed for quality control at the Consortium for Functional 
Genomics, where the data files were processed and returned as .CEL files. GeneSpring® 
imported the .CEL data, and each gene was then normalized to the total intensity of the 
chip. The data discussed in this publication have been deposited in NCBI's Gene 
Expression Omnibus (Barrett et al., 2013) and are accessible through GEO Series 
accession number GSE28920 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28920). 
 
Real-time qRT-PCR analysis 
The cDNA was synthesized using 1 μg of total RNA from each sample as 
template using Retroscript Kit (Life Technologies). Real-time RT-PCR was performed 
with Quantitect SYBR Green PCR Kit (Qiagen) using primers designed for five 
glycosylation-related genes: solute carrier family 35 (CMP-sialic acid transporter) 
[Slc35a1], ST3 β-galactoside α-2,3-sialyltransferase 3 [St3gal3], ST3 β-galactoside α-
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2,3-sialyltransferase 4 [St3gal4], ST3 β-galactoside α-2,3-sialyltransferase 6 [St3gal6], 
β(1,4)-galactosyltransferase [B4galt1], and two endogenous control genes: Actin, beta 
(Actb) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) in a Rotor-Gene 3000 
Real-Time Thermal Cycler (Qiagen). Primer sequences are listed in Table 3.1. Relative 
gene expression levels were calculated using the 2-∆∆CT method with Gapdh as an internal 
standard (Livak and Schmittgen, 2001). 
 
Statistical analysis 
For the DNA microarray data, a Welch ANOVA test using a Benjamini and 
Hochberg false discovery rate correction was used for the multiple comparisons (p ≤ 
0.05, p ≤ 0.10, and p ≤ 0.99) with Tukey Post-Hoc tests. ANOVA analysis was used to 
analyze the effect of ammonium on cell densities and growth rates (p ≤ 0.05). For real 
time qRT-PCR, a student’s two-tailed t-test was employed to determine the significant 
differences between groups, with p ≤ 0.05 being considered as statistically different. 
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Table 3.1 PCR primer sequences for analysis of NS0 cells. M. musculus primer 
sequences used for qRT-PCR analysis of elevated ammonium for NS0 cultures. 
 
Gene Forward Primer Sequence Reverse Primer Sequence 
Actb 5'- GGT GTG ATG GTG GGA ATG G -3' 5'- TCT CCA TGT CGT CCC AGT TG -3' 
B4galt1 5' TGT CTC TCC TCA CAA GGT GG 3 5' TGG TGT CTC CAG CCT GAT TG 3' 
Gapdh 5'- GCA AAT TCA ACG GCA CAG TC -3' 5'- ATA CTC AGC ACC GGC CTC AC -3' 
Slc35a1 5'- TCT ACA CGT CAG TGG TGG TG -3' 5'- AGC TCC CAG TGC AAA TGA AAG -3' 
St3gal3 5' CTG TGA TGA AGT GGC AGT CG 3' 5' CTC TCG CTG GAT GTT GTG TG 3' 
St3gal4 5'- GAG TGA TAA GAA GCG GGT GC -3' 5'- GCT TGT CTG CTG CAA TCT CC -3' 
St3gal6 5' CCC AAA CAC CCT ACA ACA GG 3' 5' ACA TGG TGG CAT TCC CGT AG 3' 
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3.4 Results 
To study the impact of elevated ammonium on gene expression using a DNA 
microarray, NS0 cells were cultured under four conditions: normal (control), elevated 
ammonium, elevated salt, and elevated ammonium with proline. The elevated salt 
treatment provided an osmolality control, while the proline-addition cultures were 
included because previous elevated ammonium studies in CHO cells showed that a 
proline-addition could reduce ammonium-induced growth inhibition and restore some 
protein glycosylation (Chen and Harcum, 2005). Initially, NS0 were cultured under 10 
mM ammonium, 10 mM salt, 10 mM ammonium with 20 mM proline; however, the 
growth rates of the ammonium-stressed cultures (with and without proline) were only 
approximately one-fifth of the control culture, while the salt-stressed culture growth rate 
was only approximately one-third of the control culture (data not shown). These very 
different growth rates were unquestionably too great to allow for meaningful gene 
expression comparisons, as samples would have to be taken at different culture ages to 
obtain similar cell densities, and the cells would be in very different growth phases. 
Interpretation of data from cultures with multiple growth rate and cell densities 
differences would have required significantly more samples than were available due to 
the high cost of DNA microarrays. Thus, cell growth rates were examined at 5 mM 
ammonium, 5 mM salt, and 5 mM ammonium with 10 mM proline. Previous studies have 
shown that ammonium levels as low as 2 mM can negatively impact glycosylation, thus a 
5 mM ammonium treatment was deemed to have the characteristics representative of 
elevated ammonium (Andersen et al., 1994; Andersen and Goochee, 1995). The growth 
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profiles for NS0 cells cultured under 5 mM ammonium, 5 mM salt, and 5 mM 
ammonium with 10 mM proline are shown in Figure 3.1 for the control and treated 
cultures shown as the average of triplicates with 95% confidence intervals. The ANOVA 
analysis of the growth rates and final cell densities indicated that the culture treatment 
was a significant factor. Further post hoc testing using paired t-tests showed no 
differences for growth rates between the control and treated cultures (p > 0.05); however, 
the paired t-tests did indicate that the final cell densities were different (p ≤ 0.05). The 
final cell densities for the control, 5 mM ammonium, and 5 mM ammonium/10 mM 
proline cultures were all different from each other; however, the final cell densities for 
salt cultures were not different from the control cultures (p > 0.05), and were not different 
from 5 mM ammonium cultures (p > 0.05). The final cell densities for salt cultures were 
also different from the 5 mM ammonium/10 mM proline cultures (p ≤ 0.05). These 
profiles and statistical analysis indicate that the culture conditions were very similar, such 
that growth rate differences would not be a contributing factor in any gene expression 
differences that might be identified and the final cell densities would only be a minor 
factor. 
For the DNA microarray experiments, the 90-h time point (indicated by a vertical 
line in Figure 3.1) was selected for RNA isolation and DNA microarray analysis to 
identify genes sensitive to ammonium in the exponentially growing cultures. The gene 
expression analysis was performed at the 90 h time point to balance several experimental 
constraints. The cultures needed to be in the same growth phase and at similar cell 
densities, where mid-exponential growth was desired. The cell density needed to be  
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 Figure 3.1. Growth profiles for NS0 cells. NS0 cells were  cultured under control, 
elevated ammonium, elevated salt, and elevated ammonium with proline conditions in a 
first-generation HyQ ADCF-Mab media with LS-250 cholesterol. RNA samples were 
taken at 90-h for gene expression analysis by DNA microarrays as shown by the vertical 
line. Error bars represent 95% confidence intervals. 
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sufficiently high to obtain enough total RNA from a single sample (50 mL). And, 
exponential growth after sampling needed to verifiable after sampling, at least another 12 
hours of growth possible in the media. Additionally, due the cost of DNA microarrays, 
only 12 DNA microarrays were available to the project from the Scripps Institute. Thus, 
for four culture conditions to be sampled in triplicate, the experiment was limited to one 
time point. As shown in Figure 3.1, all cultures continued to grow exponentially for at 
least another 12 hours. GeneSpring® was used to analyze the gene expression levels 
using a Welch ANOVA test with a Benjamini and Hochberg false discovery rate 
correction for the four conditions, where each chip was normalized to total intensity. 
Initially, the p-value cut-off was set to p ≤ 0.05; however, at this level no genes were 
determined to be significantly different. Due to the high levels of noise commonly 
observed in biological systems, the p-value cut-off was increased to p ≤ 0.10 and the data 
re-examined; however, even at this level no genes were identified as being significantly 
different between the conditions. In order to better understand why the ANOVA analysis 
was not identifying any significant genes, the p-value was increased to p ≤ 0.99, and all 
genes passed, as expected. The gene with the lowest p-value had a p-value of p = 0.964, 
which indicates no significant difference in gene expression levels between the four 
conditions examined, when gene intensities were normalized to the total chip intensity. 
This means that none of the glycosylation genes had different gene expression levels 
between any of the four conditions. 
Further analysis of the DNA microarray data demonstrated that the Affymetrix 
titrated controls had the expected dynamic range, indicating the gene chips were 
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responsive to sample-level changes. It was also determined that noise was not the reason 
for the high p-values as shown in Figure 3.2 by the high-level of reproducibility of the 
biological replicates and low noise to signal ratio. Figure 3.2 only shows the gene 
expression levels for the twelve glycosylation and two housekeeping genes previously 
examined for CHO cells, as a graph of all 952 unchanged genes would be unreadable 
(Chen and Harcum, 2006). Table 3.2 includes these selected genes with official Mus 
musculus gene names, abbreviations, and Genbank accession number on the GLYCOv3 
DNA microarray and the CHO cell (Cricetulus griseus) homolog, common name, and 
GenBank accession number. The gene expression levels for the NS0 cell culture 
conditions are connected between the conditions only to improve visualization. The 
standard error bars for each condition and gene are shown (and are barely visible for 
some genes). These very small standard error bars support that there are “no significant 
difference” due to the underlying behaviour of the biological system, and not due to a 
high signal-to-noise ratio in the data. Note: the Fut4 and Neu2 genes were identified as 
“Absent”, not expressed, under these conditions in NS0 cells. These two genes are only 
shown to highlight the range of magnitude for gene expression and because these are the 
homologs of the CHO genes previously reported to be sensitive to ammonium. At the 
other extreme are the housekeeping genes, which are commonly among the mostly highly 
expressed genes within an organism. These gene expression data for these glycosylation 
and housekeeping genes demonstrate the well-distributed dynamic range of gene 
expression levels within the study and detected by the DNA microarrays. Thus, as further 
shown in Figure 3.2, no glycosylation-related genes had significantly different gene  
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 Figure 3.2. Gene expression levels for 12 key glycosylation genes and two 
housekeeping genes in NS0 cells. The NS0 cells were cultured under control, elevated 
ammonium, elevated salt, and elevated ammonium with proline conditions in a first-
generation HyQ ADCF-Mab media with LS-250 cholesterol. Data points between the 
culture conditions are connected to assist with visualization only. The Fut4 and Neu2 
genes were “Absent”, i.e., not expressed, under these conditions. Abbreviations are listed 
in Table 3.2. Standard error bars are shown. 
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Table 3.2 Selected M. musculus and Cricetulus griseus glycosylation and 
housekeeping genes. 
Abbreviation Official Name 
GenBank 
Accession # 
(GLYCOv3) 
Gene Name (From Chen 
and Harcum, 2006) 
GenBank 
Accession # 
Actb Actin, beta M12481 Actin U20114.1 
B4galt1 
UDP-Gal:betaGlcNAc 
beta 1,4-galactosyl 
transferase, polypeptide 1 
NM_022305.2 
β(1,4)-
Galactosyltransferase 
(β(1,4)-GT) 
AF318896.1 
Dpm1 dolichol-phosphate (beta-D) mannosyltransferase 1 NM_010072.2 
Dolicholphosphate 
mannose 
synthase (DPMS) 
AF121895.1 
Fut4a fucosyltransferase 4 NM_010242 α(1,3)-Fucosyltransferase (α(1,3)-FT) AF090449 
Gapdh glyceraldehyde-3-phosphate dehydrogenase M32599 
Glyceraldehyde-3-
phosphate 
dehydrogenase (GAPDH) 
X52123.1 
Gnpda1 glucosamine-6-phosphate deaminase 1 NM_011937 
Glucosamine-6-phosphate 
isomerase Mesocricetus 
auratus (G6PI) 
X94699.1 
Gnpnat1 glucosamine-phosphate Nacetyltransferase 1 NM_019425 
UDP-GlcNAc:UDP N-
acetyl-Dglucosamine-1-
phosphate transferase 
(UDP-NAG) 
U09453.1 
Gp1 glucose phosphate isomerase 1 NM_008155 
Glucose phosphate 
isomerase (GPI) Z37977.1 
Mgat1 mannosideacetylglucosaminyltransferase 1 NM_010794.2 
N-acetylglucos-
aminyltransferase 
(NAGAT) 
U65791 
Neu2 a neuraminidase 2 NM_015750 Sialidase U06143.1 
Slc35a1 
solute carrier family 35 
(CMP sialic acid 
transporter), member 1 
NM_011895 CMP-sialic acid transporter (CMPSiaT) Y12074.1 
Slc35a2 
solute carrier family 35 
(UDPgalactose 
transporter), member A2 
AB027147 UDP-galactose transporter (UDPGalT) AF299335.1 
St3gal3b 
ST3 beta-galactoside 
alpha-2,3- 
sialyltransferase 3 
NM_009176.2 NA NA  
St3gal4 
ST3 beta-galactoside 
alpha-2,3- 
sialyltransferase 4 
NM_009178.2 
Gal(β -1,3/4)-GlcNAc-
α(2,3)-sialyltransferase 
IV (α(2,3)-ST) 
AY266675.1 
St3gal6 a,b 
ST3 beta-galactoside 
alpha-2,3- 
sialyltransferase 6 
NM_018784 NA NA 
Ugp2 UDP-glucose pyrophosphorylase 2 AF424698 
UDP-glucosepyrop 
hosphorylase (UDP-GPP) AF004368.1 
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 Table 3.2 (Continued): Selected M. musculus and Cricetulus griseus glycosylation 
and housekeeping genes. Also listed are gene abbreviations, official names, and 
Genbank accession numbers.  
 
a Fut4 , Neu2, and St3gal6 were "Absent", i.e., not expressed as assessed by DNA microarray under the 
condition studied. 
 
b St3gal3 and St3gal6 are only shown quantitatively by real time qRT-PCR 
 
NA – Not Applicable: Gene was not examined in Chen and Harcum, 2006. 
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expression levels between the four conditions examined using the DNA microarray for 
the NS0 cultures. 
As DNA microarrays are not sensitive to small gene expression changes, and to 
confirm these surprising gene expression results, the control and elevated ammonium 
conditions of the experiment were repeated and the gene expression changes were 
analyzed using real-time qRTPCR, an orthogonal and more sensitive gene expression 
quantification method (Canales et al., 2006; Provenano and Mocellin, 2007; Schefe et al., 
2006; Wurmbach, 2009). For the real-time qRT-PCR experimental repeats, several minor 
changes were necessary. Specifically, the protein-free, animal-free media originally used 
for the microarray experiments was no longer available, so the next generation of that 
media was used. The LS-1000 cholesterol supplement was used instead, since the 
previous LS-250 supplement was unavailable. The culture volume was decreased from 
1000 mL to 250 mL, since less total RNA is needed to perform real-time qRT-PCR 
analysis. New NS0 cells were purchased from the European Collection of Cell Cultures 
via Sigma. The second-generation media and LS-1000 supplement resulted in higher 
growth rates and higher final cell concentration for both the control and elevated 
ammonium cultures. Figure 3.3 shows the cell growth profiles for the control and 
elevated ammonium cultures as the average of triplicates with 95% confidence intervals. 
As with the DNA microarray experiment, the control NS0 cultures achieved higher final 
cell concentration than the ammonium-stressed cultures. Three different time points 
during the exponential growth phase were selected for RNA harvesting: 63-h, 66-h, and 
72-h. These time points were chosen to obtain similar cell densities as the NS0 cultures  
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 Figure 3.3 Growth profiles for NS0 cells cultured under control and elevated 
ammonium conditions. NS0 cells were grown in a second-generation ADCF-MAb 
Media with LS-1000 cholesterol. RNA samples for real-time qRT-PCR were taken at 63-
h, 66-h, and 72-h for gene expression analysis as shown by the vertical lines. Error bars 
represent 95% confidence intervals. 
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harvested for the DNA microarray study to allow for more appropriate comparisons. The 
real-time qRT-PCR analysis examined five glycosylation and two housekeeping genes: 
Slc35a1, B4galt1, St3gal3, St3gal4, and St3gal6, where Actb and Gapdh served as 
housekeeping genes for quantification. These five glycosylation genes were selected 
because these genes represent key control reactions that significantly impact a 
biopharmaceuticals efficacy (Damiani et al., 2009; Zhang et al., 1998). Additionally, 
St3gal4 and B4galt1 gene expression was sensitive to ammonium for CHO cells (Chen 
and Harcum, 2006), thus these two genes were thought to be more likely to have 
detectable changes in NS0 than genes that were insensitive to ammonium in CHO cells. 
The Slc35a1 gene product is a membrane protein responsible for nucleotide sugar 
transport into the Golgi (Bill et al., 1998). The B4galt1 gene product catalyses the linkage 
of a galactose onto N-acetylglucosamine on a glycoprotein (Kotani et al., 2001). The 
product of the St3gal3, St3gal4, and St3gal6 genes catalyse the addition of a sialic acid 
on the terminal galactose of a glycoprotein, which increases the efficacy of many 
therapeutic glycoproteins (Bill et al., 1998; Butler and Meneses-Acosta, 2012). The M. 
musculus primer sequences for these seven genes can be found in Table 3.1. 
The normalized gene expression levels for Slc35a1, B4galt1, St3gal3, St3gal4, 
and St3gal6 are shown in Figure 3.4 normalized to Gapdh of the time 63-h control 
cultures. Both Gapdh and Actb did not changed throughout the study (ANOVA, p > 
0.05), as expected. Additionally, there was no statistical difference between the control 
and ammonium cultures at any time point for the five-glycosylation genes, and these gene 
expression levels did not change across the nine hours examined (p > 0.05). To highlight  
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 Figure 3.4 Gene expression for Slc35a1, B4galt1, St3gal3, St3gal4, and St3gal6. 
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Figure 3.4 (Continued). Gene expression for Slc35a1, B4galt1, St3gal3, St3gal4, and 
St3gal6. NS0 cells were cultured under control and elevated ammonium conditions in a 
second generation ADCF-MAb Media with LS-1000 cholesterol. The normalized gene 
expression levels for the glycosylation genes A) Slc35a1, B) B4galt1, C) St3gal3, D) 
St3gal4, and E) St3gal6 assessed by real-time qRT-PCR. Gene expression levels were 
analyzed at 63-h, 66-h, and 72-h, and were normalized to the 63-h time point and Gapdh. 
Error bars represent 95% confidence intervals. The dark gray bars represent control 
cultures, while the white bars represent the elevated ammonium cultures. 
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 Table 3.3 Statistics on gene expression levels. The t-tests between the control and 
ammonium-treated cultures for the five genes determined that the gene expression levels 
were not different (p > 0.05). The p-values are listed for each pairs for the three time 
points examined, which correspond to the error bars shown in Figure 3.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Significance level (p-value) 63-h 66-h 72-h 
B4galt1 0.89 0.33 0.26 
Slc35a1 0.89 0.16 0.51 
St3gal3 0.33 0.60 0.37 
St3gal4 0.62 0.85 0.96 
St3gal6 0.97 0.85 0.87 
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 that these gene expression levels were not different, Table 3.3 lists the p-values for the 
paired t-test p-valves for each time point. Additionally, the relative expression levels of 
the St3gal3, St3gal4, and St3gal6 genes real-time qRT-PCR was consist with the relative 
levels observed by DNA microarrays, where the expression levels were St3gal4 > 
St3gal3 >> St3gal6. Thus, real-time qRT-PCR analysis demonstrates that NS0 cells are 
not sensitive to 5 mM ammonium with respect to these five glycosylation-related genes. 
And, the real-time qRT-PCR results confirm the DNA microarray results as accurate, 
where the DNA microarray analysis demonstrated that none of the known glycosylation-
related genes were sensitive in NS0 cells at 5 mM ammonium. 
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3.5 Discussion 
Gene expression studies have been conducted on both NS0 and hybridoma cells 
lines under hyperosmotic pressure (Gao et al., 2004; Shen and Sharfstein, 2006). Wu et 
al. (2004) examined antibody production in NS0 cells, while Shen and Sharfstein (2006) 
investigated gene expression changes in OKT3 cells, a hybridoma line, due to 
hyperosmolality (Shen and Sharfstein, 2006; Wu et al., 2004). Wu et al. (2004) focused 
their analysis on the cell physiology, thus providing few specific gene details; however, 
they did report that three carbohydrate genes were upregulated while one carbohydrate 
gene was down-regulated. Shen and Sharfstein (2006) used the Affymetrix Gene Chip 
MOE430A, which contains over 14,000 genes and 4000 EST probe sets. The GLYCOv3 
and MOE430A Chips have 482 genes in common. Of these, only two of the incommon 
genes were identified as sensitive to hyperosmolality in OKT3 cells (glucosamine-6- 
phosphate deaminase, and hexokinase 1, GenBank accession nos. NM_011937 and 
NM_010438, respectively). If the responses were proportional to the stress introduced, 
then the much lower osmotic level used in this NS0 cell study was unlikely to cause 
changes in gene expression that were significant enough to detect, as these genes only 
changed 2-fold under the hyperosmotic stress. 
 The NS0 cells used in this study did not produce a recombinant protein. A study 
that compared non-producing (parental) and producing (monoclonal antibody) strains of 
NS0 cells using DNA microarrays identified 104 genes with differential gene expression 
(Khoo et al., 2007). The functional annotation of these genes determined that the 
differentially expressed genes were involved in protein synthesis, lipid metabolism, and 
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cell cycle regulation; however, none of these affected genes were glycosylation-related. 
The absence of glycosylation-related genes sensitive to ammonium in the current study 
cannot be entirely attributed to the non-producing status of the strain; however, it is 
recognized that any genetic modifications could influence the cells’ response to elevated 
ammonium. Consequently, the current study provides a baseline for future quantification 
of the effects of elevated ammonium on recombinant NS0 cells. Sodium butyrate is cell 
culture media additive than increases productivity, yet has been observed to have variable 
effects on protein glycosylation where most studies have been conducted only with CHO 
cells (Chen et al., 2011; Chung et al., 2001; Cost et al., 2010; Crowell et al., 2008; 
Etchevarry and Ryll, 1998; Hong et al., 2011; Hossler et al., 2009; Lee et al., 2014; Liu et 
al., 2014; Mohan and Lee, 2009; Sung and Lee, 2005; Sunley and Butler, 2010; Yee et 
al., 2008a; Yee et al., 2008b). The effects of sodium butyrate on gene expression have 
been examined in both CHO and NS0 cell using two CHO cell and mouse DNA 
microarrays developed in-house (Gatti et al., 2007). Both CHO and NS0 cells were 
studied with cross-species DNA microarray hybridization, in addition to the species-
specific DNA microarray hybridization. These studies were conducted to corroborate 
physiology and gene expression observations (Gatti et al., 2007). Both in-house DNA 
microarrays contained glycosylation-related genes (Korke et al., 2004; Wlaschin et al., 
2005); however, which is unknown. Interestingly, their gene expression analysis did not 
identify any glycosylation-related genes with significant expression changes due to 
sodium butyrate in the CHO and NS0 cell lines (Gatti et al., 2007). More recently, 52 
glycosylation-related gene expression levels have been quantified in recombinant CHO 
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cells under sodium butyrate (Lee et al., 2014). Despite several biosynthetic genes having 
slightly higher levels under sodium butyrate, the glycoprotein most likely had poorer 
quality due to increased sialidase (Neu1) gene expression levels and lower b4galt2 and 
st3gal3 levels, both critical sialic acid biosynthesis genes (Lee et al., 2014). These 
differences in gene expression responses might be attributable to the nature of these cells. 
NS0 cells are a cancer cell line, while CHO cells, despite being immortal are not a 
cancerous cell line (Wlaschin et al., 2006). 
The detrimental effects of ammonium on cell growth, protein productivity, and 
protein glycosylation has results in studies to reduce the major source of ammonium, the 
glutamine. Early studies that controlled glutamine with fed-batch techniques, reported 
decreased protein glycosylation quality (Wong et al., 2005). These early results selected 
the target glucose and glutamine levels arbitrary, where is possible, their early targets in 
the ground breaking approach were just too low, but their approach was correct (Young, 
2013). Other research groups have replaced the glutamine with alternative sources 
concurrent with reducing the levels in CHO cell cultures with improved results or 
adapted cells to growth in glutamine-free media (Kim et al., 2013; Taschwer et al., 2012). 
And more recently, three different TCA cycle intermediates, α-ketoglutarate, citric acid, 
and succinic acid, were examined for recombinant CHO cells to reduced ammonia 
accumulation in culture medium (Ha and Lee, 2014). The α-ketoglutarate replacement 
decreased the growth rate, but also increased sialylation and decrease ammonium 
accumulation. The observed sialylation increase was correlated with increased ST3gal 
and decreased Neu enzyme activity (Ha and Lee, 2014). Interestingly, the relative 
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abundance of the Neu1, Neu2, and Neu3 genes shown in Kim et al., 2013 are 
significantly different than the relevant abundance of the Neu1, Neu2, and Neu3 proteins 
shown in Ha and Lee, 2014 for the control cultures, albeit the studies are from the same 
laboratory with different CHO cell host cell lines. These results demonstrate that gene 
expression and protein levels are not always proportional. Taken together, the gene 
expression results for NS0 cells and the glutamine substitution outcomes for CHO cells 
suggest that enzyme or substrate-level control is likely a very significant factor with 
respect to ammonium affects on protein glycosylation in NS0 cells. 
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3.6 Conclusion 
Sialyltransferase gene expression was anticipated to be significantly different 
between the control and elevated ammonium cultures for the NS0 cells (Chen and 
Harcum, 2006), since previous NS0 cell culture experiments observed elevated 
intracellular nucleotide sugar pools in NS0 cells compared to CHO cells (Baker et al., 
2001). Also, it was anticipated that other glycosylation genes would be identified as 
ammonium-sensitive by the NS0 cell experiments, since ammonium adversely affects 
protein glycosylation. However, the results of this work indicate that the ammonium-
sensitivity in NS0 cells for protein glycosylation is not at the gene expression level. Thus, 
the further studies should focus on translational and substrate-level control as the 
mechanism by which elevated ammonium impacts protein glycosylation changes in NS0 
cells. 
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CHAPTER FOUR: EXPANSION OF MESENCHYMAL STEM CELLS  
UNDER ATMOSPHERIC CARBON DIOXIDE 
 
4.1 Abstract 
Stem cells are needed for an increasing number of scientific applications, 
including both fundamental research and clinical disease treatment. To meet this rising 
demand, improved expansion methods to generate high quantities of high quality stem 
cells must be developed. Unfortunately, the bicarbonate buffering system – which relies 
upon an elevated CO2 environment – typically used to maintain pH in stem cell cultures 
introduces several unnecessary limitations in bioreactor systems. In addition to artificially 
high dissolved CO2 levels negatively affecting cell growth, but more importantly, the 
need to sparge CO2 into the system complicates the ability to control culture parameters. 
This control is especially important for stem cells, whose behavior and phenotype is 
highly sensitive to changes in culture conditions such as dissolved oxygen and pH. As a 
first step, this study developed a buffer to support expansion of mesenchymal stem cells 
(MSC) under an atmospheric CO2 environment in static cultures. MSC expanded under 
atmospheric CO2 with this buffer achieved equivalent growth rates without adaptation 
compared to those grown in standard conditions and also maintained a stem cell 
phenotype, self-renewal properties, and the ability to differentiate into multiple lineages 
after expansion. 
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4.2 Introduction 
Stem cells offer much potential for scientific applications. In addition to enabling 
insights into developmental biology, pathology, and toxicology, stem cells also show 
promise in treating human ailments such as spinal cord injuries, myocardial infarction, 
Parkinson’s, type I diabetes, and sickle cell anemia (Berry et al., 2006; Hanna et al., 
2007; Ashton et al., 2011; Fernandes Platzgummer et al., 2011; Kinney et al., 2011; 
Olmer et al., 2012; Serra et al., 2012; Alfred et al., 2011; Rodrigues et al., 2011). Many 
treatments require large quantities of stem cells, but currently there are no readily 
available sources that can meet these high demands (Fernandes Platzgummer et al., 2011; 
Kinney et al., 2011; Zweigerdt, 2009; Shafa et al., 2011; Ratcliffe et al., 2012). 
Consequently, in vitro expansion methods must be developed to generate high numbers 
of stem cells (Kinney et al., 2011; Serra et al., 2012; Alfred et al., 2011; Shafa et al., 
2011; Yeatts et al., 2013; King and Miller 2007; Grolms et al., 2011). In addition to high 
quantities, maintaining high quality in stem cell yields is equally important to maximize 
treatment responses (Serra et al., 2012; King and Miller, 2007). The stem cell niche —
consisting of factors such as oxygen tension, pH, and mechanical forces — influences the 
behavior of stem cells and dictates whether the stem cells will proliferate, differentiate, or 
undergo apoptosis (Ashton et al., 2011; Serra et al., 2012; Yeatts et al., 2013; Grolms et 
al., 2011; Papoutsakis, 2009; Wuertz et al., 2009; Frith et al., 2009; dos Santos et al., 
2010). Learning how these various factors regulate stem cell fate in vivo, and then 
constructing systems that can replicate the desired conditions in vitro will be crucial 
(Ashton et al., 2011; Yeatts et al., 2013). Through development of cost-efficient methods 
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that allow maintenance of optimal culture parameters during in vitro expansion, it may be 
possible to more effectively direct stem cell yields and enhance the clinical success of 
stem cell-based therapies (Rodrigues et al., 2011; Shafa et al., 2011; Yeatts et al., 2013). 
Stirred systems—in particular fed-batch, computer-controlled bioreactors—are 
capably equipped to deliver high quantities of high quality mammalian cells due to 
operational flexibility (Fernandes Platzgummer et al., 2011; Olmer et al., 2012; Ratcliffe 
et al., 2012; Yeatts et al., 2013; King and Miller 2007; Grolms et al., 2011; Schroeder et 
al., 2005). Bioreactors, where CO2 sparging is used for pH control, support the expansion 
of mammalian cells in suspension (Fernandes Platzgummer et al., 2011; Rodrigues et al., 
2009). Expansion of anchorage-dependent cells, such as mesenchymal stem cells (MSC), 
can also be achieved with the use of microcarriers in stirred bioreactors (Serra et al., 
2012; Alfred et al., 2011; Rodrigues et al., 2011; Sart et al., 2011). Through dynamic 
monitoring and online control of parameters, stirred bioreactors can enable culture 
conditions to be maintained within a desired range (Fernandes Platzgummer et al., 2011; 
Olmer et al., 2012; Rodrigues et al., 2011; Ratcliffe et al., 2012; Grolms et al., 2011; 
Schroeder et al., 2005). Additionally, bioreactors allow for scalability that is simply not 
possible with other culture formats, potentially paving the way for delivery of the large 
numbers of stem cells required for widespread clinical use (Olmer et al., 2012; Ratcliffe 
et al., 2012; Grolms et al., 2009). However, the bicarbonate buffering system used to 
regulate pH appears to be limiting the potential of stem cell expansion as it can hinder the 
ability of stirred bioreactors to provide a highly consistent culture pH environment 
(Rodrigues et al., 2011; Rodrigues et al., 2009; Goudar et al., 2006). The bicarbonate 
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buffering system relies on the equilibrium between the CO2 gas sparged into the 
bioreactor and the dissolved CO2 (dCO2) in the medium, which is maintained well above 
physiological levels and can negatively affect cell growth and behavior (Rodrigues et al., 
2009; Goudar et al., 2006; Pattison et al., 2000; Zhang et al., 2010). This situation is 
compounded by the production of CO2 by metabolically active cells (Goudar et al., 
2006). Previous efforts have been undertaken to remove excess dCO2 from the bioreactor 
by adjusting the sparging profile; however, the coupling of the CO2 supply to the oxygen 
supply complicates both dissolved oxygen and pH control (Goudar et al., 2006; Hu et al., 
2011). This mutual dependency leads to recurring cyclic fluctuations of both dissolved 
oxygen and pH in bioreactors as efforts to regulate one inadvertently affects the other 
(Olmer et al., 2012; Rodrigues et al., 2011; Grolms et al., 2009; Rodrigues et al., 2009; 
Zhang et al., 2010; Yang et al., 2007; Osman et al., 2001). Other approaches to remove 
dCO2 have modified the size of sparged bubbles, but this can compromise oxygen 
transfer (Hu et al., 2011). Thus, methods to independently control dissolved oxygen and 
pH may enable bioreactor systems to improve stem cell expansion as stem cells are 
extremely sensitive to fluctuations in both dissolved oxygen and pH (Ashton et al., 2011; 
Rodrigues et al., 2011; Grolms et al., 2009; Wuertz et al., 2009; dos Santos et al., 2010). 
One simple method to reduce the dependence between dissolved oxygen and pH control 
in mammalian cell culture is to decrease or eliminate the bicarbonate buffer’s role in pH 
buffering. This would allow atmospheric CO2 levels to be used in the air/oxygen sparging 
supplies. Several groups have developed media to support mammalian cell lines under an 
atmospheric CO2 environment. Leibovitz (1963) developed the L-15 medium, which uses 
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an amino acid buffer in addition to substituting galactose for glucose, for use in 
mammalian cell culture (Leibovitz, 1963). Battista and Weiss (1991) developed a 
medium for Chinese hamster ovary cells and baby hamster kidney (BHK) cells; however, 
it is not appropriate for undifferentiated stem cell expansion, due to the presence of β-
glycerophosphate, which induces osteogenesis (Battista and Weiss, 1991; Fiorentini et 
al., 2011). Goudar et al. (2006) developed a 3-(N-morpholino) propanesulfonic acid 
(MOPS)-histidine buffer for BHK cells; however, the low pH of 6.8 makes it too acidic 
for stem cells (Goudar et al., 2006). Swain and Pool (2009) investigated the use of 
various nonbicarbonate buffers in Tyrode’s solution, composed of salt and glucose, for 
potential use with in vitro fertilization, although they did not culture cells in their 
proposed buffer (Swain and Pool, 2009). To our knowledge, attempts to expand stem 
cells under an atmospheric CO2 environment have not been conducted. 
The overall aim of this study was to develop a buffer system for a stem cell 
medium that de-emphasized CO2-dependent pH buffering and to ensure that MSC 
expanded in this medium under atmospheric CO2 behaved similarly to those expanded 
under standard conditions. These initial studies were conducted in static cultures; 
however, by eliminating the need for elevated CO2 sparging, large-scale stem cell 
expansion could potentially be improved by preventing excessive dCO2 levels, as well as 
enabling simpler controls to increase batch-to-batch reproducibility. The first goal of this 
study was to determine whether MSC could be effectively expanded under atmospheric 
CO2 levels as this has not yet been investigated. L-15 medium and various combinations 
of MOPS-4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered media 
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were examined to select a medium buffer that maintained growth rates and final cell 
densities comparable to the standard buffer conditions without any prior adaptation 
period. One MOPS-HEPES buffered medium was selected to address the subsequent 
goals, where the second goal was to determine whether MSC maintained an 
undifferentiated state and self-renewal ability when cultured in the MOPS-HEPES 
buffered medium under atmospheric CO2 without prior adaptation. Histological staining 
and stem cell-associated gene expression markers were compared for the undifferentiated 
MSC cultured under the standard conditions and the MOPS-HEPES buffered medium 
under atmospheric CO2. The third goal of the study was to assess the differentiation 
potential of the MSC expanded under atmospheric CO2. Histological staining and 
multiple lineage gene expression markers were compared for differentiated MSC that 
were previously expanded under the standard conditions or in the MOPS-HEPES 
buffered medium under atmospheric CO2. Finally, the fourth goal was to determine 
whether MSC growth rates and stemness were maintained through multiple passages in 
the MOPS-HEPES buffer under atmospheric CO2. 
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4.3 Materials and Methods 
MSC Expansion 
Undifferentiated mouse MSC (Gibco) were maintained as anchorage-dependent 
monolayers in T-75 flasks (Nunc) under 5% CO2 at 37°C in minimal essential medium-a 
(MEM-α) (Gibco), which was supplemented with 10% fetal bovine serum (FBS) 
(Gibco). For our custom compositions developed for atmospheric CO2 conditions, MOPS 
and HEPES were added as buffering components, while sodium hydroxide was used to 
adjust the initial pH. Leibovitz L-15 medium was also supplemented with 10% FBS. For 
growth rate comparisons, undifferentiated MSC were initially seeded into 6-well plates 
(Nunc) at 3.8 x 104 cells/well, corresponding to 4.0 x 103 cells/cm2. Warmed medium was 
added to the wells (1.5 x 103 cells/mL). Plates were incubated under 5% CO2 or 
atmospheric CO2 at 37°C. Cell growth in all three media was measured at five time 
points over 57 h. Five parallel sets of cultures were grown for each condition. One set of 
cultures was harvested at each time point. Each data point represents distinct independent 
cultures in triplicate. Cell densities were quantified using the Scepter 2.0 Handheld 
Automated Cell Counter (Millipore). 
 
MSC Differentiation 
For the differentiation experiments, undifferentiated MSC were grown for 48 h in 
T-75 flasks at 37°C. The undifferentiated MSC were seeded at 4.0 x 103 cells/cm2 in 
either the standard medium or MOPS-HEPES buffered medium. The standard medium 
cultures were incubated under 5% CO2, while the MOPS-HEPES buffered medium 
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cultures were incubated under atmospheric CO2. The undifferentiated MSC were 
harvested and used to examine differentiation along the adipogenic, osteogenic, and 
chondrogenic lineages. The StemPro Differentiation kits (Gibco) were used following the 
manufacturer protocols. All differentiation cultures were incubated under 5% CO2 and 
harvested at 16 days for analysis by histological staining and gene expression. The MSC 
differentiation cultures were conducted in four triplicate sets, one set for each of the 
histological staining and qRT-PCR analysis. 
 
Extended MSC Expansion 
Undifferentiated MSC were seeded at 4.0 x 103 cells/cm2 in either the standard 
growth medium under 5% CO2 or the MOPS-HEPES buffered growth medium under 
atmospheric CO2. One T-75 flask was used to seed 3 six-well plates in parallel for end-
point cell density analysis and a single T-75 flask for subsequent passages. MSC were 
passaged every 60 h for five passages, which corresponds to approximately 75% 
confluent and a 6.25-fold expansion at the end of each passage. 
 
Histological Staining 
Osteogenic activity was measured using the Alkaline Phosphatase Detection Kit 
(Milipore). HCS LipidTox Green neutral lipid stain (Molecular Probes) was used to 
detect the presence of lipids in the adipogenic cultures. The adipocyte samples were 
mounted in SlowFade Gold Antifade reagent with DAPI (Molecular Probes), and imaged 
using an Eclipse Ti Confocal microscope. Alcian Blue (Poly Scientific) was used to stain 
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glycosaminoglycans in the chondrogenic cultures. Chondrogenic and osteogenic samples 
were mounted using Permount (Fisher Scientific) and imaged using the Nikon AZ 100 
Multizoom microscope. 
 
Real time qRT-PCR 
Total RNA was extracted from triplicate undifferentiated T-75 flask cultures or 
triplicate differentiated T-25 flask cultures. The RNeasy Mini Kit (Qiagen) was used 
following manufacturer’s protocol. cDNA was synthesized by Super-Script III First-
Strand Synthesis System for RT-PCR (Invitrogen) with 200 ng total RNA. RT2 SYBR® 
Green qPCR Mastermix (SABiosciences) was used for qPCR analysis with MyiQ Optical 
System Software Version 1.0 (Bio-Rad). Further data analysis was conducted using Real-
time PCR Miner software (UC Berkeley). Normalized gene expression values were 
obtained using the method previously outlined (Chen and Harcum, 2006). The primer 
sequences are listed in Table 4.1. 
 
Statistical Analysis 
Statistical analysis of the growth rates, final cell densities, and gene expression 
data was performed with SAS 9.3 using the general linear model procedure for the final 
cell densities and gene expression levels (p ≤ 0.05) and the regression procedure for the 
growth rate data (p ≤ 0.05). 
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Table 4.1 PCR primer sequences for analysis of MSC. 
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4.4 Results and Discussion 
Formulation of a CO2-independent medium 
Initially, the growth rate of undifferentiated MSC was evaluated in MEM-α 
buffered with various concentrations of MOPS and HEPES under atmospheric CO2 by 
endpoint assessment of cell densities. The range of MOPS and HEPES investigated were 
12 to 18 mM. The cell densities using MOPS and HEPES were compared to the cell 
densities obtained from the standard conditions using a common seed culture. Many of 
the MOPS and HEPES combinations could achieve cell densities equal to that attained in 
the standard medium under 5% CO2 (data not shown). The MOPS-HEPES buffered 
medium selected to be examined further contained 12 mM MOPS, 12 mM HEPES, and 5 
mM sodium bicarbonate (NaHCO3). This formulation was selected to minimize the 
potential cytotoxic effects associated with HEPES buffer (Zigler et al., 1985). A low level 
(5 mM) of NaHCO3 was added to the MOPS-HEPES buffered medium, because 
bicarbonate is reported to be an essential cell nutrient for mammalian cells (Swim and 
Parker, 1958).  
There are several considerations when formulating a buffer for MSC expansion 
under atmospheric CO2. Due to the multipotency of MSC, it is crucial that none of the 
buffering components interfere with the normal behavior of undifferentiated MSC during 
expansion. For instance, the β-glycerophosphate in Invitrogen’s CO2 independent-
medium can induce osteogenesis, and therefore does not promote maintenance of an 
undifferentiated MSC phenotype (Battista and Weiss, 1991; Fiorentini et al., 2011). At 
the same time, the behavior of MSC is highly pH-dependent, so the buffering 
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components must have sufficient buffering capacity within the desired pH range (Wuertz 
et al., 2009). As Swain and Pool (2009) pointed out, pH buffering must also be 
accomplished with buffer concentrations that are low enough to avoid cytotoxicity 
(Swain and Pool, 2009). Their work demonstrated that buffers used in combination allow 
for lower concentrations without compromising buffering capacity, a principle that was 
used in our work. In short, the buffering components to be substituted for bicarbonate 
must maintain pH effectively within a precise range while not altering the health or 
phenotype of the MSC. 
 
Undifferentiated MSC can be effectively expanded under an atmospheric CO2 
environment while retaining stem cell characteristics 
To evaluate the growth rates and final cell densities, undifferentiated 
MSC were first expanded in standard MEM-α medium under 5% CO2 and this common 
stock was used to seed subsequent cultures. The undifferentiated MSC were then grown 
in the standard MEM-α medium and the MOPS-HEPES buffered MEM-α medium under 
both 5% and atmospheric CO2 environments without prior adaptation. Additionally, the 
undifferentiated MSC were grown under atmospheric CO2 in Leibovitz L-15 medium. 
The L-15 medium was designed to support CO2-independent growth of mammalian cells, 
but is now mainly used to grow specific cancer cell lines and buffer solutions while 
performing analysis of cells under atmospheric conditions (Leibovitz, 1963; Maffia et al., 
2007; Mantegazza et al., 2008). To date, Leibovitz L-15 medium has not been 
investigated for stem cell expansion. As expected, the cultures grown in the standard 
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MEM-α medium under 5% CO2 had exponential growth without a lag phase, and the 
cultures grown in the MEM-a standard medium under atmospheric CO2 failed to grow 
(Figure 4.1A). In contrast, cultures grown in Leibovitz L-15 medium under atmospheric 
CO2 had observable growth, albeit at a lower rate. The lower growth rate in the L-15 
medium was most likely due to the medium’s buffering system and carbon energy source. 
The L-15 medium relied on high amino acid concentrations to provide buffering capacity. 
Elevated amino acids are not always problematic, but it has been observed that some 
amino acids in elevated concentrations reduce growth rates in mammalian cells (Chen 
and Harcum, 2005; Xing et al., 2011). Specifically, the L-15 medium contained 225 mM 
alanine compared to 25 mM in the standard MEM-a medium (Leibovitz, 1963). The L-15 
medium also substitutes galactose for glucose. Galactose has been implicated in shifting 
cell metabolism from a predominantly glycolytic state to one relying more on oxidative 
phosphorylation in several cell lines (Higuera et al., 2011; Aguer et al., 2011). Actively 
growing cells appear to rely more heavily on glycolysis than oxidative phosphorylation 
for energy production (Kinney et al., 2011; dos Santos et al., 2010; Pattappa et al., 2011), 
which means galactose may not be a suitable primary carbon source for maintaining high 
growth rates. Thus, the lower growth rates associated with MSC in the L-15 medium is 
hypothesized to be due to the presence of high amino acid levels and the use of galactose 
instead of glucose. 
The undifferentiated MSC cultures grown in the MOPS-HEPES buffered medium 
under 5% CO2 grew better than in Leibovitz L-15 medium (p ≤ 0.05), but still at a 
suboptimal rate. The decreased growth rate in the MOPS-HEPES buffered medium under 
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 Figure 4.1 Proliferation of MSC. A: Growth profiles for MSC cultured in a standard 
medium, a MOPS-HEPES buffered medium under both 5% and atmospheric CO2 
conditions as well as the Leibovitz L-15 medium under atmospheric CO2. B: Negative 
control staining for lineage-specific markers in undifferentiated MSCs cultured in MOPS-
HEPES buffered medium for 48-h. C: Oct4 normalized gene expression levels for 
undifferentiated MSCs cultured in the standard medium in 5% CO2 (Std) and the MOPS-
HEPES buffered medium in atmospheric CO2 (M-H) for 48-h as indicated in panel A. 
Error bars represent 95% confidence intervals. 
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5% CO2 can be attributed to the low culture pH. More importantly, the undifferentiated 
MSC cultures grown in the MOPS-HEPES buffered medium under atmospheric CO2 had 
exponential growth without a lag phase. The observed growth rates for the 
undifferentiated MSC in standard medium under 5% CO2 and the MOPS-HEPES 
buffered MEM-α medium under atmospheric CO2 were not significantly different (p > 
0.05) with observed growth rates of 0.033 h-1; which corresponds to a doubling time of 
21-h. These results indicate that undifferentiated MSC can be expanded in MOPS-
HEPES buffered MEM-α medium under atmospheric CO2 at an equivalent rate to 
undifferentiated MSC in standard MEM-α medium under a 5% CO2 environment, and 
also achieve final cell densities that are not significantly different. 
While growth rates were equivalent for the undifferentiated MSC cultured in the 
standard MEM-α medium under 5% CO2 and the MOPS-HEPES buffered MEM-α 
medium under atmospheric CO2, equally important is that the MSC maintained an 
undifferentiated state and self-renewal abilities. The phenotype and multipotency of 
undifferentiated MSC were assessed for MSC expanded for 48 h in the standard MEM-α 
medium under 5% CO2 and the MOPS-HEPES buffered MEM-α medium under 
atmospheric CO2. First, undifferentiated MSC were stained for markers of adipogenic, 
osteogenic, and chondrogenic differentiation after expansion as negative controls. The 
histological staining of the undifferentiated MSC showed absence of lineage markers 
(Figure 4.1B), as expected, suggesting no gross signs of differentiation for both 
conditions. Only the MSC cultured in the MOPS-HEPES buffered MEM-α medium 
under atmospheric CO2 negative control stainings are shown (Figure 4.1B), as the MSC 
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cultured in the standard MEM-a medium under 5% CO2 were not significantly different 
from negative control the images provided in the standard staining protocol. The negative 
control stainings for the undifferentiated MSC cultured in the MOPS-HEPES buffered 
MEM-a medium under atmospheric CO2 can be compared with the positive control 
stainings shown in Figure 4.2A, 4.3A, and 4.4A. Second, the MSC were analyzed for a 
gene marker indicative of an undifferentiated stem cell state after expansion. Gene 
expression levels for Oct4 (p = 0.75) (Figure 4.1C) were not significantly different 
between undifferentiated MSC cultured in either the standard MEM-α medium under 5% 
CO2 and the MOPS-HEPES buffered MEM-a medium under atmospheric CO2, 
representing a similar extent of stemness. 
These results indicate that undifferentiated MSC can be expanded under 
atmospheric CO2 without compromising growth rates or the stem cell phenotype as 
determined by gene expression markers, and supported by the undifferentiated appear 
under histological staining. This is important because many MSC-based treatments rely 
on undifferentiated MSC. Even in applications where the differentiated progeny of MSC 
are desired, differentiation is typically induced after initial expansion generates a 
sufficient quantity of undifferentiated MSC (Sart et al., 2011). These results indicate that 
MSC can be effectively expanded without prior adaptation to the MOPS-HEPES buffer 
and atmospheric CO2 conditions. The lack of an adaptation phase would allow for easier 
translation to clinical applications. 
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MSC retain multilineage differentiation potential after prior expansion under 
atmospheric CO2 
In order to characterize the differentiation potential of MSC cultured under 
atmospheric CO2, cells were obtained from T-75 flasks that had been cultured for 48 h in 
either the standard MEM-α medium under 5% CO2 or the MOPS-HEPES buffered 
MEM-a medium under atmospheric CO2. These MSC were then differentiated along the 
adipogenic, osteogenic, and chondrogenic lineages under 5% CO2 to assess multipotency. 
As shown in Figure 4.2A, staining for lipid vesicle formation indicated a similar extent of 
adipogenic differentiation between the two conditions. Also, adipogenic gene expression 
levels for lipoprotein lipase (p = 0.095), PPARγ2 (p = 0.86), and C/EBPα (p = 0.47) were 
not significantly different between the two conditions (Figure 4.2B). As shown in Figure 
4.3A, staining for alkaline phosphatase activity indicated a similar extent of osteogenic 
differentiation between the two conditions. Also, osteogenic gene expression levels for 
collagen I (p = 0.89), osteonectin (p = 0.088), and CBFα1 (p = 0.99) were not 
significantly different between the two conditions (Figure 4.3B). As shown in Figure 
4.4A, staining for glycosaminoglycan production indicated a similar extent of 
chondrogenic differentiation between the two conditions. Also, chondrogenic gene 
expression levels for collagen II (p = 0.22), aggrecan (p = 0.55), and Sox9 (p = 0.94) 
were not significantly different between the two conditions (Figure 4.4B). These results 
demonstrate that the tri-lineage differentiation potential of undifferentiated MSC along 
the adipogenic, osteogenic, and chondrogenic lineages were not impacted by prior 
expansion in the MOPS-HEPES buffered medium under atmospheric CO2.
 114 
 Figure 4.2. Adipogenic differentiation of MSC. A: Histological staining of MSC 
cultured in a standard medium under 5% CO2 (Std) and in a MOPS-HEPES buffered 
medium under atmospheric CO2 (M-H). The stain HCS LipidTox was used to visualize 
lipids (green) and DAPI was used to visualize the nuclei (blue). B: Lipoprotein lipase, 
PPARγ2, and C/EBPα normalized gene expression levels in adipogenically differentiated 
MSC. Error bars represent 95% confidence intervals. 
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 Figure 4.3 Osteogenic differentiation of MSC. A: Histological staining of MSC 
cultured in a standard medium under 5% CO2 (Std) and in a MOPS-HEPES buffered 
medium under atmospheric CO2 (M-H). The stains FRV and Napthol Phosphate were 
used to visualize alkaline phosphatase activity in pink. B: Collagen I, Osteonectin, and 
CBFα1 normalized gene expression levels in osteogenically differentiated MSC. Error 
bars represent 95% confidence. 
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 Figure 4.4 Chondrogenic differentiation of MSC.  A: Histological staining of MSC 
cultured in a standard medium under 5% CO2 (Std) and in a MOPS-HEPES buffered 
medium under atmospheric CO2 (M-H). The stain Alcian Blue was used to visualize 
glycosaminoglycans in blue. B: Collagen II, Aggrecan, and SOX9 normalized gene 
expression levels in chondrogenically differentiated MSC. Error bars represent 95% 
confidenceintervals. 
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Undifferentiated MSC retain expansion potential and stem cell characteristics after 
multiple passages under atmospheric CO2 
While expanding MSC effectively without prior adaptation to the MOPS-HEPES 
buffer and atmospheric CO2 enables easier translation to clinical applications, prolonged 
expansion may be required to generate larger quantities of undifferentiated stem cells. To 
this end, serial passages of undifferentiated MSC were conducted. Both the standard 
medium under 5% CO2 and the MOPS-HEPES buffered medium under atmospheric CO2 
were examined for five passages. To ensure that growth rates were maintained in the 
exponential phase, the cultures were only expanded to approximately 75% confluent at 
the 60-h time point representing a potential fold-expansion in each passage of 6.25-fold. 
The final cell densities for all five passages were not significantly different between MSC 
expanded in the standard medium under 5% CO2 and the MOPS-HEPES buffered 
medium under atmospheric CO2 (p > 0.05) (Figure 4.5A). Additionally, the final cell 
densities were not different between the passages (p > 0.05). These end-point cell 
densities correspond to an overall growth rate of 0.031 h-1 over 60-h, which is not 
statistically different (p > 0.05) from the 57-h overall growth rates observed for the 
passage 1 MSC cultured in the standard medium under 5% CO2 and the MOPS-HEPES 
buffered medium under atmospheric CO2 (Figure 4.1A). Gene expression levels for Oct4 
were not significantly different for the undifferentiated MSC expanded in the standard 
medium under 5% CO2 and the MOPS-HEPES buffered medium under atmospheric CO2 
after passage five (p > 0.05) (Figure 4.5B). It has been previously shown that MSC 
growth rates change in vitro after only five passages (Wall et al., 2007), thus maintenance 
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 Figure 4.5  Extended MSC expansion. A: End-point cell density analysis for 
undifferentiated MSC through five passages cultured in a standard medium under 5% 
CO2 (Std) and in a MOPS-HEPES buffered medium under atmospheric CO2 (M-H). B: 
Oct4 normalized gene expression for undifferentiated MSC after passage 5. Error bars 
represent 95% confidence intervals. 
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 of growth rate in the MOPS-HEPES buffer under atmospheric CO2 for this duration 
would meet current expected outcomes. Additionally, in vitro MSC growth rates are a 
highly sensitive indicator of stemness and were shown to decrease prior to changes in 
differentiation markers (Wall et al., 2007). It has been previously shown that Oct4 gene 
expression levels are highly correlated with a more primitive stem cell-like state capable 
of extended proliferation, increased colony forming potential, and multilineage 
differentiation. For example, hypoxia increased MSC stemness as determined by the 
potential for proliferation, colony formation, and differentiation and coincided with the 
upregulation of Oct4 and Rex-1 gene expression (Grayson et al., 2006). In addition, 
overexpression of Oct4 and Nanog were shown to enhance stem cell properties in MSC 
as determined by proliferation and differentiation potential, while knockdown of Oct4 
and Nanog decreased proliferation and differentiation potential (Tsai et al., 2012). 
Therefore, the similar Oct4 expression levels and similar growth patterns that were 
observed indicate similar levels of stemness between the MSC grown in 5% CO2 and 
those MSC grown in atmospheric CO2. 
 
Potential impacts of CO2 independence on large-scale stem cell expansion in stirred 
bioreactors 
Stirred bioreactors—with unmatched scalability—represent a very promising 
culture format for delivering high yields of either suspension or anchorage-dependent 
stem cells with uniform properties (Fernandes Platzgummer et al., 2011; Serra et al., 
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2012; King and Miller, 2007; Grolms et al., 2009). The online monitoring and control 
capabilities allow culture parameters to be adjusted throughout the duration of expansion, 
which can provide crucial batch-to-batch reproducibility (Shafa et al. 2011). The 
biopharmaceutical industry has long taken significant advantage of these systems, but 
stem cell expansion techniques have lagged behind and not yet transitioned into truly 
large-scale vessels (Olmer et al., 2012; Zweigerdt, 2009). Many stem cell-based 
treatments require large quantities of stem cells, and because native stem cells are 
relatively scarce in adult tissues, sufficient quantities of stem cells must be expanded in a 
timely manner in vitro for use in treatments. Additionally, adult stem cells decline in 
quantity and quality over time in a person, thus reducing the ability to harvest autologous 
supplies (dos Santos et al., 2010). These considerations have led some to suggest that 
establishing stem cell banks may be a more practical solution (Serra et al., 2012). 
Allogenic stem cell stocks would allow patients access to stem cells on demand, in much 
the same way that blood banks currently work. These stem cell banks would further 
necessitate large-scale cultivation at optimal growth rates to produce sufficient quantities 
of cells. The MSC cultured in the MOPS-HEPES buffer under atmospheric CO2 were 
able to maintain high/optimal growth rates for five passages, which would allow for 
large-scale cultivation. 
As stem cell expansion moves toward large-scale, issues similar to those currently 
encountered in other large-scale mammalian cell cultures will likely be encountered. 
Many of these problems result from the widespread use of the bicarbonate buffering 
system to regulate culture pH. In contrast to pH buffer redundancies in the body, the 
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bicarbonate buffering system essentially functions alone in typical mammalian cell 
culture. In cell culture media, elevated levels of NaHCO3 are added, which necessitates 
the use of high CO2 levels in the gas phase that are significantly higher than physiological 
levels (See Figure 4.6) (Goudar et al., 2006; Pattison et al., 2000). The indirect 
equilibrium between the CO2 from the gas phase and the NaHCO3 added to the medium 
maintains pH, via H+ concentration. Due to the nonpolar nature of CO2, it can freely 
diffuse across cell membranes. At high concentrations, it can lower intracellular pH. 
(Goudar et al., 2006; Pattison et al., 2000) In addition to affecting growth rates, these 
elevated dCO2 levels can also alter the metabolism, productivity, and glycosylation 
profiles in other mammalian cell lines, although this has not yet been reported in stem 
cells (Goudar et al., 2006; Pattison et al., 2000; Hu et al., 2011). As cell densities increase 
in large-scale cultures, additional CO2 is produced by the actively growing cells, which 
causes a buildup of dCO2 and gas phase CO2 levels (Goudar et al., 2006). This dCO2 
buildup can negatively impact cells grown in stirred bioreactors, and the effects increase 
with vessel size (Goudar et al., 2006; Hu et al., 2011). The use of a nonbicarbonate buffer 
would reduce dCO2 buildup and potentially improve growth. 
In stirred bioreactors, oxygen and CO2 gases are sparged into the vessel as 
bubbles, to increase mass transfer between the gas and liquid phases (King and Miller, 
2007). The breakup of these bubbles at the gas–liquid interface is responsible for the 
majority of cell death and damage during stirred bioreactor cultures (Rodrigues et al., 
2011; Papoutsakis, 2009; Zhang et al., 2010). Interestingly, managing the size of these 
bubbles has been proposed as a solution to the problem of dCO2 buildup (Pattison et al.,  
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 Figure 4.6 Bicarbonate buffer equilibrium. NaHCO3 salt is commonly added to 
mammalian cell culture medium to provide buffering in concert with elevated gas phase 
CO2, which will equilibrate with dCO2. 
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2000; Zhang et al., 2010; Hu et al., 2011). Larger bubbles are more effective in stripping 
dCO2, while smaller bubbles are more effective at delivering oxygen to the culture (Hu et 
al., 2011). With both oxygen and CO2 being supplied via the same sparged gas phase, 
only one bubble size distribution can be supplied. As vessels are scaled-up, the dCO2 
buildup becomes problematic, such that sparger designs allow for larger bubbles to strip 
dCO2 at the expense of adequate oxygen supply (Hu et al., 2011). Hu et al. (2011) 
proposed decoupling the oxygen and CO2 supplies by supplying pure oxygen via 
microspargers into the bioreactor, and air via standard spargers; however, they were 
concerned about the added control complexity (Hu et al., 2011). A nonbicarbonate buffer 
would allow for a single gas supply (air/oxygen), thus decreasing controller complexity. 
The coupling of the oxygen and CO2 supplies complicates control of culture 
parameters and allows for pH and dissolved oxygen variability that is unacceptable, 
particularly for stem cells (Serra et al., 2012; Rodrigues et al., 2011; Yeatts et al., 2013; 
Wuertz et al., 2009; dos Santos et al., 2010). Several researchers have indicated that this 
pH/CO2/O2 interdependence complicates bioreactor control and have gone on to quantify 
the effects of pH, CO2, or dissolved oxygen variability on growth or productivity 
(Rodrigues et al., 2009); however, few have suggested replacing the bicarbonate buffer 
system as a means to improve pH control (Goudar et al., 2006). Yet it would appear far 
simpler to use a nonbicarbonate buffer—such as the MOPS-HEPES combination used in 
this study—that does not rely on elevated dCO2 levels for pH control. This work was the 
first to demonstrate that the bicarbonate buffering system and an elevated CO2 
environment are not required for effective expansion of undifferentiated MSC. 
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Elimination of the bicarbonate buffer should lead to improved control of culture 
conditions and enhanced stem cell expansion in bioreactors. 
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4.5 Conclusion 
Stem cells will be used in increasing numbers of scientific applications in the 
future, ranging from basic research to clinical treatments. To provide stem cells for these 
applications, new large-scale stem cell expansion methods must be developed. Stirred 
bioreactors possess many advantages that allow for generation of large quantities of 
uniform stem cells in a reproducible manner. Unfortunately, the bicarbonate buffer used 
in mammalian cell culture, and the excessive CO2 sparging required by that system 
hinder the ability to optimize process controls and generate stem cell yields of the highest 
quality. This work developed a MOPS-HEPES buffering system that de-emphasized the 
role of CO2 in pH buffering. Undifferentiated MSC were expanded without prior 
adaptation under an atmospheric CO2 environment in the presence of the MOPS-HEPES 
buffer at growth rates equal to those expanded under 5% CO2 in the presence of the 
standard bicarbonate buffer. Additionally, the undifferentiated MSC expanded under an 
atmospheric CO2 environment retained equivalent differentiation potential along the 
adipogenic, osteogenic, and chondrogenic lineages compared to undifferentiated MSC 
previously expanded under 5% CO2, as determined by histological staining and gene 
expression markers. Furthermore, serial passaging of MSC in the MOPS-HEPES 
buffered medium under atmospheric CO2 did not hinder MSC expansion or decrease 
stemness gene expression markers as compared to MSC serially passaged under standard 
conditions. Utilization of CO2-independent buffers, such as the MOPS-HEPES buffer 
developed here, has the potential to improve stem cell bioreactor expansion by allowing 
for tighter control of pH and dissolved oxygen. 
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CHAPTER 5: IMPACT OF HIGH EXTRACELLULAR LACTATE  
ON THE METABOLISM OF THREE BREAST CANCER CELL LINES: 
MCF10A, MCF7, AND MDA-MB-231 
 
5.1 Abstract 
 Metabolism is a crucial component of cancer’s malignant arsenal, and flexibility 
with respect to nutrient sources allow it to survive harsh conditions as well as efforts to 
treat it. Lactate, which accumulates in tumors and was long thought to be simply a waste 
product that results from the Warburg Effect, is now becoming appreciated for its ability 
to serve as a metabolic substrate for cancer cells to utilize. Additionally, lactate has also 
been shown to promote metastasis, gene expression patterns consistent with the “cancer 
stem cell” phenotype, and treatment resistance in tumors. Therefore, to better understand 
the impact of extracellular lactate on the metabolism of cancer, three breast cancer cell 
line – MCF-10A, MCF-7, and MDA-MB-231 - were analyzed using 13C-metabolic flux 
analysis in response to being cultured in high-lactate conditions. Metabolic flux maps that 
quantify individual pathway activity were generated for each cell line and each condition, 
and compared between the control and high-lactate cultures, and between the cell lines. 
 
 
 
 
 
 136 
5.1 Introduction 
Cell metabolism plays a pivotal role in cancer. Metabolism governs the energy 
production, macromolecular synthesis, and intracellular redox balance necessary for cell 
replication and other vital processes, and therefore when normal metabolism becomes 
unbalanced it can enable malignant behaviors.  The Warburg effect – defined as glucose 
to lactate conversion rates even in the presence of adequate oxygen – has been witnessed 
in many types of cancer since its discovery in the 1920s. Since then, additional metabolic 
mechanisms have been discovered and have been shown to play a significant role in 
cancer progressions and malignancy. One of these important alternative mechanisms 
centers around lactate. Lactate accumulation in tumors is associated with increased 
malignant activity and poor patient prognosis (Kennedy and Dewhirst, 2010). Secreted 
from glycolytic cancer cells and autophagic carcinoma-associated fibroblasts, lactate can 
be utilized metabolically by other cancer cell populations, a process known as the 
Reverse Warburg effect (Kennedy and Dewhirst, 2010; Kennedy et al., 2013; Martinez-
Outschoorn et al., 2011; Pavlides et al., 2010; Sonveaux et al., 2008). For example, when 
lactate was injected into mice with xenografts of the human breast cancer cell line MDA-
MB-231, metastasis increased ten-fold (Bonuccelli et al., 2010). Additionally, when the 
human breast cancer cell line MCF-7 was exposed to lactate in vitro, genes associated 
with “stemness” were upregulated and gene expression patterns consistent with the 
“cancer stem cell” phenotype were observed (Martinez-Outschoorn et al., 2011). In 
several other types of cancers, intratumoral lactate levels – which can sometimes rise to 
as high as 40 mM – correlate with treatment resistance as well as poor patient prognosis 
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(Kennedy and Dewhirst, 2010). It has been shown in xenotransplants and mouse cancer 
models that inhibiting the ability of cancer cells to utilize lactate can force cells to 
become glycolytic and retard tumor growth through glucose starvation, while rendering 
the remaining cells more susceptible to radiation treatments (Sonveaux et al., 2008). 
Since lactate accumulation and its subsequent utilization by surrounding cells appears to 
negatively affect cancer patient outcomes, deciphering the role of lactate at the metabolic 
level within central metabolism is crucial.  
Metabolic flux analysis (MFA) is a tool that can be used to quantify metabolic 
fluxes through individual metabolic pathways, and thus can be used to compare changes 
in metabolic activity rates due to various factors. MFA uses extracellular uptake and 
secretion rates of nutrients and waste products, and a discrete metabolic network model 
of the relevant metabolic reactions (Hiller and Metallo, 2012). The use of stable isotopic 
tracers, typically 13C-labeled nutrients, and the resulting mass isotopomer distribution 
(MID) data increases the resolution of individual fluxes within the defined metabolic 
reaction network. Several mammalian systems have been characterized including Chinese 
hamster ovary (CHO) cells at both stationary and exponential growth phases, MDA-MB-
231 cells under various nutrient considerations, and several other cancer cell lines under 
hypoxia (Ahn and Antoniewicz, 2011; Ahn and Antoniewicz, 2013; Gaglio et al., 2011). 
Several software tools – all relying upon regression analysis to solve the system of linear 
equations specified by the metabolic network - exist to allow researchers to conduct MFA 
without having to develop programming code, including Metran, OpenFLUX, 13CFlux2, 
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and FiatFlux (Ahn and ANtoniewicz 2011; Quek et al., 2009; Weitzel et al., 2013; 
Zamboni et al., 2009). 
The aim of this study was to determine the role of extracellular lactate on the 
metabolism of proliferating breast cancer cells during exponential growth. Three human 
breast cell lines were examined that represent three different stages of breast cancer. 
MCF-10A cells are a non-tumorigenic breast cell line, MCF-7 cells are a tumorigenic, 
luminal breast cancer cell line, and MDA-MB-231 cells are metastatic, basal breast 
cancer cell line (Zancan et al., 2010). Each cell line was grown in both a control 
condition without a lactate addition, as well as a high-lactate condition for which lactate 
was added to the extracellular culture medium. The high-lactate concentration was 
selected for each cell line to allow equivalent growth rates between the control and high-
lactate conditions. Three isotopic tracers were used individually, in parallel labeling 
studies: [1,2-13C] glucose - as it has been shown to most accurately resolve fluxes in 
glycolysis and the pentose-phosphate pathway (PPP) (Metallo et al., 2009); [U-13C] L-
glutamine - as it has been shown to most accurately resolve fluxes in the mitochondrial 
TCA cycle (Metallo et al., 2009); and [U-13C] sodium lactate - to elucidate lactate 
metabolism. For the control cultures, only [1,2-13C] glucose and [U-13C] L-glutamine 
tracers were used, since no extracellular lactate was added to these cultures. Metran was 
used to solve the metabolic fluxes using the glucose and glutamine data. The lactate 
tracer data for the high-lactate conditions was able to characterize the distribution of 
labeled carbon within the intracellular metabolites. Metabolic flux maps for each cell line 
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and each condition were generated, and compared between the control and high-lactate 
cultures, and between the cell lines. 
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5.2 Materials & Methods 
Cell lines and media formulations 
MCF-10A (ATCC® CRL-10317TM) and MCF-7 (ATCC® HTB-22TM) cells were 
purchased from ATCC, while MDA-MB-231 (ATCC® CRL-10317TM) were kindly 
provided to us by Dr. Brian Booth of Clemson University. Dulbecco’s modified Eagle 
medium (DMEM) without glucose, glutamine, sodium pyruvate, and phenol red (Life 
Technologies) was used as the growth media. The growth media was supplemented with 
5 mM glucose (FIsher), 3 mM glutamine (Life Technologies), 10% dialyzed fetal bovine 
serum (dFBS, Life Technologies) and 1% penicillin-streptomycin solution (Life 
Technologies). High-lactate cultures were supplemented with 10 mM sodium L-lactate 
(Sigma) for the MCF-10A cultures and 20 mM for the MCF-7 and MDA-MB-231 
cultures. The isotopic tracers used in this study were [1,2-13C] glucose, [U-13C] L-
glutamine, and [U-13C] sodium lactate. All isotopes were purchased from Sigma-Aldrich. 
 
Cell growth and parallel labeling experiments 
All cell lines were initially seeded at 2 x 104 cells/cm2 in the control growth media. Cells 
were cultured at 37°C in a 5% CO2 humidified incubator. At 24-h, the media for the 
MDA-MB-231 cultures was exchanged and the experimental conditions were introduced. 
For MCF-10A and MCF-7 the media was replenished at 24-h, and at 48-h the media was 
exchanged to introduce the experimental conditions. The later start point for the MCF-
10A and MCF-7 cultures was due to a reproducible longer lag phase. For clarity, the full 
experimental setup is shown in Figure 5.1. Cell numbers and extracellular metabolite 
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concentrations were measured at two time points, 24-h and 48-h after the media 
exchange. Cell numbers and glucose and lactate concentrations were obtained from the 
six-well plates, while the amino acid concentrations were obtained from the T-25 flasks. 
The intracellular MIDs were obtained from the T-25s at 24-h after the media exchange. 
The control condition had parallel cultures for both glucose  (95% molar enriched [1,2-
13C] glucose) and glutamine tracers (95% molar enriched [U-13C] L-glutamine), whereas 
the high-lactate cultures also had parallel replicates for the lactate tracer (50% molar 
enriched [U-13C] sodium L-lactate). Six-well plates (Nunc) were used to obtain cell 
numbers and glucose and lactate concentrations with six replicates for each time point. T-
25 flasks were used to obtain extracellular amino acid concentrations and intracellular 
MID measurements in triplicate. 
 
Cell numbers, and glucose and lactate concentrations 
Cell numbers were obtained using the Scepter 2.0 Handheld Automated Cell 
Counter (Millipore). Glucose and lactate concentrations were measured using a YSI 2700 
Bioanalyzer. 
 
Preparation of samples for GC-MS analysis 
The methods used here for the extraction and derivatization of intracellular and 
extracellular metabolites, as well as the specific metabolite fragments used for 
identification, were performed according to the protocol outlined by Ahn and 
Antoniewicz (2011), with a few minor alterations. Samples were incubated and allowed 
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to derivatize for 60 min, and the sample volumes were increased to 1 mL after 
derivatization. The injection volume used was 3 µL and samples were injected in splitless 
mode. Amino acid standards were used .to calculate amino acid concentrations in the [U–
13C] algal amino acid solution, which were then used to quantify the amino acid 
concentrations in the extracellular medium.  
 
Extracellular amino acid concentrations and intracellular MID measurements 
GC-MS analysis was performed using a Hewlett Packard 7683 GC equipped with 
an HP-5 (30 m x 0.32 mm i.d. x 0.25 µm; J&W Scientific) capillary column, interfaced 
with a Hewlett Packard 5973 MS operating under ionization by electron impact as 2000 
eV and 200°C ion source temperature. The injection port and interface temperatures were 
both 250°C while helium flow was maintained at 1 mL/min. Mass spectra were recorded 
in full scan mode for amino acid quantification and in single ion mode (SIM) for MIDs as 
well as internal standards and standardization curves. MIDs were obtained by integration 
of single ion chromatograms, and corrected for natural isotope abundances using the 
Metran software (Fernandez et al., 1996; Yoo et al., 2008). 
 
Determination of biomass specific consumption and production rates 
Specific consumption and production rates for nutrients and waste metabolites in 
the extracellular medium were determined based on cell growth rate and nutrient time 
profiles using the previously described method of Meadows et al. (2008). Each sample 
was independent, so average values were used to calculate fluxes. Prior to the flux 
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Figure 5.1. Experimental setup for parallel labeling experiment for each of the three 
breast cancer cell lines. Six-well plates and T-25 flasks were all seeded together. Times 
indicate when the plates or flasks were harvested for analysis relative to the media 
exchange. Isotopic labeling is graphically shown by shading. Clear for no isotope, gray 
for glucose, blue for glutamine, and yellow for lactate. None of the six-well plates 
contained isotopically-labeled media. 
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calculations, statistical analysis of the amino acid concentration data was conducted using 
jmp 10.0.0 (SAS Institute, Inc). The generalized linear model was used where cell line, 
condition, and time were examined as effectors of the amino acid concentration (p ≤ 
0.05). Amino acid concentrations were averaged if determined not to be statistically 
different with respect to the cell lines, condition, or time (p ≤ 0.05). All amino acid 
concentrations were significantly affected by time (p ≤ 0.05). Several amino acid 
concentrations were not significantly affected by cell line, condition, or both (p ≤ 0.05). 
In those cases, the similar values were averaged to calculate fluxes. The spontaneous 
glutamine degradation rate was accounted for in the glutamine flux calculation. The 
lactate flux into the cells for the high-lactate cultures was estimated from the change in 
the extracellular M3 labeled lactate species concentration between 24 and 48-h after the 
media change. 
 
Metabolic network model 
To model central carbon metabolism for the three breast cancer cell lines, a 
general mammalian cell model was used. This generalized mammalian cell model was 
adapted from the previously developed framework by Ahn and Antoniewicz (2013). The 
major reactions for glycolysis, PPP, the TCA cycle, amino acid metabolism, lactate 
metabolism, and fatty acid metabolism were included in the mammalian cell model. Due 
to the varying lipid content reported across the breast cancer cell lines and breast cancer 
tissue (Abramczyk et al., 2015), a two-compartment biomass description was used, where 
the Main Biomass includes proteins, nucleotides, and carbohydrates (Ahn and 
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Antoniewicz, 2013). The protein amino acid composition appears to be relatively 
consistent between the three cell lines by Raman spectra (Talari et al., 2015). Lipid 
Biomass includes lipids and phospholipid (Bonarius et al., 1996). The two intracellular 
compartments were modeled; cytosolic and mitochondrial, as well as a pyruvate sink to 
account for reactions and pathways not explicitly included in the metabolic network 
model (Ahn and Antoniewicz, 2013; Metallo et al., 2009; Metallo et al., 2012). Cofactor 
balances, such as NADH and NADPH were not included in the model, as different 
isoenzymes have varying cofactor requirements and the inclusion of these assumptions 
can skew subsequent analysis (Ahn and Antoniewicz, 2011). Carbon dioxide was treated 
as an unbalanced metabolite, and was not measured. Oxygen uptake was excluded from 
the model and was also not measured. For the high-lactate cultures, an additional 
extracellular reaction was included to account for the uptake of the labeled lactate tracer. 
The control condition mammalian cell model has 73 reactions and the high-lactate 
condition mammalian cell model has 74 reactions. The full metabolic network model 
with atom transitions can be found in the Appendix A.  
 
Metabolic flux analysis 
13C-Metabolic flux analysis was performed using the software package Metran 
(Yoo et al. 2008), which utilizes the elementary metabolite unit (EMU) framework 
(Antoniewicz et al., 2007b) Metabolic fluxes were estimated using experimentally 
measured-values for consumption and production rates and from mass isotopomer 
distributions for intracellular metabolites. In Metran, the metabolic fluxes were based on 
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the quantities that minimized the variance-weighted sum of squared residuals (SSRes) 
between the measured and simulated values. Metran can handle MID data from parallel 
labeling experiments to be used simultaneously to generate a single flux map, per 
condition and cell line, a capability that has been validated by MFA experiments for both 
E. coli and CHO cells (Leighty and Antoniewicz, 2012; Ahn and Antoniewicz, 2013). 
For this study, random initial fluxes were used and the MID error was 0.7 mol%. The 
MIDs for each tracer were: glucose [3-phosphoglycerate (3PG), phosphoenolpyruvate 
(PEP), dihydroxyacetone phosphate (DHAP), pyruvate, lactate, and alanine] and 
glutamine [succinate, malate, α-oxoglutarate (AKG), glutamate, citrate, glutamine, 
pyruvate, and lactate]. The MIDs from the lactate tracer for the high-lactate condition 
were not included in the Metran simulations; however, the lactate tracer flux was 
included. The fluxes for glucose, lactate, and glutamine were assigned 10% error, while 
the other amino acid fluxes were assigned 50% error, due to the low concentration values 
limiting precision. The main biomass and lipid biomass fluxes were assigned 25% error, 
due to the imprecision of previous estimates of cancer cell lipid content (Abramczyk et 
al., 2015). The lactate tracer flux was assigned 50% error, due to assumptions regarding 
how the value was calculated. Namely, the M3 isotope was only an approximation of 
total extracellular lactate, and the extracellular fluxes of M1 and M2 isotopes out of the 
cells were not accounted for. The simulations were determined to have converged when a 
global solution was achieved that satisfied the accepted SSRes criteria. This was 
determined from analyzing the simulated fit results via a chi-square statistical test to 
measure goodness-of-fit (Antoniewicz et al., 2006; Antoniewicz et al., 2007a). After 
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convergence, 95% confidence intervals were generated for all parameters based on the 
SSRes parameter (Antoniewicz et al., 2006). 
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5.3 Results and Discussion 
Cell growth  
To determine the effects of high extracellular lactate on breast cancer metabolism, 
three human breast cell lines, MCF-10A, MCF-7, and MDA-MB-231, were grown under 
both control and high-lactate conditions. For MCF-10A, the high-lactate culture media 
contained 10 mM lactate, while for MCF-7 and MDA-MB-231 the high-lactate culture 
media contained 20 mM lactate. In order to have more control over the nutrient 
conditions in the media and the isotopic labeling enrichment, the growth media used did 
not contain sodium pyruvate, and glucose and glutamine had to be added. The dialyzed 
FBS (dFBS) was also selected to minimize the carry over of glucose and other small 
molecules. The high-lactate concentration selected for the high-lactate condition was 
representative of lactate concentrations found within tumors that have been shown to 
elicit the malignant effects associated with lactate accumulation (Kennedy and Dewhirst, 
2010; Martinez-Outschoorn et al., 2011), yet also allowed for equivalent growth rates 
between the control and high-lactate conditions. To characterize cell growth, cell counts 
were taken every 24-h for several days and the resulting growth profiles for the three cell 
lines are shown in Figure 5.2. All three cultures had significant lag phases; which were 
reproducible and predictable for each cell line  (48-h for MCF-10A and MCF-7 and 24-h 
for MDA-MB-231). After the lag phase, the cultures were switched to the test conditions, 
as indicated by the arrow in Figure 5.2. For control condition cultures the media 
composition did not change, only isotopes were added; however, the cultures to be tested 
under the high-lactate condition, the media was switched to the high-lactate media. All 
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cultures exhibited exponential growth for 48-h after the media exchange, indicating that 
the high-lactate condition did not significantly affect the overall growth rates for each cell 
line (p > 0.05). The exponential growth rates were 0.017, 0.018, and 0.021 h-1, 
respectively, for the MCF-10A, MCF-7, and MDA-MB-231 cell lines. In previous work 
 with mammalian cell lines, it has been shown that isotopic steady-state is reached for 
glycolysis and the PPP metabolites with glucose labeling while TCA metabolites reach 
close to isotopic steady-state with glutamine labeling within this time frame (Ahn and 
Antoniewicz, 2013). Thus, samples for MID analysis were taken 24-h after the media 
change, indicated by the black arrow, while all cultures were in the mid-exponential 
phase (Figure 5.2). 
 
Glucose, lactate, and amino acid metabolism 
The glucose and lactate time profiles for each of the cell lines for each condition 
are shown in Figure 5.3. The calculated flux rates are listed in Table 5.1, while the 
concentrations for the 24-h and 48-h samples are listed in Appendix B. The three control 
cultures had high glycolytic efficiency, or conversion of glucose into lactate, where the 
theoretical maximum glycolytic efficiency is 2.0 mol lactate / mol glucose. Specifically, 
the control condition cultures had glycolytic efficiencies of 1.7, 1.5, and 1.8, respectively, 
for the MCF-10A, MCF-7, and MDA-MB-231 cell lines. The high-lactate condition 
cultures had glycolytic efficiencies of 1.4, 0.8 and 1.3, respectively, for MCF-10A, MCF-
7, and MDA-MB-231 cell lines. The high extracellular lactate concentration caused all 
three cell lines to have decreased glycolytic efficiencies. 
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Figure 5.2. Growth profiles for the three breast cancer cell lines. A) The growth 
profiles of MCF-10A shown in red, B) The growth profiles of  MCF-7 shown in blue, and 
C) The growth profiles of MDA-MB-231 shown in purple. The control cultures are 
represented by solid markers, while the high-lactate cultures represented by hollow 
markers. The media exchange occurred at the time point indiciated by the black arrow. 
Error bars represent 95% confidence intervals. 
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 With respect to amino acid fluxes, the statistical analysis showed that several amino acid 
concentrations between cell lines or condition were not different (p > 0.05); however, 
they were different between 24-h and 48-h. Specifically, the glutamine, methionine, 
phenylalanine, and tyrosine concentrations were not significantly different (p > 0.05) 
between the cell lines or between conditions (p > 0.05). The concentrations of aspartate, 
glutamate, glycine, and threonine were significantly different between cell lines (p ≤ 
0.05), but within the same cell line were not significantly different between the control 
and high-lactate conditions (p > 0.05). Leucine concentrations were not significantly 
different between cell lines (p > 0.05), but were significantly different between the 
control and high-lactate conditions (p ≤ 0.05). The amino acid flux rates are listed in 
Table 5.1, while the amino acid concentrations for the 24-h and 48-h samples are listed in 
Appendix B. 
 
Lactate tracer uptake rate 
 To calculate the lactate tracer flux for the high-lactate condition, the amount of 
the M3 lactate isotope – corresponding to the [U-13C] lactate tracer – that was taken up by 
the cells from the extracellular media was determined from the change in the M3 lactate 
isotope concentration (after it was corrected for natural isotope abundance) from 24-h to 
48-h. Specifically, the lactate flux was assumed to be double this change, since only 50% 
of the initial extracellular lactate was labeled. It is possible that some of the M3 lactate 
was secreted into the extracellular media unaltered; however, it was assumed that this 
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was balanced by the M1/M2 lactate species secreted into the extracellular media. Table 
5.1 lists the calculated lactate tracer uptake fluxes for the three cell lines.  
To further understand the impact of the high extracellular lactate concentrations 
on metabolism, the distribution of labeled intracellular metabolites in central metabolism 
was examined. These MID values were obtained for intracellular metabolites cultured in 
the high-lactate condition where 50% of the extracellular lactate was [U-13C] lactate. The 
intracellular metabolites that were labeled included pyruvate, lactate, alanine, citrate, 
AKG, glutamate, succinate, proline, aspartate, and malate. Though only intracellular 
metabolites were measured in this study, the labeling is in agreement with a previous 
labeling study where MCF-7 and MDA-MB-231 cells were incubated in a glucose-free 
media with 10 mM 3-13C-lactate. In that glucose-free study, labeled alanine and 
glutamate were observed, which could only have been generated if alanine and glutamate 
were labeled intracellularly. In contrast, the labeling of the TCA metabolites and other 
amino acids had significantly lower labeling, with an average carbon labeling of only 
~1%. 
One notable characteristic of the intracellular labeling due to the lactate tracer, 
was the high fraction of M1 species relative to M2 species for both the intracellular 
pyruvate, alanine, and lactate, as well as TCA metabolites. Since the lactate tracer was 
[U-13C] labeled, one might expect to observe mostly M3, then M2, followed by M1, if 
lactate were the sole carbon source and no lactate were being produced from the 
metabolism of glucose and glutamine. In a case where lactate was the sole carbon source
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 Figure 5.3 Glucose and lactate profiles for the three breast cancer cell lines. A) The 
left graph shows the glucose concentrations over time for the three breast cancer cell 
lines, while B) The right graph shows the net lactate concentrations over time adjusting 
for the initial extracellular lactate in the high-lactate cultures. MCF-10A is represented in 
red, MCF-7 in blue, and MDA-MB-231 in purple. The control cultures are represented by 
solid markers, while the high-lactate cultures are represented by hollow markers. All 
error bars represent 95% confidence intervals. 
 
 
 
 
‘ 
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Table 5.1. Glucose, lactate, and amino acid fluxes for the three breast cancer cell 
lines for the control and high-lactate conditions. Fluxes are given in nmol /106 cells/h, 
and correspond to the measured flux between the 24-h and 48-h time points. 
Flux (nmol/106 cells/h) 
 MCF10-A MCF-7 MDA-MB-231 
Metabolite Control High-Lactate Control 
High-
Lactate Control 
High-
Lactate 
Glucose -222 -181 -210 -159 -337 -268 
Lactate 379 252 318 132 606 344 
Alanine 10.6 10.7 13.7 11.7 10.2 8.2 
Aspartate 4.9 3.7 6.6 5.4 3.5 4.5 
Glutamate 12.1 10.2 11.5 11.6 8.6 10.4 
Glutamine -48 -55 -53 -64 -44 -55 
Glycine 6.2 5.7 9.7 9.4 7.8 7 
Isoleucine -8.3 -8.4 -9.5 -9.2 -4.7 -8.4 
Leucine -6.7 -7.5 -8.3 -7.4 -4.7 -8.8 
Methionine -2.6 -1.5 -3.1 -2.2 -1.4 -2.2 
Phenylalanine -4.7 -4.5 -3.8 -3.8 -3.4 -4 
Proline 1.5 1.3 2.8 2.3 0.83 1.3 
Serine -18.7 -20.3 -19.7 -22.5 -15.8 -19.8 
Threonine -1.9 -1.9 -1.2 -1.2 -1.2 -1.6 
Tyrosine -3.6 -3.7 -4 -3.8 -3.5 -3.8 
Valine -5.8 -6.3 -9.5 -10.4 -6.4 -9.1 
 155 
 and continuously consumed, labeled lactate would enter the cell and label pyruvate as M3 
and the TCA metabolites as M2 after one turn of the TCA cycle, as shown in Figure 
5.4A. If M3 lactate continued to enter the mitochondria as the primary source of acetyl-
CoA, then the TCA metabolites would stay enriched with 13C. However, since the labeled 
lactate flux into the cell and to pyruvate was relatively low compared to the unlabeled 
glucose flux to pyruvate, the majority of the pyruvate becoming acetyl-CoA in the 
mitochondria would be M0 labeled, as seen in Figure 5.4B. Therefore, when the M2-
labeled oxaloacetate from the first TCA cycle run, indicated by the blue box in Figure 
5.4A and 5.4B, goes through the TCA cycle again, the majority of the time it combine 
with an M0 acetyl-CoA, and will produce the M1-labeled the TCA metabolites from the 
lactate tracer, as was seen in this study.  
The MID data from the high-lactate conditions demonstrated that the labeled 
lactate was consumed by the cells. Also, the presence of high extracellular lactate alters 
intracellular metabolism for all three breast cancer cell lines. Specifically, the high 
extracellular lactate concentration decreased glucose consumptions rates and decreased 
lipid production rates.  
 
Intracellular labeling from [1,2-13C] glucose 
 A [1,2-13C] glucose isotope was used for this study because previous studies have 
shown it to be an optimal tracer for the glycolytic pathway for mammalian cells (Metallo 
et al., 2009). The composition of the tracer in the extracellular medium was 95% molar 
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enrichment, and 24-h has been shown to be sufficient to achieve isotopic steady-state for 
intermediate metabolites in the glycolytic pathway for CHO cells, another mammalian 
cell line with a similar growth rate (Ahn and Antoniewicz, 2013). The complete glucose- 
derived MID measurements for all cell lines and conditions can be found in Appendix C. 
All of the MID data was corrected for natural isotope abundances. 
The average carbon labeling for PEP, 3PG, DHAP, pyruvate, alanine, and lactate 
was at least 20% for all three cell lines, and the labeling concentrations did not drastically 
change between the three cell lines, nor between the control and high-lactate conditions. 
This reflects the consistently high flux through glycolysis for each of the three cell lines, 
and makes sense considering that all three cell lines grew at an exponential rate for both 
the control and high-lactate conditions. 
 
Intracellular labeling from [U-13C] glutamine 
 The [U-13C] glutamine isotope was used for this study because previous studies 
have shown it to be an optimal tracer for the TCA cycle pathway for mammalian cells 
(Metallo et al., 2009). The composition of the tracer in the extracellular medium was 95% 
molar enrichment, and the 24-h to be sufficient to nearly achieve isotopic steady-state for 
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Figure 5.4 Generation of M1-labeled TCA metabolites from extracellular U-13C 
lactate. A) Initial labeled lactate produces M2 TCA metabolites. B) M1 labeled 
metabolites will form on the second run, where the M2 oxaloacetate (OAA) will most 
likely encounter an M0 acetyl-CoA. For clarity, some reaction pathways were condensed. 
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intermediate metabolites in the TCA cycle for CHO cells (Ahn and Antoniewicz 2013). 
The complete glutamine-derived MID measurements for all cell lines and conditions can 
be found in Appendix C. All of the MID data was corrected for natural isotope 
abundances.  
 In all cell lines and conditions, glutamine, AKG, and glutamate were heavily 
enriched from the glutamine tracer. Pyruvate and lactate were minimally enriched from 
the glutamine isotope for all cell lines and conditions. In MCF-10A and MDA-MB-231, 
the high-lactate condition led to a higher average carbon labeling in pyruvate and lactate 
as compared to the control condition. In MCF-7, the trend seen in MCF-10A and MDA-
MB-231 was reversed: decreased labeling in pyruvate and lactate was observed under the 
high-lactate condition compared to the control condition. The increased labeling of 
pyruvate and lactate from glutamine in MCF-10A and MDA-MB-231 under the high-
lactate condition suggests that glutamine anaplerosis was enhanced to provide energy via 
oxidative phosphorylation, and then secreted as alanine and lactate, in response to 
decreased glucose consumption and decreased energy generation via glycolysis. While 
glucose consumption (and hence energy generation via glycolysis) decreased in MCF-7 
cells under the high-lactate condition, the decreased labeling in pyruvate and lactate from 
glutamine suggests the glutamine-derived intermediates continued through the TCA cycle 
rather than being secreted as alanine and lactate. 
 The TCA metabolites succinate, malate, and citrate also showed significant 
labeling from the glutamine tracer. Succinate and malate had similar average carbon 
labeling in all three cell lines for both conditions, whereas citrate labeling was relatively 
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similar between the different cell lines, but had some notable differences between the 
control and high-lactate conditions. In response to the high-lactate conditions, all three 
breast cancer cell lines showed a much greater proportion of M5 citrate compared to the 
control condition, as can be seen in Figure 5.5. Increased M5 citrate was likely due to the 
TCA cycle running in “reverse” through the reductive carboxylation pathway, as seen in 
Figure 5.6. If correct, this labeling trend would be reflected – and it was - in the three cell 
lines having higher exchange fluxes from AKG to citrate for the high-lactate condition 
compared to the control. These results suggest that cancer cells continue to replenish 
TCA intermediates through glutamine anaplerosis, and use glutamine for citrate synthesis 
and fatty acid production via reductive carboxylation. Mammalian cells, including several 
cancer cell lines, have been observed to increase reductive carboxylation of glutamine 
under hypoxia (Metallo et al., 2012; Wise et al., 2011), but this is the first time it has 
been observed in response to high-lactate levels. 
 
Metabolic flux analysis 
To quantify the metabolic activity, Metran was used to simulate the metabolite 
flux rates, MIDs from parallel glucose and glutamine tracer labeling, and compare them 
to the measured results for the model. A flux map was generated for each cell line for 
each condition (Leighty and Antoniewicz, 2012; Ahn and Antoniewicz, 2013). Flux maps 
for all cell lines and conditions are shown in Figures 5.6-5.11, and listed in Appendix D. 
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Figure 5.5 MID labeling of citrate from [U-13C] glutamine.  The fractional abundance 
of the M0, M4, and M5 labeled forms of citrate for MCF-10A, MCF-7, and MDA-MB-
231 cultures for both control and high-lactate conditions. 
 161 
  
Figure 5.6 Reductive carboxylation of AKG to citrate. When AKG is oxidized through 
the normal TCA pathway shown by the black arrows, the resulting citrate will be M4. 
When AKG is carboxylated to isocitrate, the resulting citrate will be M5. For clarity, 
some reaction pathways were condensed. 
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 Figure 5.7A Metabolic flux map for MCF-10A cells for the control condition. Line 
thicknesses reflect relative flux values, which are in nmol/106 cells/h. 
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 Figure 5.7B Metabolic flux map for MCF-10A cells for the high-lactate condition. 
Line thicknesses reflect relative flux values, which are in nmol/106 cells/h. 
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 Figure 5.7C Metabolic flux map for MCF-7 cells for the control condition. Line 
thicknesses reflect relative flux values, which are in nmol/106 cells/h. 
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 Figure 5.7D Metabolic flux map for MCF-7 cells for the high-lactate condition. Line 
thicknesses reflect relative flux values, which are in nmol/106 cells/h. 
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 Figure 5.7E Metabolic flux map for MDA-MB-231 cells for the control condition. 
Line thicknesses reflect relative flux values, which are in nmol/106 cells/h. 
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 Figure 5.7F Metabolic flux map for MDA-MB-231 cells for the high-lactate 
condition. Line thicknesses reflect relative flux values, which are in nmol/106 cells/h. 
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 For all three cell lines, the reactions in glycolysis had the highest fluxes in both 
the control and high-lactate conditions. Compared to the control condition, all three cell 
lines were characterized by decreased glucose consumption and decreased lactate 
production when cultured in the high-lactate conditions. This agrees with previous studies 
that showed lactate accumulation correlated with reduced entry of pyruvate into the TCA 
cycle in leukemia cells (Samudio, et al., 2009). In the mitochondria, the high-lactate 
condition resulted in decreased fluxes of acetyl-CoA into citrate for all three cell lines; 
however, production of citrate from AKG via reductive carboxylation (characterized by 
the exchange flux between AKG and citrate) increased for all three cell lines for the high-
lactate condition and likely compensated for the lack of citrate produced from acetyl-
CoA. This is consistent with the increased M5 citrate labeling for all three cell lines for 
the high-lactate condition shown in Figure 5.5, and in accordance with the behavior of 
several other cancer cell lines when exposed to hypoxia, suggesting a possible link 
between hypoxia and not only lactate accumulation but also consumption. The flux of 
citrate from the mitochondria to the cytosol – and subsequent conversion into acetyl-CoA 
for fatty acid synthesis – decreased for all three cell lines for the high-lactate condition 
compared the control condition. This is surprising, considering that the decreased flux of 
glucose into the mitochondria should make cells more dependent on glutamine-derived 
citrate for fatty acid synthesis. Previous studies demonstrated that MDA-MB-231 cells 
have a higher lipid content than MCF-7, which have a higher lipid content than MCF-
10A (Abramczyk et al., 2015). These lipid biomass content values were obtained form 
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Raman spectra and staining. Without this data, the model would have assumed one lipid 
content for all three cell lines; however, the lipid concentrations were not precise enough 
to allow high confidence in the fatty acid lipid biomass fluxes.  
 
Lactate’s effects on cancer cell metabolism and behavior 
 In this study, the metabolic responses of three breast cancer cell lines, MCF-10A, 
MCF-7, and MDA-MB-231, to high lactate were examined using 13C-MFA. MCF-10A 
represents normal, precancerous breast cells, MCF-7 represents early-stage breast cancer, 
and MDA-MB-231 represents a malignant and metastatic advanced breast cancer. Three 
isotope tracers were used to aid resolution of central carbon metabolism and the resulting 
fluxes and MID data sets were paired with a mammalian metabolic network model to 
develop intracellular metabolic activity maps for each cell line under the control 
condition, as well as the high-lactate condition. The three breast cancer cell lines cultured 
in high-lactate conditions continued to grow exponentially at equivalent rates (p > 0.05), 
despite having lower glucose consumption rates (p ≤ 0.05). While lactate was consumed 
by MCF-10A, MCF-7, and MDA-MB-231 when exposed to high concentrations of 
extracellular lactate, the lactate consumption might have even been reduced in these 
conditions compared to in vivo conditions, due to the presence of glucose. MCF-7 and 
MDA-MB-231 have been shown to utilize lactate as the main carbon source in the 
absence of glucose (Kennedy et al., 2013). Most notably, all three cell lines exhibited 
increased reductive carboxylation, as determined by increased M5 citrate labeling, which 
can only occur if glutamine is metabolized through the reverse TCA cycle.  Increased 
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reductive carboxylation has previously been observed in several types of cancer cells in 
response to hypoxia (Metallo et al., 2012; Wise et al., 2011).  These results indicate that 
there may be a link between hypoxia and lactate metabolism in tumor cells, even when 
oxygen is sufficient, since oxygen was sufficient in the present experiments. 
Interestingly, both hypoxia and elevated lactate correlate with resistance to treatments 
that rely on induction of oxidative stress because lactate consumption allows cells to 
utilize its antioxidant capacity to reduce oxidative stress and hypoxia limits formation of 
reactive oxygen species (Groussard et al., 2000; Keith et al., 2007, Kennedy and 
Dewhirst, 2010). Additionally, both exposure to elevated lactate, and hypoxia seem to 
promote the “cancer stem cell” (CSC) phenotype independently (Heddleston et al., 2009, 
Hill et al., 2009; Martinez-Outschoorn et al., 2011). Furthermore, upon injection of 
lactate into mice with MDA-MB-231 xenografts, metastasis increased ten-fold 
(Bonuccelli et al., 2010; Martinez-Outschoorn et al., 2011). Hypoxia has also been 
implicated in increasing the metastatic potential of cancer cells (Hill et al., 2009; Pani et 
al., 2010). All of these malignant behaviors – treatment resistance, stem cell gene 
signatures, and increased metastasis – are correlated with tumor recurrence and poor 
patient prognosis. All of these behaviors have also been shown to be promoted by both 
hypoxia and elevated lactate. While cancer cells have long been known to produce high 
levels of lactate, especially in hypoxic tumor regions, cancer cells can also consume and 
metabolize lactate as a substrate (Kennedy et. al, 2013; Pavlides et al., 2009; Sonveaux et 
al., 2008). The findings in this study highlight that elevated extracellular lactate 
conditions can shift cancer cell metabolism towards a state normally thought to be 
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characteristic of hypoxia, even in the presence of sufficient oxygen. 
Metabolic flexibility appears to play an important role in enabling cancer to thrive 
and survive in our bodies, against the harsh environmental factors encountered, including 
inflammation, oxidative stress, and extreme nutrient and oxygen fluctuations (Dayem et 
al., 2010; Pavlides, et al., 2010; Reuter et al., 2010). As a result, the ability to metabolize 
lactate offers potential advantages to cancer cells. To gain a better understanding of 
lactate uptake and metabolism, one study inhibited the main lactate transporter, MCT1, in 
cervical cancer cells. This induced a switch from lactate-fueled respiration to glycolysis 
(Sonveaux et al., 2008). In the same study, blocking MCT1 in a mouse lung cancer model 
as well as a colorectal cancer xenotransplant slowed tumor growth by forcing the lactate-
consuming cells to switch to glucose consumption. These cells were then more sensitive 
to radiation treatment (Sonveaux et al., 2008). Even if the cancer cells that consume 
lactate are not dependent on it – though it is believed to promote treatment resistance 
through antioxidant effects – inhibiting lactate consumption can have downstream effects 
on other tumor cells, and indeed compromise the tumor itself (Hirschhaeuser et al., 2011; 
Kennedy and Dewhirst, 2010).  
The findings of this study suggest that breast cancer cells adapt to high lactate 
concentrations by increasing reductive carboxylation within the TCA cycle. Reductive 
carboxylation is also observed to increase under hypoxia. In addition, both elevated 
lactate and hypoxia have been linked to treatment resistance, metastasis, and the 
promotion of the cancer stem cell phenotype. This suggests a potential connection 
between these behaviors. Normally, oxygen is required for lactate to be used as the sole 
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carbon source by tumors via oxidative phosphorylation in the TCA cycle (Kennedy et al., 
2013); however, lactate’s effect on TCA cycle activity – namely, increased reductive 
carboxylation of glutamine - has thus far not been reported.  If elevated lactate can indeed 
mediate malignant behavior in cancer cells via this metabolic pathway as well as serve as 
a substrate, approaches to prevent lactate-induced changes should be re-evaluated, 
especially when targeting cancer cells residing in hypoxic niches.  
13C-MFA should continue to play an important role in future studies aimed at 
precisely determining the effects of elevated lactate on cancer cell metabolism. In order 
to increase resolution of the MIDs, the extracellular lactate should be entirely isotopically 
labeled. Additionally, low glucose and low extracellular pH should be used to promote 
lactate uptake. These results demonstrated that lactate plays an important role in changing 
cancer cell metabolism, which might contribute to the increased metastasis, treatment 
resistance, and patient death rates observed to be associated with elevated lactate 
accumulation. Additionally, the surprising link to hypoxia should be further investigated. 
Moving forward, there are several details that could be refined to `improve the 
results of this MFA study.  First, the metabolic network model contained two additional 
pyruvate pools (pyr.snk and pyr.mII) to manage the multiple reactions at the pyruvate 
node as well as to account for reactions not explicitly defined in the network (Ahn and 
Antoniewicz, 2013). Due to the high flux of pyruvate into the sink under the high-lactate 
conditions, it may be necessary to constrain or remove this pool. The additional pyruvate 
mitochondrial pool (pyr.mII) was included to model potential pyruvate channeling (Ahn 
and Antoniewicz, 2013); however, this assumption may not be supported by the cancer 
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MID data. Additionally, the reversibility of several reactions, could be modified to allow 
acetyl-CoA to re-enter the mitochondria via citrate, to account for fatty acid oxidation. 
Second, the lipid composition used for the breast cancer cells was for cells cultured under 
glucose with limited precision and only included the lipid droplets, and not the total lipid 
content (Abramczyk et al., 2015). Furthermore, the effects of high extracellular lactate on 
the lipid content of breast cancer cells was not obtained. Therefore, accurate estimates for 
lipid biomass for each of the cell lines under each condition is needed to resolve the 
intracellular fluxes. Finally, the lactate tracer used was only 50% enriched, which 
significantly reduced the fractional abundance of the MIDs obtained for the high-lactate 
cultures. In the future, using a higher enrichment for the lactate tracer would increase the 
fractional abundances of the MIDs, such that the MID data could be used in the MFA 
simulations to estimate intracellular fluxes. 
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5.5 Conclusion 
 While cancer cells have long been known to exhibit excessive glycolytic behavior 
resulting in the production of high levels of lactate, the role of lactate after its initial 
secretion has only recently come to be appreciated and has focused mainly on gene 
expression, metastatic potential, and correlations regarding treatment outcome and patient 
prognosis. In this study, the effect of high concentrations of extracellular lactate on the 
intracellular metabolic activity of three breast cancer cell lines was examined for the first 
time. Under high-lactate conditions, all three cell lines reduced glucose consumption and 
decreased lactate consumption. Additionally, the high-lactate condition resulted in lactate 
consumption and incorporation into intracellular metabolites in all three cell lines, as well 
as stimulation of the reverse TCA cycle via reductive carboxylation, activity that has 
been associated with hypoxia and correlates with several malignant behaviors. There 
remains much more to learn concerning lactate’s role in cancer – both metabolic and 
otherwise – but MFA should serve as a valuable tool to decipher lactate’s role in cancer 
metabolism, and along with inquiries from other angles, may allow us to further unravel 
the complex web of factors that make cancer so difficult to treat. 
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CHAPTER 6: FUTURE WORK 
 
The research contained within this dissertation employed several complementary 
tools to elucidate the inner workings of cells – from the expression of genes, to the 
display of surface phenotype markers, to the intracellular fluxes in metabolic pathways. 
The importance of examining cellular behavior from many independent angles cannot be 
understated. With respect to the metabolism of breast cancer cells, MFA was used to 
estimate the activity of internal metabolic pathways in response to high-lactate. While 
metabolite levels and intracellular labeling patterns provide information regarding the 
inputs, outputs, and direction of the substrates in central metabolism, examining the 
cellular responses using orthogonal methods would improve the results, as well as 
suggest possible refinements to the MFA framework, that could be used to inform and 
improve future studies. For instance, using DNA microarrays to examine the expression 
of genes that code for the enzymes involved in central carbon metabolism could provide 
insight with regards to control in the MFA studies. Specifically, are the genes that encode 
isocitrate dehydrogenase and aconitase – the enzymes that enable the reductive 
carboxylation of α-ketoglutarate into citrate – upregulated by elevated lactate? If not, the 
increased flux would be controlled at the substrate level. Histological staining could be 
used to visualize the lipid content or highlight the activity of the mitochondria under 
elevated lactate, thus confirming or rejecting the model simulation of lower lipid levels of 
mitochondrial pathway activity, respectively.  
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Furthermore, future work to decipher the specific roles that lactate plays in the 
progression of cancer should mimic more closely the tumor microenvironment. 
Specifically, tumors are known to have regions that are hypoxic. Using 3D cultures might 
be one method to capture different microenvironments. Another approach might be to 
have cultures that can allow the cells to communicate via paracrine secretions through a 
porous membrane, but also keep the cells separated to allow for independent harvesting 
of intracellular MIDs. Thus, an oxygen gradient could be established that exposes some 
subpopulations of cancer cells to hypoxia, while others have access to sufficient oxygen.  
Similar setups could also create chemogradients that expose different cancer cell 
subpopulations to different levels of nutrients.  These more complex models of tumor 
compartmentalization would more accurately reflect the reality within tumors. Unlike 
traditional 2D models, which assume all the cells consist of a single homogeneous 
population, a 3D model would enable researchers to shed light on the dynamic interplay 
between different subsets of tumor cells, which are known to be quite heterogeneous. 
While the 2D culture results provide a necessary baseline, the results of 3D studies could 
then be compared to these 2D culture results to determine if heterogeneity plays a role or 
just the lactate concentration is the important factor.  
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Appendix A 
Reactions in the metabolic network used for 13C-MFA. 
 
Table A.1 The metabolic network specified for use in 13C-MFA for the three breast 
cancer cell lines. The cultures grown under the control conditions only used 73 reactions 
for the model, while the high-lactate metabolic model contained an extra reaction, v74. 
 
 
  v1 Gluc.ext (abcdef) -> G6P.c (abcdef) 
v2 G6P.c (abcdef) <=> F6P.c (abcdef) 
v3 F6P.C (abcdef) -> FBP.C (abcdef) 
v4 FBP.c (abcdef) <=>DHAP.c (cba) + GAP.c  (def) 
v5 DHAP.c (abc) <=> GAP.c (abc) 
v6 GAP.c (abc) <=> 3PG.c (abc) 
v7 3PG.c (abc)<=> PEP.c (abc) 
v8 PEP.c (abc) -> Pyr.c (abc) 
v9 G6P.c (abcdef) -> CO2 (a) + Ru5P.c (bcdef) 
v10 Ru5P.c <=> R5P.c 
v11 X5P.c (abcde) <=> EC2.c (ab) + GAP.c (cde) 
v12 F6P.c (abcdef) <=> EC2.c (ab)+ E4P.c (cdef) 
v13 S7P.c  (abcdefg) <=> EC2.c (ab) + R5P.c (cdefg) 
v14 F6P.c (abcdef) <=> EC3.c (abc) + GAP.c (def 
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Table A.1 The metabolic network specified for use in 13C-MFA for the three breast 
cancer cell lines. The cultures grown under the contol conditions only used 73 reactions 
for the model, while the high-lactate metabolic model contained an extra reaction, v74. 
 
 
v15 S7P.c (abcdefg) <=> EC3.c (abc) + E4P.c (defg) 
v16 Pyr.c (abc) <=> Lact.c (abc) 
v17 Pyr.c (abc) -> Pyr.snk (abc) 
v18 Pyr.c (abc) -> Pyr.m (abc) 
v19 Pyr.m (abc) -> CO2 (a) + AcCoA.m (bc) 
v20 AcCoA.m (ab) + OAC.m (cdef) -> Cit.m (fedbac) 
v21 Cit.m(abcdef) <=> AKG.m (abcde) + CO2 (f) 
v22 AKG.m (abcde) -> CO2 (a)+ Suc.m (bcde) 
v23 Suc.m (abcd) <=> Fum.m (abcd) 
v24 Fum.m (abcd) <=> Mal.m (abcd) 
v25 Mal.m (abcd) <=> OAC.m (abcd) 
v26 Mal.m (abcd)-> Pyr.mII (abc)+ CO2 (d) 
v27 Pyr.mII (abc) + CO2 (d) -> OAC.m (abcd) 
v28 Pyr.m (abc) <=> Pyr.mII (abc) 
v29 Mal.c (abcd) -> Pyr.c (abc) + CO2 (d) 
v30 Mal.m (abcd) <=> Mal.c (abcd) 
v31 Mal.c (abcd) <=> OAC.c (abcd) 
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 Table A.1 The metabolic network specificed for use in 13C-MFA for the three breast 
cancer cell lines. The cultures grown under the control conditions only used 73 reactions 
for the model, while the high-lactate metabolic model contained an extra reaction, v74. 
 
 
v32 OAC.c (abcd) -> PEP.c (abc) + CO2 (d) 
v33 Cit.m (abcdef) <=> Cit.c (abcdef) 
v34 Cit.c (abcdef) -> AcCoA.c (ab) + OAC.c (cdef) 
v35 AcCoA.c (ab) -> FA.c (ab) 
v36 Gln.c (abcde) -> Glu.c (abcde) 
v37 Glu.c (abcde) <=> AKG.m (abcde) 
v38 Glu.c  (abcde) <=> Pro.c (abcde) 
v39 Asp.c (abcd) <=> OAC.c (abcd) 
v40 Asp.c (abcd) -> Asn.c (abcd) 
v41 Pyr.c (abc) <=> Ala.c (abc) 
v42 Ser.c (abc) <=> Pyr.c (abc) 
v43 Ser.c (abc) -> Gly.c (ab) + MEETHF (c) 
v44 Thr.c (abcd)-> AcCoA.c (cd) + Gly.c (ab) 
v45 Met.c (abcde) + CO2 (f) -> Suc.m (bcdf) + CO2 (a) + C1 (e) 
v46 Val.c (abcde) + CO2 (f) -> Suc.m (dcef) + 2CO2 (a,b) 
v47 Ile.c (abcdef) + CO2 (g) -> Suc.m (bcdg) + AcCoA.m (ef) + CO2 (a) 
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 Table A.1 (continued): The metabolic network specified for use in 13C-MFA for the 
three breast cancer cell lines. The cultures grown under the control conditions only used 
73 reactions for the model, while the high-lactate metabolic model contained an extra 
reaction, v74. 
 v48   Phe.c (abcddefghi) -> Fum.m (defg) + 2 AcCoA.m (bc, hi) + CO2 (a) 
v49 Tyr.c (abcdefghi) -> Fum.m (defg) + 2 AcCoA.m (bc, hi) + CO2 (a) 
v50 Leu.c (abcdef) + CO2 (g) -> 3 AcCoA.m (bc, de, gf) + CO2 (a) 
v51 Gln.ext (abcde) -> Gln.c (abcde) 
v52 Asp.c (abcd) -> Asp.ext (abcd) 
v53 Ile.ext (abcdef) -> Ile.c (abcdef) 
v54 Leu.ext (abcdef) -> Leu.c (abcdef) 
v55 Met.ext (abcde) -> Met.c (abcde) 
v56 Phe.ext (abcdefghi) -> Phe.c (abcdefghi) 
v57 Ser.ext (abc) -> Ser.c (abc) 
v58 Tyr.ext (abcdefghi) -> Tyr.c (abcdefghi) 
v59 Val.ext (abcde) -> Val.c (abcde) 
v60 Thr.ext (abcd) -> Thr.c (abcd) 
v61 Arg.ext (abcdef) -> Arg.c (abcdef) 
v62 Cys.ext (abc) -> Cys.c (abc) 
v63 His.ext (abcdef)-> His.c (abcdef) 
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Table A.1 (continued): The metabolic network specified for use in 13C-MFA for the 
three breast cancer cell lines. The cultures grown under the control conditions only used 
73 reactions for the model, while the high-lactate metabolic model contained an extra 
reaction, v74. 
 
v64 Lys.ext (abcdef) -> Lys.c (abcdef) 
v65 Trp.ext (abcdefghijk) -> Trp.c (abcdefghijk) 
v66 Ala.c (abc) -> Ala.ext (abc) 
v67 Gly.c (ab) -> Gly.ext (ab) 
v68 Pro.c (abcde) -> Pro.ext (abcde) 
v69 Glu.c (abcde) -> Glu.ext (abcde) 
v70 Lact.c (abc) -> Lact.ext (abc) 
v71 Ru5P.c (abcde) <=> X5P.c (abcde) 
v72 
0.0862 Ala + 0.0519 Arg + 0.0495 Asp + 0.0397 Asn + 0.0200 Cys + 0.0444 Glu+ 
0.0532 Gln + 0.0742 Gly + 0.0197 His + 0.0446 Ile + 0.0777 Leu + 0.0785 Lys + 
0.0191 Met + 0.0302 Phe + 0.0432 Pro + 0.0592 Ser + 0.0532 Thr + 0.0061 Trp + 0.025 
Tyr + 0.0573 Val + 0.0384 G6P + 0.0321 Ru5P -> Biomass 
v73 FA.c -> Lipids 
v74 Lact.tr (abc) -> Lact.c (abc)       
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Appendix B 
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 Appendix C 
Measured and simulated MID values for 
intracellular metabolites from glucose and glutamine tracers. 
 
Figure C.1 MID values for intracellular metabolites from [1,2-13C] glucose for 
MCF-10A for the control condition. All MIDs were corrected for natural isotope 
abundances. 
 192 
 Figure C.2 MID values for intracellular metabolites from [1,2-13C] glucose for 
MCF-10A for the high-lactate condition. All MIDs were corrected for natural isotope 
abundances.
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 Figure C.3 MID values for intracellular metabolites from [1,2-13C] glucose for 
MCF-7 for the control condition. All MIDs were corrected for natural isotope 
abundances. All MIDs were corrected for natural isotope abundances.
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 Figure C.4 MID values for intracellular metabolites from [1,2-13C] glucose for 
MCF-7 for the high-lactate condition. All MIDs were corrected for natural isotope 
abundances.
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 Figure C.5 MID values for intracellular metabolites from [1,2-13C] glucose for 
MDA-MB-231 for the control condition. All MIDs were corrected for natural isotope 
abundances.
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 Figure C.6 MID values for intracellular metabolites from [1,2-13C] glucose for 
MDA-MB-231 for the high-lactate condition. All MIDs were corrected for natural 
isotope abundances.
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 Figure C.7 MID values for intracellular metabolites from [U-13C] glutamine for 
MCF-10A for the control condition. All MIDs were corrected for natural isotope 
abundances.
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 Figure C.8 MID values for intracellular metabolites from [U-13C] glutamine for 
MCF-10A for the high-lactate condition. All MIDs were corrected for natural isotope 
abundances.
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 Figure C.9 MID values for intracellular metabolites from [U-13C] glutamine for 
MCF-7 for the control condition. All MIDs were corrected for natural isotope 
abundances.
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 Figure C.10 MID values for intracellular metabolites from [U-13C] glutamine for 
MCF-7 for the high-lactate condition. All MIDs were corrected for natural isotope 
abundances. All MIDs were corrected for natural isotope abundances.
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 Figure C.11 MID values for intracellular metabolites from [U-13C] glutamine for 
MDA-MB-231 for the control condition. All MIDs were corrected for natural isotope 
abundances.
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 Figure C.12 MID values for intracellular metabolites from [U-13C] glutamine for 
MDA-MB-231 for the high-lactate condition. All MIDs were corrected for natural 
abundances. 
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 Appendix D 
MFA results for the three breast cancer cell lines 
Table D.1 MFA results for the MCF-10A cells for the control condition. Fluxes measured 
in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
 
1. 216.087 ± 17.834   8.4 %  Gluc.ext -> G6P.c    ( 186.31, 255.86) 
2. 137.526 ± 11.225   8.4 %  G6P.c <=> F6P.c (net)    ( 117.38, 161.16) 
3. ( >1000, >1e4) ± >1000  >100 %  G6P.c <=> F6P.c (exch)                 ( 148.72, >10000) 
4. 187.450 ± 15.761   8.6 %  F6P.c -> FBP.c      ( 161.20, 222.67) 
5. 187.450 ± 15.761   8.6 %  FBP.c <=> DHAP.c + GAP.c (net)   ( 161.20, 222.67) 
6. ( 0.0, >1e4) ± >10000  >100 %  FBP.c <=> DHAP.c + GAP.c (exch)  ( 0.00, >10000) 
7. 187.450 ± 15.761   8.6 %  DHAP.c <=> GAP.c (net)    ( 161.20, 222.67) 
8. 303.069 ± 29.134   9.9 %  DHAP.c <=> GAP.c (exch)   ( 251.94, 365.56) 
9. 399.862 ± 33.612   8.5 %  GAP.c <=> 3PG.c (net)    ( 343.93, 475.02) 
10. ( 0.0, >1000) ± >1000  >100 %  GAP.c <=> 3PG.c (exch)    ( 0.00, >10000) 
11. 399.862 ± 33.612   8.5 %  3PG.c <=> PEP.c (net)    ( 343.93, 475.02) 
12. ( 0.0, 3.7) ± 72.604  >100 %  3PG.c <=> PEP.c (exch)    ( 0.00, 283.16) 
13. 417.958 ± 35.917   8.8 %  PEP.c -> Pyr.c     ( 357.76, 497.83) 
14. 76.565 ± 8.307   11.0 %  G6P.c -> CO2 + Ru5P.c    ( 61.29, 93.69) 
15. 24.962 ± 2.782   11.3 %  Ru5P.c <=> R5P.c (net)    ( 19.86, 30.72) 
16. ( 102.2, >1e4) ± >1000  >100 %  Ru5P.c <=> R5P.c (exch)    ( 0.00, >10000) 
17. 49.924 ± 5.565   11.3 %  X5P.c <=> EC2.c + GAP.c (net)   ( 39.73, 61.43) 
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Table D.1 (continued) MFA results for the MCF-10A cells for the control condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
18. ( 39.4, >1e4) ± >1000  >100 %  X5P.c <=> EC2.c + GAP.c (exch)   ( 0.00, >10000) 
19. -24.962 ± 2.782   10.8 % F6P.c <=> EC2.c + E4P.c (net)   ( -30.72, -19.86) 
20. 0.000 ± 2.452   >100 %  F6P.c <=> EC2.c + E4P.c (exch)   ( 0.00, 9.56) 
21. -24.962 ± 2.782   10.8 %  S7P.c <=> EC2.c + R5P.c (net)   ( -30.72, -19.86) 
22. ( 1.9, >1e4) ± >1000  >100 %  S7P.c <=> EC2.c + R5P.c (exch)   ( 0.00, >10000) 
23. -24.962 ± 2.782   10.8 %  F6P.c <=> EC3.c + GAP.c (net)   ( -30.72, -19.86) 
24. ( 466.6, >1e4) ± >1000  >100 %  F6P.c <=> EC3.c + GAP.c (exch)   ( 0.00, >10000) 
25. 24.962 ± 2.782   11.3 %  S7P.c <=> EC3.c + E4P.c (net)   ( 19.86, 30.72) 
26. ( 1.8, >1e4) ± >1000 >100 %  S7P.c <=> EC3.c + E4P.c (exch)   ( 0.00, >10000) 
27. 385.000 ± 35.901   9.6 %  Pyr.c <=> Lact.c (net)    ( 309.95, 449.96) 
28. ( 0.0, >1e4) ± >1000  >100 %  Pyr.c <=> Lact.c (exch)    ( 0.00, >10000) 
29. 18.413 ± 35.396   >100 %  Pyr.c -> Pyr.snk     ( 0.00, 138.04) 
30. 42.283 ± 11.652   28.5 %  Pyr.c -> Pyr.m     ( 23.67, 69.12) 
31. 42.284 ± 10.069   24.9 %  Pyr.m -> CO2 + AcCoA.m   ( 23.08, 62.35) 
32. 66.073 ± 8.056   12.5 %  AcCoA.m + OAC.m -> Cit.m   ( 50.89, 82.31) 
33. 40.537 ± 4.792   12.0 %  Cit.m <=> AKG.m + CO2 (net)   ( 32.39, 51.08) 
34. 0.000 ± 0.410   >100 %  Cit.m <=> AKG.m + CO2 (exch)   ( 0.00, 1.60) 
35. 64.128 ± 5.258   8.3 %  AKG.m -> CO2 + Suc.m    ( 55.36, 75.87) 
36. 75.803 ± 8.363   11.2 %  Suc.m <=> Fum.m (net)    ( 61.08, 93.70) 
37. ( 0.0, >1e4) ± >1000  >100 %  Suc.m <=> Fum.m (exch)    ( 0.00, >10000) 
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Table D.1 (continued) MFA results for the MCF-10A cells for the control condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
38. 82.509 ± 9.134   11.2 %  Fum.m <=> Mal.m (net)    ( 66.38, 102.00) 
39. ( 0.0, 7.5) ± >1000  >100 %  Fum.m <=> Mal.m (exch)   ( 0.00, >10000) 
40. 54.364 ± 7.749   14.6 %  Mal.m <=> OAC.m (net)    ( 39.54, 69.76) 
41. 85.624 ± 88.638   >100 %  Mal.m <=> OAC.m (exch)   ( 17.51, 363.20) 
42. 11.710 ± 2.205   20.3 %  Mal.m -> Pyr.mII + CO2    ( 8.19, 16.79) 
43. 11.709 ± 4.273   37.9 %  Pyr.mII + CO2 -> OAC.m   ( 8.55, 25.22) 
44. -0.000 ± 3.316   >100 %  Pyr.m <=> Pyr.mII (net)    ( -0.62, 12.31) 
45. 0.000 ± 3.157  >100 %  Pyr.m <=> Pyr.mII (exch)   ( 0.00, 12.31) 
46. 14.658 ± 8.418   59.1 %  Mal.c -> Pyr.c + CO2    ( 0.00, 32.83) 
47. 16.435 ± 8.707   56.8 %  Mal.m <=> Mal.c (net)    ( 1.34, 35.29) 
48. ( 0.0, >1e4) ± >1000  >100 %  Mal.m <=> Mal.c (exch)    ( 0.00, >10000) 
49. 1.778 ± 10.088   >100 %  Mal.c <=> OAC.c (net)    ( -18.01, 21.34) 
50. ( 158.8, >1e4) ± >1000  >100 %  Mal.c <=> OAC.c (exch)    ( 0.00, >10000) 
51. 18.096 ± 7.548   46.9 %  OAC.c -> PEP.c + CO2    ( 4.01, 33.45) 
52. 25.536 ± 6.810   28.6 %  Cit.m <=> Cit.c (net)    ( 12.41, 38.97) 
53. ( 0.0, >1e4) ± >10000  >100 %  Cit.m <=> Cit.c (exch)    ( 0.00, >10000) 
54. 25.536 ± 6.810   28.6 %  Cit.c -> AcCoA.c + OAC.c   ( 12.41, 38.97) 
55. 25.536 ± 6.810   28.6 %  AcCoA.c -> FA.c    ( 12.41, 38.97) 
56. 44.627 ± 3.866   8.7 %  Gln.c -> Glu.c     ( 37.73, 52.81) 
57. 23.591 ± 3.424   14.6 %  Glu.c <=> AKG.m (net)    ( 17.62, 30.98) 
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Table D.1 (continued) MFA results for the MCF-10A cells for the control condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
58. 467.362 ± >100   46.3 %  Glu.c <=> AKG.m (exch)   ( 284.20, >1000) 
59. 3.306 ± 0.663   21.4 %  Glu.c <=> Pro.c (net)    ( 1.98, 4.57) 
60. ( 0.0, >1e4) ± >10000  >100 %  Glu.c <=> Pro.c (exch)    ( 0.00, >10000) 
61. -9.218 ± 2.102   21.9 %  Asp.c <=> OAC.c (net)    ( -13.24, -5.04) 
62. ( 0.0, >1e4) ± >1000  >100 %  Asp.c <=> OAC.c (exch)    ( 0.00, >10000) 
63. 2.100 ± 0.426   21.6 %  Asp.c -> Asn.c     ( 1.22, 2.88) 
64. 15.356 ± 5.541   40.9 %  Pyr.c <=> Ala.c (net)    ( 4.50, 26.11) 
65. ( 0.0, >1e4) ± >1000  >100 %  Pyr.c <=> Ala.c (exch)    ( 0.00, >10000) 
66. 28.436 ± 6.271   23.9 %  Ser.c <=> Pyr.c (net)    ( 15.27, 39.73) 
67. ( 660.8, >1e4) ± >1000  >100 %  Ser.c <=> Pyr.c (exch)    ( 30.41, >10000) 
68. 9.761 ± 3.088   35.1 %  Ser.c -> Gly.c + MEETHF   ( 3.71, 15.75) 
69. 0.000 ± 0.393   >100 %  Thr.c -> AcCoA.c + Gly.c   ( 0.00, 1.53) 
70. 1.026 ± 0.771   >100 %  Met.c + CO2 -> Suc.m + CO2 + MEETHF  ( 0.00, 3.01) 
71. 3.210 ± 2.331   99.6 %  Val.c + CO2 -> Suc.m + 2 CO2   ( 0.00, 9.09) 
72. 7.439 ± 3.811   60.4 %  Ile.c + CO2 -> Suc.m + AcCoA.m + CO2  ( 0.00, 14.86) 
73. 3.216 ± 1.802   67.8 %  Phe.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.00, 7.03) 
74. 3.490 ± 1.864   63.8 %  Tyr.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.00, 7.27) 
75. 0.980 ± 1.284   >100 %  Leu.c + CO2 -> 3 AcCoA.m + CO2  ( 0.00, 5.01) 
76. 46.937 ± 3.977   8.5 %  Gln.ext -> Gln.c     ( 39.83, 55.33) 
77. 4.546 ± 1.940   49.0 %  Asp.c -> Asp.ext     ( 0.74, 8.31) 
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Table D.1 (continued) MFA results for the MCF-10A cells for the control condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
78. 9.801 ± 3.826   44.5 %  Ile.ext -> Ile.c     ( 2.19, 17.11) 
79. 5.074 ± 1.514   34.1 %  Leu.ext -> Leu.c    ( 2.75, 8.66) 
80. 2.023 ± 0.839   49.1 %  Met.ext -> Met.c     ( 0.70, 3.97) 
81. 4.791 ± 1.850   44.2 %  Phe.ext -> Phe.c     ( 1.30, 8.51) 
82. 41.295 ± 5.609   14.2 %  Ser.ext -> Ser.c     ( 29.48, 51.35) 
83. 4.802 ± 1.892   45.1 %  Tyr.ext -> Tyr.c     ( 1.14, 8.51) 
84. 6.203 ± 2.520   46.1 %  Val.ext -> Val.c     ( 2.12, 11.94) 
85. 2.782 ± 0.644   24.6 %  Thr.ext -> Thr.c     ( 1.65, 4.16) 
86. 2.730 ± 0.553   21.6 %  Arg.ext -> Arg.c     ( 1.59, 3.75) 
87. 1.050 ± 0.213   21.6 %  Cys.ext -> Cys.c     ( 0.61, 1.44) 
88. 1.050 ± 0.213   21.6 %  His.ext -> His.c     ( 0.61, 1.44) 
89. 4.147 ± 0.841   21.6 %  Lys.ext -> Lys.c     ( 2.42, 5.69) 
90. 0.315 ± 0.064   21.5 %  Trp.ext -> Trp.c     ( 0.18, 0.43) 
91. 10.999 ± 5.498   59.4 %  Ala.c -> Ala.ext     ( 0.28, 21.72) 
92. 5.876 ± 3.002   60.4 %  Gly.c -> Gly.ext     ( 0.07, 11.78) 
93. 1.049 ± 0.497   55.9 %  Pro.c -> Pro.ext     ( 0.07, 2.01) 
94. 14.947 ± 4.066   29.1 %  Glu.c -> Glu.ext     ( 6.67, 22.53) 
95. 385.000 ± 35.901   9.6 %  Lact.c -> Lact.ext    ( 309.95, 449.96) 
96. 49.924 ± 5.565   11.3 %  Ru5P.c <=> X5P.c (net)    ( 39.73, 61.43) 
97. ( 39.4, >1e4) ± >1000  >100 %  Ru5P.c <=> X5P.c (exch)    ( 0.00, >10000) | 
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98. 52.499 ± 10.639   Biomass Equation (v72)     ( 30.59, 72.09) 
99. 25.536 ± 6.810   28.6 %  FA.c -> Lipids     ( 12.41, 38.97) 
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Table D.2 MFA results for the MCF-10A cells for the high-lactate condition. Fluxes 
measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
 
1. 178.106 ± 14.923   8.6 %  Gluc.ext -> G6P.c    ( 148.54, 206.74)  
2. 134.782 ± 11.032   8.4 %  G6P.c <=> F6P.c (net)    ( 113.09, 156.11)  
3. ( 145.6, >1e4) ± >1000  >100 %  G6P.c <=> F6P.c (exch)    ( 0.00, >10000)  
4. 161.499 ± 13.478   8.6 %  F6P.c -> FBP.c     ( 134.76, 187.32)  
5. 161.499 ± 13.478   8.6 % FBP.c <=> DHAP.c + GAP.c (net)   ( 134.76, 187.32)  
6. ( 0.0, >1e4) ± >10000  >100 % FBP.c <=> DHAP.c + GAP.c (exch)  ( 0.00, >10000)  
7. 161.499 ± 13.478   8.6 %  DHAP.c <=> GAP.c (net)    ( 134.76, 187.32)  
8. ( >1000, >1000) ± >1000  42.6 %  DHAP.c <=> GAP.c (exch)   ( >1000, >1000)   
9. 336.355 ± 28.452   8.7 %  GAP.c <=> 3PG.c (net)    ( 279.96, 390.93)  
10. ( 0.0, >1000) ± >1000  >100 %  GAP.c <=> 3PG.c (exch)    ( 0.00, >10000)  
11. 336.355 ± 28.452   8.7 %  3PG.c <=> PEP.c (net)    ( 279.96, 390.93)  
12. ( 0.0, >1e4) ± >10000  >100 %  3PG.c <=> PEP.c (exch)     ( 0.00, >10000) 
13. 336.355 ± 28.452   8.7 %  PEP.c -> Pyr.c     ( 279.96, 390.93)  
14. 41.561 ± 7.107   18.1 %  G6P.c -> CO2 + Ru5P.c    ( 25.28, 53.00)  
15. 13.358 ± 2.383   18.9 %  Ru5P.c <=> R5P.c (net)    ( 7.92, 17.22)  
16. ( >1000, >1e4) ± >1000  >100 %  Ru5P.c <=> R5P.c (exch)    ( 0.00, >10000)  
17. 26.717 ± 4.765   18.9 %  X5P.c <=> EC2.c + GAP.c (net)   ( 15.85, 34.43)  
18. ( >1e4, >1e4) ± >10000  >100 %  X5P.c <=> EC2.c + GAP.c (exch)   ( 0.00, >10000)  
19. -13.358 ± 2.383   17.1 %  F6P.c <=> EC2.c + E4P.c (net)   ( -17.22, -7.92)  
20. 1.710 ± 3.513   >100 %  F6P.c <=> EC2.c + E4P.c (exch)   ( 0.00, 13.70)   
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Table D.2 (continued) MFA results for the MCF-10A cells for the high-lactate condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
21. -13.358 ± 2.383   17.1 %  S7P.c <=> EC2.c + R5P.c (net)   ( -17.22, -7.92)  
22. ( >1000, >1e4) ± >10000  >100 %  S7P.c <=> EC2.c + R5P.c (exch)   ( 0.00, >10000)  
23. -13.358 ± 2.383   17.1 %  F6P.c <=> EC3.c + GAP.c (net)   ( -17.22, -7.92)  
24. 1.096 ± 2.898   >100 %  F6P.c <=> EC3.c + GAP.c (exch)   ( 0.00, 11.30)  
25. 13.358 ± 2.383   18.9 %  S7P.c <=> EC3.c + E4P.c (net)   ( 7.92, 17.22)  
26. ( >1000, >1e4) ± >10000  >100 %  S7P.c <=> EC3.c + E4P.c (exch)   ( 0.00, >10000)  
27. 259.478 ± 28.071   11.2 %  Pyr.c <=> Lact.c (net)    ( 204.70, 314.18)  
28. ( >1e4, >1e4) ± >10000  88.4 %  Pyr.c <=> Lact.c (exch)                ( 422.37, >10000)  
29. 112.236 ± 47.312   47.5 %  Pyr.c -> Pyr.snk     ( 19.28, 203.79)  
30. 23.143 ± 12.503   69.2 %  Pyr.c -> Pyr.m     ( 0.01, 48.78)   
31. 19.393 ± 9.948   58.9 %  Pyr.m -> CO2 + AcCoA.m   ( 0.00, 38.80)  
32. 61.342 ± 6.497   11.0 %  AcCoA.m + OAC.m -> Cit.m   ( 46.02, 71.36)  
33. 47.663 ± 4.754   10.3 %  Cit.m <=> AKG.m + CO2 (net)   ( 37.24, 55.78)  
34. 21.424 ± 2.324   11.1 %  Cit.m <=> AKG.m + CO2 (exch)   ( 16.66, 25.73)  
35. 81.418 ± 6.179   7.7 %  AKG.m -> CO2 + Suc.m    ( 69.68, 93.78)  
36. 96.201 ± 8.607   9.1 %  Suc.m <=> Fum.m (net)    ( 78.87, 112.43)  
37. ( 0.0, >1000) ± >1000  >100 %  Suc.m <=> Fum.m (exch)    ( 0.00, >10000)  
38. 103.768 ± 9.163   9.0 %  Fum.m <=> Mal.m (net)    ( 85.12, 120.85)  
39. ( >1000, >1e4) ± >1000  81.9 %  Fum.m <=> Mal.m (exch)   ( 26.33, >10000)  
40. 57.591 ± 8.226   15.1 %  Mal.m <=> OAC.m (net)    ( 38.80, 70.89)  
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Table D.2 (continued) MFA results for the MCF-10A cells for the high-lactate condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
41. ( >1000, >1e4) ± >1000  45.7 %  Mal.m <=> OAC.m (exch)   ( >1000, >10000)  
42. 0.000 ± 1.531   >100 %  Mal.m -> Pyr.mII + CO2    ( 0.00, 5.97)  
43. 3.750 ± 4.212   >100 %  Pyr.mII + CO2 -> OAC.m   ( 0.00, 16.43)  
44. 3.750 ± 4.255   >100 %  Pyr.m <=> Pyr.mII (net)    ( -0.37, 16.23)  
45. ( 0.0, >1e4) ± >10000  >100 %  Pyr.m <=> Pyr.mII (exch)   ( 0.00, >10000)  
46. 51.461 ± 6.902   13.9 %  Mal.c -> Pyr.c + CO2    ( 35.59, 62.50)  
47. 46.177 ± 7.135   16.3 %  Mal.m <=> Mal.c (net)    ( 33.11, 60.93)  
48. ( >1000, >1e4) ± >1000  61.7 %  Mal.m <=> Mal.c (exch)    ( >1000, >10000)  
49. -5.284 ± 5.685   90.0 %  Mal.c <=> OAC.c (net)    ( -13.03, 9.14)  
50. ( >1000, >1e4) ± >1000  83.0 %  Mal.c <=> OAC.c (exch)    ( >1000, >10000)  
51. -0.000 ± 2.754   >100 %  OAC.c -> PEP.c + CO2    ( 0.00, 10.74)  
52. 13.679 ± 4.529   36.8 %  Cit.m <=> Cit.c (net)    ( 2.61, 20.28)  
53. ( 0.0, >1e4) ± >10000  >100 %  Cit.m <=> Cit.c (exch)    ( 0.00, >10000)  
54. 13.679 ± 4.529   36.8 %  Cit.c -> AcCoA.c + OAC.c   ( 2.61, 20.28)  
55. 13.679 ± 4.568   37.1 %  AcCoA.c -> FA.c    ( 2.61, 20.43)  
56. 51.080 ± 4.110   8.2 %  Gln.c -> Glu.c     ( 43.44, 59.47)   
57. 33.755 ± 3.913   12.0 %  Glu.c <=> AKG.m (net)    ( 26.65, 41.91)  
58. ( 272.8, >1e4) ± >1000  >100 %  Glu.c <=> AKG.m (exch)            ( 247.06, >10000)  
59. 3.017 ± 0.703   24.8 %  Glu.c <=> Pro.c (net)    ( 1.60, 4.35)  
60. ( 0.0, >1e4) ± >10000  >100 %  Glu.c <=> Pro.c (exch)    ( 0.00, >10000)  
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Table D.2 (continued) MFA results for the MCF-10A cells for the high-lactate condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
61. -8.395 ± 2.196   24.5 %  Asp.c <=> OAC.c (net)    ( -12.66, -4.09)  
62. ( 0.0, >1e4) ± >1000  >100 % Asp.c <=> OAC.c (exch)    ( 0.00, >10000)  
63. 1.857 ± 0.469   26.6 %  Asp.c -> Asn.c     ( 0.88, 2.71)  
64. 13.849 ± 5.087   40.8 %  Pyr.c <=> Ala.c (net)    ( 3.93, 23.76)  
65. ( 0.0, >1e4) ± >10000  >100 %  Pyr.c <=> Ala.c (exch)    ( 0.00, >10000)  
66. 20.889 ± 7.360   39.8 %  Ser.c <=> Pyr.c (net)    ( 6.68, 35.38)  
67. ( 754.3, >1e4) ± >1000  >100 %  Ser.c <=> Pyr.c (exch)    ( 0.00, >10000)  
68. 9.442 ± 3.256   37.6 %  Ser.c -> Gly.c + MEETHF   ( 2.78, 15.48)  
68. 9.442 ± 3.256   37.6 %  Ser.c -> Gly.c + MEETHF   ( 2.78, 15.48)  
70. 1.243 ± 0.828   89.9 %  Met.c + CO2 -> Suc.m + CO2 + MEETHF  ( 0.00, 3.23)  
71. 4.490 ± 2.614   71.1 %  Val.c + CO2 -> Suc.m + 2 CO2   ( 0.00, 10.20)  
72. 9.050 ± 3.724   46.6 %  Ile.c + CO2 -> Suc.m + AcCoA.m + CO2  ( 1.54, 16.06)  
73. 3.669 ± 1.916   62.2 %  Phe.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.00, 7.47)  
74. 3.899 ± 1.948   58.6 %  Tyr.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.09, 7.69)  
75. 5.921 ± 3.048   60.1 %  Leu.c + CO2 -> 3 AcCoA.m + CO2  ( 0.00, 11.89)  
76. 53.122 ± 4.164   8.0 % Gln.ext -> Gln.c     ( 45.38, 61.62)  
77. 4.263 ± 1.959   53.7 %  Asp.c -> Asp.ext     ( 0.42, 8.06)  
78. 11.139 ± 3.748   37.3 %  Ile.ext -> Ile.c     ( 3.63, 18.25)  
79. 9.542 ± 3.039   34.8 %  Leu.ext -> Leu.c     ( 3.65, 15.50)  
80. 2.125 ± 0.890   49.1 %  Met.ext -> Met.c     ( 0.60, 4.07)  
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Table D.2 (continued) MFA results for the MCF-10A cells for the high-lactate condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
81. 5.061 ± 1.932   43.0 %  Phe.ext -> Phe.c     ( 1.29, 8.82)  
82. 33.070 ± 6.619   21.5 %  Ser.ext -> Ser.c     ( 20.33, 46.15)  
83. 5.060 ± 1.941   43.2 %  Tyr.ext -> Tyr.c     ( 1.26, 8.82)  
84. 7.136 ± 2.765   44.6 %  Val.ext -> Val.c     ( 2.02, 12.80)  
85. 2.460 ± 0.743   31.9 %  Thr.ext -> Thr.c     ( 1.34, 4.24)  
86. 2.414 ± 0.609   26.6 %  Arg.ext -> Arg.c     ( 1.15, 3.52)  
87. 0.928 ± 0.234   26.6 %  Cys.ext -> Cys.c     ( 0.44, 1.36)  
88. 0.928 ± 0.234   26.6 %  His.ext -> His.c     ( 0.44, 1.36)  
89. 3.667 ± 0.925   26.6 %  Lys.ext -> Lys.c     ( 1.74, 5.35)  
90. 0.279 ± 0.070   26.6 %  Trp.ext -> Trp.c     ( 0.13, 0.41)  
91. 9.996 ± 4.998   59.4 %  Ala.c -> Ala.ext     ( 0.25, 19.75) 
92. 6.007 ± 3.006   57.1 %  Gly.c -> Gly.ext     ( 0.13, 11.86)  
93. 1.021 ± 0.499   55.9 %  Pro.c -> Pro.ext     ( 0.04, 1.99)  
94. 11.847 ± 4.262   40.6 %  Glu.c -> Glu.ext     ( 3.30, 19.92)  
95. 280.600 ± 28.088   10.3 %  Lact.c -> Lact.ext    ( 225.69, 335.24)  
96. 21.122 ± 1.977   9.6 %  Lact.tr -> Lact.c     ( 17.26, 24.97)  
97. 26.717 ± 4.765   18.9 %  Ru5P.c <=> X5P.c (net)    ( 15.85, 34.43)  
98. ( >1e4, >1e4) ± >10000  >100 %  Ru5P.c <=> X5P.c (exch)    ( 0.00, >10000)  
99. 46.421 ± 11.713   Biomass Equation (v72)     ( 22.07, 67.76)   
100. 13.679 ± 4.568   37.1 %  FA.c -> Lipids     ( 2.61, 20.43)  
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Table D.3 MFA results for the MCF-7 cells for the control condition. Fluxes measured in 
nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
 
1. 205.809 ± 18.276   9.1 %  Gluc.ext -> G6P.c    ( 171.39, 242.66)  
2. 162.152 ± 14.524   9.2 %  G6P.c <=> F6P.c (net)    ( 134.74, 191.39)  
3. ( >1000, >1e4) ± >1000  >100 %  G6P.c <=> F6P.c (exch)    ( 0.00, >10000)  
4. 189.819 ± 16.839   9.1 %  F6P.c -> FBP.c     ( 158.01, 223.68)  
5. 189.819 ± 16.839   9.1 %  FBP.c <=> DHAP.c + GAP.c (net)  ( 158.01, 223.68)  
6. ( 0.0, >1e4) ± >10000  >100 %  FBP.c <=> DHAP.c + GAP.c (exch)  ( 0.00, >10000)  
7. 189.819 ± 16.839   9.1 %  DHAP.c <=> GAP.c (net)    ( 158.01, 223.68)  
8. ( >1000, >1000) ± >1000  57.6 %  DHAP.c <=> GAP.c (exch)   ( >1000, >10000)   
9. 393.472 ± 35.037   9.1 %  GAP.c <=> 3PG.c (net)    ( 327.30, 463.95)  
10. ( 205.5, 646.5) ± >1000  >100 %  GAP.c <=> 3PG.c (exch)    ( 0.00, >10000)  
11. 393.472 ± 35.037   9.1 %  3PG.c <=> PEP.c (net)    ( 327.30, 463.95)   
12. ( >1000, >1e4) ± >1000  >100 %  3PG.c <=> PEP.c (exch)                ( 236.98, >10000)  
13. 410.146 ± 36.903   9.3 %  PEP.c -> Pyr.c     ( 340.60, 484.52)  
14. 42.487 ± 7.252   17.9 %  G6P.c -> CO2 + Ru5P.c    ( 27.37, 55.65)  
15. 13.834 ± 2.431   18.4 %  Ru5P.c <=> R5P.c (net)    ( 8.78, 18.26)  
16. ( >1000, >1e4) ± >1000  >100 % Ru5P.c <=> R5P.c (exch)    ( 0.00, >10000)  
17. 27.667 ± 4.861   18.4 %  X5P.c <=> EC2.c + GAP.c (net)   ( 17.55, 36.51)  
18. ( 402.5, >1e4) ± >1000  >100 %  X5P.c <=> EC2.c + GAP.c (exch)   ( 0.00, >10000)  
19. -13.834 ± 2.431   16.9 %  F6P.c <=> EC2.c + E4P.c (net)   ( -18.26, -8.78)  
20. 0.000 ± 2.752   >100 %  F6P.c <=> EC2.c + E4P.c (exch)   ( 0.00, 10.73)  
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Table D.3 (continued) MFA results for the MCF-7 cells for the control condition. Fluxes 
measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
21. -13.834 ± 2.431   16.9 %  S7P.c <=> EC2.c + R5P.c (net)   ( -18.26, -8.78)  
22. 4.655 ± 3.330   95.3 %  S7P.c <=> EC2.c + R5P.c (exch)   ( 0.00, 12.99)  
23. -13.834 ± 2.431   16.9 %  F6P.c <=> EC3.c + GAP.c (net)   ( -18.26, -8.78)  
24. ( 675.1, >1e4) ± >1000  >100 %  F6P.c <=> EC3.c + GAP.c (exch)   ( 0.00, >10000)  
25. 13.834 ± 2.431   18.4 %  S7P.c <=> EC3.c + E4P.c (net)   ( 8.78, 18.26)  
26. ( >1000, >1e4) ± >1000  >100 %  S7P.c <=> EC3.c + E4P.c (exch)   ( 0.00, >10000)  
27. 331.000 ± 33.045   10.3 %  Pyr.c <=> Lact.c (net)    ( 266.48, 395.35)  
28. ( 0.0, >1e4) ± >1000  >100 %  Pyr.c <=> Lact.c (exch)    ( 0.00, >10000)  
29. 56.896 ± 44.056   >100 %  Pyr.c -> Pyr.snk     ( 0.00, 171.82)  
30. 60.250 ± 17.573   32.2 %  Pyr.c -> Pyr.m     ( 25.72, 94.25)  
31. 60.250 ± 17.573   32.2 %  Pyr.m -> CO2 + AcCoA.m   ( 25.72, 94.25)  
32. 94.227 ± 14.882   16.4 %  AcCoA.m + OAC.m -> Cit.m   ( 65.05, 123.10)  
33. 40.127 ± 5.041   13.1 %  Cit.m <=> AKG.m + CO2 (net)   ( 30.55, 50.21)  
34. 3.967 ± 1.659   47.6 %  Cit.m <=> AKG.m + CO2 (exch)   ( 1.00, 7.47)  
35. 69.094 ± 6.349   9.4 %  AKG.m -> CO2 + Suc.m    ( 56.96, 81.72)  
36. 87.333 ± 11.084   13.2 %  Suc.m <=> Fum.m (net)    ( 65.93, 109.16)  
37. 10.895 ± 14.681   >100 %  Suc.m <=> Fum.m (exch)    ( 0.00, 57.26)  
38. 94.976 ± 11.765   12.8 %  Fum.m <=> Mal.m (net)    ( 72.21, 118.09)  
39. ( 0.0, >1e4) ± >1000  >100 %  Fum.m <=> Mal.m (exch)   ( 0.00, >10000)  
40. 79.960 ± 15.910   21.0 %  Mal.m <=> OAC.m (net)    ( 48.57, 110.62)  
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Table D.3 (continued) MFA results for the MCF-7 cells for the control condition. Fluxes 
measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
41. ( 110.4, 182.5) ± >100  >100 %  Mal.m <=> OAC.m (exch)   ( 1.38, >1000)  
42. 14.267 ± 3.536   26.8 %  Mal.m -> Pyr.mII + CO2    ( 7.63, 21.42)  
43. 14.267 ± 4.837   36.7 %  Pyr.mII + CO2 -> OAC.m   ( 7.63, 26.50)  
44. 0.000 ± 2.930   >100 %  Pyr.m <=> Pyr.mII (net)    ( -1.57, 9.86)  
45. -0.000 ± 0.424   >100 %  Pyr.m <=> Pyr.mII (exch)   ( -0.00, 1.65)  
46. 28.870 ± 8.750   33.6 %  Mal.c -> Pyr.c + CO2    ( 12.22, 46.35)  
47. 0.749 ± 17.414   >100 %  Mal.m <=> Mal.c (net)    ( -32.56, 35.36)  
48. ( 413.7, >1e4) ± >1000  >100 %  Mal.m <=> Mal.c (exch)    ( 0.00, >10000)  
49. -28.121 ± 15.864   48.8 %  Mal.c <=> OAC.c (net)    ( -59.10, 2.77)  
50. ( >1000, >1e4) ± >1000  >100 %  Mal.c <=> OAC.c (exch)    ( >1000, >10000)  
51. 16.673 ± 6.548   44.5 %  OAC.c -> PEP.c + CO2    ( 4.86, 30.40)  
52. 54.100 ± 14.859   30.0 %  Cit.m <=> Cit.c (net)    ( 24.72, 82.67)  
53. ( 0.0, >1e4) ± >10000  >100 %  Cit.m <=> Cit.c (exch)    ( 0.00, >10000)  
54. 54.100 ± 14.859   30.0 %  Cit.c -> AcCoA.c + OAC.c   ( 24.72, 82.67)  
55. 54.100 ± 14.859   30.0 %  AcCoA.c -> FA.c    ( 24.72, 82.67)  
56. 46.696 ± 4.090   8.9 %  Gln.c -> Glu.c     ( 38.79, 54.74)  
57. 28.967 ± 4.193   15.1 %  Glu.c <=> AKG.m (net)    ( 20.86, 37.22)  
58. ( >1000, >1000) ± >1000  >100 %  Glu.c <=> AKG.m (exch)              ( 639.25, >10000)  
59. 2.352 ± 0.605   27.8 %  Glu.c <=> Pro.c (net)    ( 1.17, 3.53)  
60. ( 0.0, >1e4) ± >10000  >100 %  Glu.c <=> Pro.c (exch)   ( 0.00, >10000)  
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Table D.3 (continued) MFA results for the MCF-7 cells for the control condition. Fluxes 
measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
61. -9.306 ± 2.986   29.5 %  Asp.c <=> OAC.c (net)    ( -15.13, -3.49)  
62. ( 0.0, >1e4) ± >10000  >100 %  Asp.c <=> OAC.c (exch)    ( 0.00, >10000)  
63. 1.232 ± 0.320   28.2 %  Asp.c -> Asn.c     ( 0.60, 1.85)  
64. 16.557 ± 7.028   49.0 %  Pyr.c <=> Ala.c (net)    ( 2.85, 30.26)  
65. ( 0.0, >1e4) ± >10000  >100 %  Pyr.c <=> Ala.c (exch)   ( 0.00, >10000)  
66. 25.688 ± 7.937   33.9 %  Ser.c <=> Pyr.c (net)    ( 10.32, 41.27)  
67. ( >1000, >1e4) ± >1000  >100 %  Ser.c <=> Pyr.c (exch)    ( 17.54, >10000)  
68. 11.241 ± 4.536   46.3 %  Ser.c -> Gly.c + MEETHF   ( 2.40, 20.09)  
69. 0.000 ± 0.168   >100 %  Thr.c -> AcCoA.c + Gly.c   ( 0.00, 0.66)  
70. 1.381 ± 0.859   80.8 %  Met.c + CO2 -> Suc.m + CO2 + MEETHF  ( 0.00, 3.35)  
71. 6.572 ± 3.863   74.4 %  Val.c + CO2 -> Suc.m + 2 CO2   ( 0.00, 15.07)  
72. 10.286 ± 4.894   53.8 %  Ile.c + CO2 -> Suc.m + AcCoA.m + CO2  ( 0.74, 19.82)  
73. 3.744 ± 1.960   62.7 %  Phe.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.00, 7.64)  
74. 3.900 ± 1.997   60.9 %  Tyr.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.00, 7.79)  
75. 2.801 ± 1.748   80.1 %  Leu.c + CO2 -> 3 AcCoA.m + CO2  ( 0.00, 6.82)  
76. 48.051 ± 4.132   8.8 %  Gln.ext -> Gln.c     ( 40.06, 56.17) 
77. 6.564 ± 2.919   51.6 %  Asp.c -> Asp.ext     ( 0.88, 12.26)  
78. 11.672 ± 4.866   46.6 %  Ile.ext -> Ile.c     ( 2.18, 21.16)  
79. 5.204 ± 1.848   40.4 %  Leu.ext -> Leu.c     ( 1.83, 9.04)  
80. 1.967 ± 0.899   54.4 %  Met.ext -> Met.c     ( 0.41, 3.91)  
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Table D.3 (continued) MFA results for the MCF-7 cells for the control condition. Fluxes 
measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
81. 4.668 ± 1.974   49.0 %  Phe.ext -> Phe.c     ( 0.84, 8.55)  
82. 38.747 ± 6.530   17.7 %  Ser.ext -> Ser.c     ( 26.10, 51.57)  
83. 4.670 ± 1.989   49.4 %  Tyr.ext -> Tyr.c     ( 0.79, 8.55) 
84. 8.328 ± 3.983   54.9 %  Val.ext -> Val.c     ( 1.26, 16.80)  
85. 1.633 ± 0.420   27.9 %  Thr.ext -> Thr.c     ( 0.81, 2.45)  
86. 1.602 ± 0.416   28.2 %  Arg.ext -> Arg.c     ( 0.78, 2.40)  
87. 0.616 ± 0.160   28.2 %  Cys.ext -> Cys.c     ( 0.30, 0.92)  
88. 0.616 ± 0.160   28.2 %  His.ext -> His.c     ( 0.30, 0.92)  
89. 2.433 ± 0.632   28.2 %  Lys.ext -> Lys.c     ( 1.19, 3.65)  
90. 0.185 ± 0.048   28.2 %  Trp.ext -> Trp.c     ( 0.09, 0.28)  
91. 14.001 ± 6.998   59.4 %  Ala.c -> Ala.ext     ( 0.35, 27.65)  
92. 8.962 ± 4.498   59.7 %  Gly.c -> Gly.ext     ( 0.19, 17.73)  
93. 1.028 ± 0.499   57.7 %  Pro.c -> Pro.ext     ( 0.05, 2.00)  
94. 13.744 ± 4.607   37.5 %  Glu.c -> Glu.ext     ( 4.77, 22.74)  
95. 331.000 ± 33.045   10.3 %  Lact.c -> Lact.ext    ( 266.48, 395.35)  
96. 27.667 ± 4.861   18.4 %  Ru5P.c <=> X5P.c (net)    ( 17.55, 36.51)  
97. ( 402.5, >1e4) ± >1000  >100 %  Ru5P.c <=> X5P.c (exch)    ( 0.00, >10000)  
98. 30.802 ± 8.006   Biomass equation (v72)     ( 15.02, 46.24)  
99. 54.100 ± 14.859   30.0 %  FA.c -> Lipids     ( 24.72, 82.67)   
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Table D.4 MFA results for the MCF-7 cells for the high-lactate condition. Fluxes 
measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
 
1. 169.893 ± 15.016   9.1 %  Gluc.ext -> G6P.c    ( 139.99, 198.55 ) 
2. 128.736 ± 12.726   10.2 %  G6P.c <=> F6P.c (net)    ( 104.37, 154.00)  
3. ( 543.3, >1e4) ± >1000  >100 %  G6P.c <=> F6P.c (exch)    ( 0.00, >10000)  
4. 154.467 ± 13.998   9.4 %  F6P.c -> FBP.c     ( 126.57, 181.16)  
5. 154.467 ± 13.998   9.4 %  FBP.c <=> DHAP.c + GAP.c (net)   ( 126.57, 181.16)  
6. ( 0.0, >1e4) ± >10000  >100 %  FBP.c <=> DHAP.c + GAP.c (exch)  ( 0.00, >10000)  
7. 154.467 ± 13.998   9.4 %  DHAP.c <=> GAP.c (net)   ( 126.57, 181.16)  
8. 547.530 ± 75.292   14.3 %  DHAP.c <=> GAP.c (exch)   ( 424.97, 718.61)  
9. 321.800 ± 29.029   9.3 %  GAP.c <=> 3PG.c (net)    ( 263.96, 377.18)  
10. ( 0.0, >1000) ± >1000  >100 %  GAP.c <=> 3PG.c (exch)    ( 0.00, >10000)  
11. 321.800 ± 29.029   9.3 %  3PG.c <=> PEP.c (net)    ( 263.96, 377.18)  
12. ( 1.8, 64.2) ± >100  >100 %  3PG.c <=> PEP.c (exch)    ( 0.00, 744.14)  
13. 340.597 ± 31.547   9.5 %  PEP.c -> Pyr.c     ( 278.00, 401.03)  
14. 39.767 ± 6.463   16.7 %  G6P.c -> CO2 + Ru5P.c    ( 25.04, 50.25)  
15. 12.866 ± 2.141   17.1 %  Ru5P.c <=> R5P.c (net)    ( 8.00, 16.35)  
16. ( 361.1, >1e4) ± >1000  >100 %  Ru5P.c <=> R5P.c (exch)    ( 0.00, >10000)  
17. 25.731 ± 4.282   17.1 % X5P.c <=> EC2.c + GAP.c (net)   ( 15.99, 32.69)  
18. ( 54.9, >1e4) ± >1000  >100 %  X5P.c <=> EC2.c + GAP.c (exch)   ( 0.00, >10000)  
19. -12.866 ± 2.141   15.9 %  F6P.c <=> EC2.c + E4P.c (net)   ( -16.35, -8.00)  
20. 0.000 ± 2.052  >100 %  F6P.c <=> EC2.c + E4P.c (exch)   ( 0.00, 8.00)  
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Table D.4 (continued) MFA results for the MCF-7 cells for the high-lactate condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
21. -12.866 ± 2.141   15.9 %  S7P.c <=> EC2.c + R5P.c (net)   ( -16.35, -8.00)  
22. ( 285.1, >1e4) ± >1000  >100 %  S7P.c <=> EC2.c + R5P.c (exch)   ( 0.00, >10000)  
23. -12.866 ± 2.141   15.9 %  F6P.c <=> EC3.c + GAP.c (net)   ( -16.35, -8.00)  
24. ( 0.0, >1e4) ± >1000  >100 %  F6P.c <=> EC3.c + GAP.c (exch)   ( 0.00, >10000)  
25. 12.866 ± 2.141   17.1 %  S7P.c <=> EC3.c + E4P.c (net)   ( 8.00, 16.35)  
26. ( 283.5, >1e4) ± >1000  >100 %  S7P.c <=> EC3.c + E4P.c (exch)   ( 0.00, >10000)  
27. 133.279 ± 19.894   15.7 %  Pyr.c <=> Lact.c (net)    ( 91.83, 169.42)  
28. 279.857 ± >100   67.1 %  Pyr.c <=> Lact.c (exch)    ( 64.65, 729.62)  
29. 167.594 ± 40.602   24.8 %  Pyr.c -> Pyr.snk     ( 92.44, 250.79)  
30. 39.915 ± 13.667   38.8 %  Pyr.c -> Pyr.m     ( 13.31, 66.61)  
31. 39.915 ± 12.927   36.7 %  Pyr.m -> CO2 + AcCoA.m   ( 13.31, 63.73)  
32. 65.995 ± 8.067   12.6 %  AcCoA.m + OAC.m -> Cit.m  ( 48.02, 79.48)  
33. 34.845 ± 4.598   13.7 %  Cit.m <=> AKG.m + CO2 (net)   ( 25.28, 43.21)  
34. 29.833 ± 3.822   13.3 %  Cit.m <=> AKG.m + CO2 (exch)   ( 21.85, 36.76)  
35. 53.962 ± 5.337   10.3 %  AKG.m -> CO2 + Suc.m    ( 42.98, 63.79)  
36. 66.222 ± 7.798   12.1 %  Suc.m <=> Fum.m (net)    ( 49.14, 79.55)  
37. ( 58.5, >1e4) ± >1000  >100 %  Suc.m <=> Fum.m (exch)    ( 0.00, >10000)  
38. 70.945 ± 7.927   11.4 %  Fum.m <=> Mal.m (net)    ( 53.79, 84.70)  
39. ( 26.3, >1000) ± >1000  >100 %  Fum.m <=> Mal.m (exch)   ( 0.00, >10000)  
40. 61.376 ± 7.827   12.9 %  Mal.m <=> OAC.m (net)    ( 44.79, 75.31)  
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Table D.4 (continued) MFA results for the MCF-7 cells for the high-lactate condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
41. ( 16.9, 37.2) ± >1000  >100 %  Mal.m <=> OAC.m (exch)   ( 0.00, >10000)  
42. 4.618 ± 1.799   39.9 %  Mal.m -> Pyr.mII + CO2    ( 0.98, 7.99)  
43. 4.618 ± 3.027   72.6 %  Pyr.mII + CO2 -> OAC.m   ( 0.81, 12.61)  
44. 0.000 ± 2.500   >100 %  Pyr.m <=> Pyr.mII (net)    ( -1.17, 8.58)  
45. 0.000 ± 0.300   >100 %  Pyr.m <=> Pyr.mII (exch)   ( 0.00, 1.17)   
46. 4.951 ± 4.072   >100 %  Mal.c -> Pyr.c + CO2    ( 0.00, 15.88)  
47. 4.951 ± 7.500   >100 %  Mal.m <=> Mal.c (net)    ( -5.06, 24.19)  
48. ( 0.0, >1e4) ± >1000  >100 % Mal.m <=> Mal.c (exch)    ( 0.00, >10000) 
49. -0.000 ± 9.823   >100 %  Mal.c <=> OAC.c (net)    ( -14.02, 24.29)  
50. ( 0.0, 1.0) ± >1000  >100 %  Mal.c <=> OAC.c (exch)    ( 0.00, >10000)   
51. 18.797 ± 5.457   31.8 %  OAC.c -> PEP.c + CO2    ( 8.66, 29.94)  
52. 31.150 ± 8.164   27.6 %  Cit.m <=> Cit.c (net)    ( 12.02, 43.86)  
53. ( 0.0, >1e4) ± >10000  >100 %  Cit.m <=> Cit.c (exch)    ( 0.00, >10000)  
54. 31.150 ± 8.164   27.6 %  Cit.c -> AcCoA.c + OAC.c   ( 12.02, 43.86)  
55. 31.150 ± 7.203   24.3 %  AcCoA.c -> FA.c    ( 15.55, 43.64)  
56. 43.820 ± 3.913   9.1 %  Gln.c -> Glu.c     ( 36.04, 51.30)  
57. 19.117 ± 3.432   18.4 %  Glu.c <=> AKG.m (net)    ( 12.23, 25.61)  
58. 134.232 ± 18.456   14.3 %  Glu.c <=> AKG.m (exch)    ( 101.63, 173.61)  
59. 3.803 ± 1.030   29.3 %  Glu.c <=> Pro.c (net)    ( 1.81, 5.83)  
60. ( 0.0, >1e4) ± >10000  >100 %  Glu.c <=> Pro.c (exch)    ( 0.00, >10000)  
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Table D.4 (continued) MFA results for the MCF-7 cells for the high-lactate condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
61. -12.353 ± 2.846   21.8 %  Asp.c <=> OAC.c (net)    ( -17.97, -6.87)  
62. ( 0.0, >1e4) ± >10000  >100 %  Asp.c <=> OAC.c (exch)    ( 0.00, >10000)  
63. 1.463 ± 0.240   16.5 %  Asp.c -> Asn.c     ( 1.11, 2.04)  
64. 13.999 ± 5.510   44.9 %  Pyr.c <=> Ala.c (net)    ( 3.24, 24.73)  
65. ( 0.0, >1e4) ± >10000  >100 %  Pyr.c <=> Ala.c (exch)    ( 0.00, >10000)  
66. 9.239 ± 10.787   >100 %  Ser.c <=> Pyr.c (net)    ( -11.46, 30.61)  
67. ( 389.9, >1e4) ± >1000 >100 %  Ser.c <=> Pyr.c (exch)    ( 0.00, >10000)  
68. 11.653 ± 4.513   44.0 %  Ser.c -> Gly.c + MEETHF   ( 2.85, 20.45)   
69. 0.000 ± 0.124   >100 %  Thr.c -> AcCoA.c + Gly.c   ( 0.00, 0.48)  
70. 1.221 ± 0.811   79.5 %  Met.c + CO2 -> Suc.m + CO2 + MEETHF  ( 0.00, 3.16)  
71. 5.697 ± 3.255   61.6 %  Val.c + CO2 -> Suc.m + 2 CO2   ( 0.00, 12.70)  
72. 5.342 ± 3.108   62.7 %  Ile.c + CO2 -> Suc.m + AcCoA.m + CO2  ( 0.00, 12.12)  
73. 2.201 ± 1.602   83.9 %  Phe.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.00, 6.25)  
74. 2.522 ± 1.645   74.2 %  Tyr.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.00, 6.42)  
75. 3.764 ± 2.626   95.3 %  Leu.c + CO2 -> 3 AcCoA.m + CO2  ( 0.00, 10.24)  
76. 45.429 ± 3.936   8.8 %  Gln.ext -> Gln.c     ( 37.61, 52.96)  
77. 9.099 ± 2.815   33.7 %  Asp.c -> Asp.ext     ( 3.70, 14.68)  
78. 6.988 ± 3.171   48.0 %  Ile.ext -> Ile.c     ( 1.48, 13.85)  
79. 6.616 ± 2.707   48.5 %  Leu.ext -> Leu.c     ( 2.42, 12.98) |  
80. 1.916 ± 0.830   48.6 %  Met.ext -> Met.c    ( 0.60, 3.84)  
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Table D.4 (continued) MFA results for the MCF-7 cells for the high-lactate condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
81. 3.298 ± 1.639   54.6 %  Phe.ext -> Phe.c     ( 0.94, 7.33)  
82. 23.050 ± 9.789   47.6 %  Ser.ext -> Ser.c     ( 4.37, 42.55)  
83. 3.436 ± 1.672   53.4 %  Tyr.ext -> Tyr.c     ( 0.80, 7.32)  
84. 7.782 ± 3.329   45.2 %  Val.ext -> Val.c     ( 1.90, 14.88)  
85. 1.938 ± 0.339   18.5 %  Thr.ext -> Thr.c     ( 1.14, 2.46)  
86. 1.902 ± 0.311   16.5 %  Arg.ext -> Arg.c     ( 1.44, 2.66)  
87. 0.731 ± 0.120   16.5 %  Cys.ext -> Cys.c     ( 0.55, 1.02)  
88. 0.731 ± 0.120   16.5 %  His.ext -> His.c     ( 0.55, 1.02)  
89. 2.889 ± 0.473   16.5 %  Lys.ext -> Lys.c     ( 2.19, 4.04)  
90. 0.219 ± 0.036   16.5 %  Trp.ext -> Trp.c     ( 0.17, 0.31)  
91. 10.963 ± 5.498   59.4 %  Ala.c -> Ala.ext     ( 0.28, 21.72)  
92. 8.947 ± 4.497   59.4 %  Gly.c -> Gly.ext     ( 0.22, 17.76)  
93. 2.231 ± 0.988   50.5 %  Pro.c -> Pro.ext     ( 0.33, 4.19)  
94. 18.962 ± 4.446   24.9 %  Glu.c -> Glu.ext     ( 10.43, 27.77)  
95. 175.999 ± 17.520   10.3 %  Lact.c -> Lact.ext    ( 141.51, 209.84)  
96. 42.719 ± 12.711   31.1 %  Lact.tr -> Lact.c     ( 23.23, 72.81)  
97. 25.731 ± 4.282   17.1 %  Ru5P.c <=> X5P.c (net)    ( 15.99, 32.69)  
98. ( 54.9, >1e4) ± >1000  >100 %  Ru5P.c <=> X5P.c (exch)    ( 0.00, >10000)  
99. 36.571 ± 5.988   16.5 % Biomass equation (v72)    ( 27.73, 51.09)  
100. 31.150 ± 7.203   24.3 %  FA.c -> Lipids     ( 15.55, 43.64)  
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Table D.5 MFA results for the MDA-MB-231 cells for the control condition. Fluxes 
measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
 
1. 367.744 ± 29.665   8.3 %  Gluc.ext -> G6P.c    ( 314.56, 430.25)  
2. 286.820 ± 25.084   9.0 %  G6P.c <=> F6P.c (net)    ( 241.50, 339.33)  
3. ( 0.0, >1000) ± >1000  >100 % G6P.c <=> F6P.c (exch)    ( 0.00, >10000)  
4. 339.152 ± 26.946   8.2 %  F6P.c -> FBP.c     ( 291.03, 396.12)  
5. 339.152 ± 26.946   8.2 %  FBP.c <=> DHAP.c + GAP.c (net)   ( 291.03, 396.12) 
6. ( 0.0, >1e4) ± >10000  >100 %  FBP.c <=> DHAP.c + GAP.c (exch)  ( 0.00, >10000)  
7. 339.152 ± 26.946   8.2 %  DHAP.c <=> GAP.c (net)    ( 291.03, 396.12)  
8. 1224.863 ± >100   12.4 %  DHAP.c <=> GAP.c (exch)   ( 982.48, >1000)  
9. 704.470 ± 56.310   8.2 %  GAP.c <=> 3PG.c (net)    ( 603.67, 823.28)  
10. ( 0.0, >1000) ± >1000  >100 %  GAP.c <=> 3PG.c (exch)    ( 0.00, >10000)  
11. 704.470 ± 56.310   8.2 %  3PG.c <=> PEP.c (net)    ( 603.67, 823.28)  
12. ( 697.2, >1e4) ± >1000  >100 %  3PG.c <=> PEP.c (exch)    ( 0.00, >10000)  
13. 709.705 ± 57.900   8.4 %  PEP.c -> Pyr.c     ( 606.71, 832.52)  
14. 79.607 ± 13.946   18.7 %  G6P.c -> CO2 + Ru5P.c    ( 53.92, 108.31)  
15. 26.166 ± 4.647   19.0 %  Ru5P.c <=> R5P.c (net)    ( 17.61, 35.74)  
16. ( 0.0, >1e4) ± >10000  >100 %  Ru5P.c <=> R5P.c (exch)    ( 0.00, >10000)  
17. 52.332 ± 9.293   19.0 %  X5P.c <=> EC2.c + GAP.c (net)   ( 35.23, 71.47)  
18. ( 0.0, >1e4) ± >1000  >100 %  X5P.c <=> EC2.c + GAP.c (exch)   ( 0.00, >10000)  
19. -26.166 ± 4.647   16.6 %  F6P.c <=> EC2.c + E4P.c (net)   ( -35.74, -17.61)  
20. 6.289 ± 6.347   >100 %  F6P.c <=> EC2.c + E4P.c (exch)   ( 0.00, 24.75)  
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21. -26.166 ± 4.647   16.6 %  S7P.c <=> EC2.c + R5P.c (net)   ( -35.74, -17.61)  
22. ( 0.0, >1e4) ± >1000  >100 %  S7P.c <=> EC2.c + R5P.c (exch)   ( 0.00, >10000)  
23. -26.166 ± 4.647   16.6 %  F6P.c <=> EC3.c + GAP.c (net)   ( -35.74, -17.61)  
24. ( 0.0, >1e4) ± >1000  >100 %  F6P.c <=> EC3.c + GAP.c (exch)   ( 0.00, >10000)  
25. 26.166 ± 4.647   19.0 %  S7P.c <=> EC3.c + E4P.c (net)   ( 17.61, 35.74)  
26. ( 0.0, >1e4) ± >10000  >100 %  S7P.c <=> EC3.c + E4P.c (exch)   ( 0.00, >10000)  
27. 615.000 ± 55.905   9.4 %  Pyr.c <=> Lact.c (net)    ( 495.11, 713.15) 
28. ( 0.0, >1e4) ± >1000  >100 %  Pyr.c <=> Lact.c (exch)    ( 0.00, >10000)  
29. ( 0.0, 43.7) ± 51.914  >100 %  Pyr.c -> Pyr.snk     ( 0.00, 202.46)  
30. 101.038 ± 30.524   36.2 %  Pyr.c -> Pyr.m     ( 49.49, 168.53)  
31. 93.498 ± 27.433   33.9 %  Pyr.m -> CO2 + AcCoA.m   ( 46.40, 153.39)  
32. 113.406 ± 26.704   26.5 %  AcCoA.m + OAC.m -> Cit.m   ( 66.91, 171.05)  
33. 34.300 ± 4.465   14.1 %  Cit.m <=> AKG.m + CO2 (net)   ( 23.20, 40.61)  
34. 5.606 ± 1.624   31.2 %  Cit.m <=> AKG.m + CO2 (exch)   ( 2.69, 9.02)  
35. 52.635 ± 5.817   11.5 %  AKG.m -> CO2 + Suc.m    ( 40.25, 62.94)  
36. 62.617 ± 8.055   13.4 %  Suc.m <=> Fum.m (net)    ( 45.41, 76.83)  
37. ( 0.0, >1e4) ± >1000  >100 %  Suc.m <=> Fum.m (exch)    ( 0.00, >10000)  
38. 68.821 ± 8.852   13.4 %  Fum.m <=> Mal.m (net)    ( 50.17, 84.70)  
39. ( 0.0, 6.2) ± >1000  >100 %  Fum.m <=> Mal.m (exch)   ( 0.00, >10000)  
40. 91.078 ± 23.928   29.2 %  Mal.m <=> OAC.m (net)    ( 50.09, 143.41)  
41. 22.999 ± 42.782   >100 %  Mal.m <=> OAC.m (exch)   ( 0.00, 166.85)  
42. 14.787 ± 2.568   17.5 %  Mal.m -> Pyr.mII + CO2    ( 10.22, 20.24)  
43. 22.328 ± 6.977   38.8 %  Pyr.mII + CO2 -> OAC.m   ( 10.13, 37.35)  
44. 7.540 ± 5.901   >100 %  Pyr.m <=> Pyr.mII (net)    ( -1.13, 21.89)  
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Table D.5 (Continued) MFA results for the MDA-MB-231 cells for the control condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
45. 0.000 ± 0.663  >100 %  Pyr.m <=> Pyr.mII (exch)   ( 0.00, 2.59)  
46. 33.742 ± 12.740   44.3 %  Mal.c -> Pyr.c + CO2    ( 3.90, 53.58)  
47. ( -45.6, -33.8) ± 20.667  45.4 %  Mal.m <=> Mal.c (net)    ( -85.00, -4.40)  
48. ( 0.0, 2.0) ± >1000  >100 %  Mal.m <=> Mal.c (exch)    ( 0.00, >10000)  
49. ( -82.5, -59.3) ± 26.084  31.6 %  Mal.c <=> OAC.c (net)    (-128.92, -27.20)  
50. ( 0.0, >1e4) ± >1000  >100 %  Mal.c <=> OAC.c (exch)    ( 0.00, >10000)  
51. 5.235 ± 9.700   >100 %  OAC.c -> PEP.c + CO2    ( 0.00, 37.83)  
52. 79.106 ± 24.083   35.0 %  Cit.m <=> Cit.c (net)    ( 39.36, 133.28)  
53. ( 0.0, >1e4) ± >10000  >100 %  Cit.m <=> Cit.c (exch)    ( 0.00, >10000)  
54. 79.106 ± 24.083   35.0 %  Cit.c -> AcCoA.c + OAC.c   ( 39.36, 133.28)  
55. 79.106 ± 24.145   35.1 %  AcCoA.c -> FA.c    ( 39.12, 133.28)  
56. 39.828 ± 4.040   10.5 %  Gln.c -> Glu.c     ( 32.54, 48.29)  
57. 18.335 ± 4.199   24.7 %  Glu.c <=> AKG.m (net)    ( 10.90, 27.27)  
58. ( >1000, >1e4) ± >1000  >100 %  Glu.c <=> AKG.m (exch)             ( 612.11, >10000)  
59. 2.561 ± 0.610   25.7 %  Glu.c <=> Pro.c (net)    ( 1.37, 3.75)  
60. ( 0.0, >1e4) ± >10000 >100 %  Glu.c <=> Pro.c (exch)    ( 0.00, >10000)  
61. -3.085 ± 0.939   28.3 %  Asp.c <=> OAC.c (net)    ( -5.32, -1.66)  
62. ( 0.0, >1e4) ± >10000  >100 %  Asp.c <=> OAC.c (exch)    ( 0.00, >10000)  
63. 1.386 ± 0.329   25.4 %  Asp.c -> Asn.c     ( 0.74, 2.03)  
64. 13.877 ± 5.540   45.7 %  Pyr.c <=> Ala.c (net)    ( 3.08, 24.68)  
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Table D.5 (Continued) MFA results for the MDA-MB-231 cells for the control condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
65. ( 0.0, >1e4) ± >10000  >100 %  Pyr.c <=> Ala.c (exch)    ( 0.00, >10000)  
66. 5.253 ± 8.372   >100 %  Ser.c <=> Pyr.c (net)    ( -10.67, 21.98)  
67. ( 812.9, >1e4) ± >1000  >100 %  Ser.c <=> Pyr.c (exch)              ( 812.88, >10000)  
68. 10.561 ± 4.047   43.6 %  Ser.c -> Gly.c + MEETHF   ( 2.67, 18.45)  
69. 0.000 ± 0.138   >100 %  Thr.c -> AcCoA.c + Gly.c   ( 0.00, 0.54)  
70. 1.350 ± 0.852   82.8 %  Met.c + CO2 -> Suc.m + CO2 + MEETHF  ( 0.00, 3.32)  
71. 5.124 ± 3.073   76.6 %  Val.c + CO2 -> Suc.m + 2 CO2   ( 0.00, 11.98)  
72. 3.509 ± 2.160   79.6 %  Ile.c + CO2 -> Suc.m + AcCoA.m + CO2  ( 0.00, 8.42)  
73. 3.015 ± 1.782   74.8 %  Phe.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.00, 6.95)  
74. 3.189 ± 1.825   71.4 %  Tyr.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.00, 7.12)  
75. 1.331 ± 1.389   >100 %  Leu.c + CO2 -> 3 AcCoA.m + CO2  ( 0.00, 5.42)  
76. 41.353 ± 4.074   10.2 %  Gln.ext -> Gln.c     ( 33.99, 49.88)  
77. 0.000 ± 0.497   >100 %  Asp.c -> Asp.ext     ( 0.00, 1.94)  
78. 5.068 ± 2.255   52.7 %  Ile.ext -> Ile.c     ( 1.14, 9.93) 
79. 4.034 ± 1.598   47.0 %  Leu.ext -> Leu.c     ( 1.70, 7.94)  
80. 2.008 ± 0.895   52.9 %  Met.ext -> Met.c     ( 0.47, 3.96)  
81. 4.055 ± 1.841   53.8 %  Phe.ext -> Phe.c     ( 0.78, 7.96)  
82. 17.858 ± 7.209   44.9 %  Ser.ext -> Ser.c     ( 4.24, 32.36)   
83. 4.055 ± 1.869   54.6 %  Tyr.ext -> Tyr.c     ( 0.67, 7.96)  
84. 7.099 ± 3.194   53.2 %  Val.ext -> Val.c     ( 1.46, 13.92)  
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Table D.5 (Continued) MFA results for the MDA-MB-231 cells for the control condition. 
Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
85. 1.837 ± 0.435   25.4 %  Thr.ext -> Thr.c     ( 0.99, 2.68)  
86. 1.802 ± 0.427   25.4 %  Arg.ext -> Arg.c     ( 0.97, 2.63)  
87. 0.693 ± 0.164   25.4 %  Cys.ext -> Cys.c     ( 0.37, 1.01)  
88. 0.693 ± 0.164   25.4 %  His.ext -> His.c     ( 0.37, 1.01)  
89. 2.738 ± 0.649   25.4 %  Lys.ext -> Lys.c     ( 1.47, 4.00)  
90. 0.208 ± 0.049   25.4 %  Trp.ext -> Trp.c     ( 0.11, 0.30)  
91. 11.000 ± 5.498   59.4 %  Ala.c -> Ala.ext     ( 0.28, 21.72)  
92. 7.996 ± 3.999   59.4 %  Gly.c -> Gly.ext    ( 0.20, 15.79)   
93. 1.071 ± 0.500   54.7 %  Pro.c -> Pro.ext     ( 0.10, 2.05)  
94. 17.095 ± 4.297   27.1 %  Glu.c -> Glu.ext     ( 8.80, 25.56)  
95. 615.000 ± 55.905   9.4 %  Lact.c -> Lact.ext    ( 495.11, 713.15)  
96. 52.332 ± 9.293   19.0 %  Ru5P.c <=> X5P.c (net)    ( 35.23, 71.47)  
97. ( 0.0, >1e4) ± >1000  >100 %  Ru5P.c <=> X5P.c (exch)    ( 0.00, >10000)  
98. 34.660 ± 8.216   25.4 %  Biomass equation (v72)    ( 18.60, 50.64)  
99. 79.106 ± 24.145   35.1 %  FA.c -> Lipids     ( 39.12, 133.28)  
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Table D.6 MFA results for the MDA-MB-231 cells for the high-lactate condition. Fluxes 
measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
 
1. 223.612 ± 18.929   8.7 %  Gluc.ext -> G6P.c    ( 184.77, 258.60)  
2. 174.917 ± 14.716   8.6 %  G6P.c <=> F6P.c (net)    ( 144.40, 201.79)  
3. ( >1000, >1e4) ± >1000  >100 %  G6P.c <=> F6P.c (exch)    ( 57.35, >10000)  
4. 206.134 ± 17.295   8.6 %  F6P.c -> FBP.c     ( 170.13, 237.58)  
5. 206.134 ± 17.295   8.6 %  FBP.c <=> DHAP.c + GAP.c (net)   ( 170.13, 237.58)  
6. ( 0.0, >1e4) ± >10000  >100 %  FBP.c <=> DHAP.c + GAP.c (exch)  ( 0.00, >10000)  
7. 206.134 ± 17.295   8.6 %  DHAP.c <=> GAP.c (net)    ( 170.13, 237.58)  
8. ( >1000, >1000) ± >1000  34.6 %  DHAP.c <=> GAP.c (exch)   ( >1000, >10000)  
9. 427.878 ± 36.033   8.7 %  GAP.c <=> 3PG.c (net)    ( 352.92, 493.45)  
10. ( 728.7, >1000) ± >1000  >100 % GAP.c <=> 3PG.c (exch)    ( 0.00, >10000)  
11. 427.878 ± 36.033   8.7 %  3PG.c <=> PEP.c (net)    ( 352.92, 493.45)  
12. 0.000 ± 18.112   >100 %  3PG.c <=> PEP.c (exch)    ( 0.00, 70.64)  
13. 492.882 ± 40.788   8.5 %  PEP.c -> Pyr.c     ( 407.35, 566.43)  
14. 47.681 ± 6.178   13.5 %  G6P.c -> CO2 + Ru5P.c    ( 36.14, 60.24)  
15. 15.609 ± 2.040   13.6 %  Ru5P.c <=> R5P.c (net)    ( 11.67, 19.62)  
16. ( >1000, >1e4) ± >1000  84.2 %  Ru5P.c <=> R5P.c (exch)            ( >1000, >10000)  
17. 31.218 ± 4.080   13.6 %  X5P.c <=> EC2.c + GAP.c (net)   ( 23.34, 39.25)  
18. ( 0.0, >1e4) ± >1000  >100 %  X5P.c <=> EC2.c + GAP.c (exch)   ( 0.00, >10000)  
19. -15.609 ± 2.040   12.9 %  F6P.c <=> EC2.c + E4P.c (net)   ( -19.62, -11.67)  
20. 0.000 ± 2.420   >100 %  F6P.c <=> EC2.c + E4P.c (exch)   ( 0.00, 9.44)  
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Table D.6 (Continued) MFA results for the MDA-MB-231 cells for the high-lactate 
condition. Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
21. -15.609 ± 2.040   12.9 %  S7P.c <=> EC2.c + R5P.c (net)   ( -19.62, -11.67)  
22. ( >1000, >1e4) ± >1000  >100 %  S7P.c <=> EC2.c + R5P.c (exch)   ( >1000, >10000)  
23. -15.609 ± 2.040   12.9 %  F6P.c <=> EC3.c + GAP.c (net)   ( -19.62, -11.67)  
24. ( >1000, >1e4) ± >1000  >100 % F6P.c <=> EC3.c + GAP.c (exch)   ( 0.00, >10000)  
25. 15.609 ± 2.040   13.6 %  S7P.c <=> EC3.c + E4P.c (net)   ( 11.67, 19.62)  
26. 5.821 ± 4.101   73.3 %  S7P.c <=> EC3.c + E4P.c (exch)   ( 0.00, 15.99)  
27. 319.887 ± 39.362   12.9 %  Pyr.c <=> Lact.c (net)    ( 240.49, 394.00)  
28. ( >1000, >1000) ± >1000  >100 %  Pyr.c <=> Lact.c (exch)              ( 610.82, >10000)  
29. 151.385 ± 60.019   43.9 % Pyr.c -> Pyr.snk     ( 27.75, 261.82)  
30. 29.456 ± 14.042   53.5 % Pyr.c -> Pyr.m     ( 7.07, 61.83)   
31. 29.456 ± 13.983   53.3 %  Pyr.m -> CO2 + AcCoA.m   ( 7.07, 61.60)  
32. 83.441 ± 11.740  14.8 %  AcCoA.m + OAC.m -> Cit.m   ( 64.67, 110.46)  
33. 52.152 ± 5.596   11.1 %  Cit.m <=> AKG.m + CO2 (net)   ( 41.31, 63.13)  
34. 33.556 ± 4.761   14.8 %  Cit.m <=> AKG.m + CO2 (exch)   ( 25.71, 44.28)  
35. 91.381 ± 7.623   8.5 %  AKG.m -> CO2 + Suc.m    ( 76.83, 106.56)  
36. 114.345 ± 9.941   8.9 %  Suc.m <=> Fum.m (net)    ( 95.10, 133.87)  
37. ( 23.6, 57.9) ± >100  >100 %  Suc.m <=> Fum.m (exch)    ( 0.00, 715.93)  
38. 123.152 ± 9.921   8.2 % Fum.m <=> Mal.m (net)    ( 103.82, 142.51)  
39. ( >1000, >1e4) ± >1000  >100 % Fum.m <=> Mal.m (exch)   ( 85.61, >10000)  
40. 83.441 ± 12.509   15.8 % Mal.m <=> OAC.m (net)    ( 61.67, 110.46)  
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Table D.6 (Continued) MFA results for the MDA-MB-231 cells for the high-lactate 
condition. Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
41. ( 0.0, >1e4) ± >10000  >100 % Mal.m <=> OAC.m (exch)   ( 0.00, >10000)  
42. -0.000 ± 0.191   >100 %  Mal.m -> Pyr.mII + CO2    ( -0.00, 0.74)  
43. 0.000 ± 2.704   >100 %  Pyr.mII + CO2 -> OAC.m   ( 0.00, 10.55)  
44. 0.000 ± 2.895   >100 %  Pyr.m <=> Pyr.mII (net)    ( -0.74, 10.55)  
45. ( 0.0, >1e4) ± >10000  >100 %  Pyr.m <=> Pyr.mII (exch)   ( 0.00, >10000)  
46. 0.000 ± 1.840   >100 % Mal.c -> Pyr.c + CO2    ( 0.00, 7.18) | 
47. 39.711 ± 13.998 39.1 % Mal.m <=> Mal.c (net)     ( 8.59, 63.18)  
48. ( >1000, >1e4) ± >1000  >100 %  Mal.m <=> Mal.c (exch)    ( >1000, >10000)  
49. 39.711 ± 13.941   39.0 %  Mal.c <=> OAC.c (net)    ( 8.59, 62.96)  
50. ( 70.3, 209.5) ± >1000  >100 %  Mal.c <=> OAC.c (exch)    ( 23.17, >10000)  
51. 65.004 ± 6.011   9.5 %  OAC.c -> PEP.c + CO2    ( 52.77, 76.21)  
52. 31.289 ± 12.826   48.0 %  Cit.m <=> Cit.c (net)    ( 12.83, 62.85)  
53. ( 0.0, >1e4) ± >10000  >100 %  Cit.m <=> Cit.c (exch)    ( 0.00, >10000)  
54. 31.289 ± 12.826   48.0 %  Cit.c -> AcCoA.c + OAC.c   ( 12.83, 62.85)  
55. 31.289 ± 12.826   48.0 %  AcCoA.c -> FA.c    ( 12.83, 62.85)  
56. 50.097 ± 3.745   7.6 %  Gln.c -> Glu.c     ( 42.81, 57.42)  
57. 39.229 ± 4.026   10.6 %  Glu.c <=> AKG.m (net)    ( 31.14, 46.84)  
58. 567.474 ± >100   40.0 %  Glu.c <=> AKG.m (exch)    ( 354.06, >1000)  
59. 2.121 ± 0.553   26.6 %  Glu.c <=> Pro.c (net)    ( 1.14, 3.30)  
60. ( 0.0, >1e4) ± >10000  >100 %  Glu.c <=> Pro.c (exch)    ( 0.00, >10000)  
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Table D.6 (Continued) MFA results for the MDA-MB-231 cells for the high-lactate 
condition. Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
61. -5.996 ± 1.874   28.2 %  Asp.c <=> OAC.c (net)    ( -10.04, -2.74)  
62. ( 0.0, >1e4) ± >10000  >100 %  Asp.c <=> OAC.c (exch)    ( 0.00, >10000)   
63. 1.068 ± 0.326   31.3 %  Asp.c -> Asn.c     ( 0.42, 1.69)  
64. 11.218 ± 4.241   39.9 %  Pyr.c <=> Ala.c (net)    ( 3.54, 20.08) 
65. ( 0.0, >1e4) ± >10000  >100 %  Pyr.c <=> Ala.c (exch)    ( 0.00, >10000)  
66. 19.064 ± 9.322   58.7 %  Ser.c <=> Pyr.c (net)    ( -0.68, 35.68)  
67. ( 436.5, >1e4) ± >1000  >100 %  Ser.c <=> Pyr.c (exch)    ( 0.00, >10000)  
68. 9.949 ± 3.650   38.0 %  Ser.c -> Gly.c + MEETHF   ( 3.59, 17.83)  
69. 0.000 ± 0.236   >100 %  Thr.c -> AcCoA.c + Gly.c   ( 0.00, 0.92)  
70. 1.598 ± 0.848   66.1 %  Met.c + CO2 -> Suc.m + CO2 + MEETHF  ( 0.00, 3.31)  
71. 9.616 ± 3.754   43.2 % Val.c + CO2 -> Suc.m + 2 CO2   ( 2.11, 16.75)  
72. 11.749 ± 3.662   34.5 % Ile.c + CO2 -> Suc.m + AcCoA.m + CO2  ( 4.51, 18.79)  
73. 4.337 ± 1.862   49.8 % Phe.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.62, 7.88)  
74. 4.470 ± 1.883   48.6 % Tyr.c -> Fum.m + 2 AcCoA.m + CO2  ( 0.75, 8.10)  
75. 8.207 ± 2.872   39.4 % Leu.c + CO2 -> 3 AcCoA.m + CO2   ( 2.25, 13.45)  
76. 51.271 ± 3.641   7.2 %  Gln.ext -> Gln.c     ( 44.40, 58.61)  
77. 3.620 ± 1.894   63.2 %  Asp.c -> Asp.ext     ( 0.00, 7.39)  
78. 12.950 ± 3.502   28.0 %  Ile.ext -> Ile.c     ( 6.41, 20.06)  
79. 10.289 ± 2.996   31.9 %  Leu.ext -> Leu.c     ( 4.62, 16.31)  
80. 2.106 ± 0.931   51.9 %  Met.ext -> Met.c     ( 0.41, 4.04)  
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Table D.6 (Continued) MFA results for the MDA-MB-231 cells for the high-lactate 
condition. Fluxes measured in nmol/106 cells/h. 
 
Flux ± SD   %SD Reaction  Confidence Interval 
81. 5.138 ± 1.860   41.0 %  Phe.ext -> Phe.c     ( 1.61, 8.87)  
82. 30.589 ± 9.170   33.1 %  Ser.ext -> Ser.c     ( 12.63, 48.40)  
83. 5.138 ± 1.860   41.0 %  Tyr.ext -> Tyr.c     ( 1.61, 8.87)  
84. 11.138 ± 3.636   34.2 %  Val.ext -> Val.c     ( 4.15, 18.33)  
85. 1.415 ± 0.383   29.7 %  Thr.ext -> Thr.c     ( 0.58, 2.07)  
86. 1.388 ± 0.424   31.3 %  Arg.ext -> Arg.c     ( 0.55, 2.20)  
87. 0.534 ± 0.163   31.3 %  Cys.ext -> Cys.c     ( 0.21, 0.85)  
88. 0.534 ± 0.163   31.3 %  His.ext -> His.c     ( 0.21, 0.85)  
89. 2.109 ± 0.645   31.3 %  Lys.ext -> Lys.c     ( 0.83, 3.34)  
90. 0.160 ± 0.049   31.2 %  Trp.ext -> Trp.c     ( 0.06, 0.25)  
91. 9.002 ± 4.499   59.4 %  Ala.c -> Ala.ext     ( 0.23, 17.77)  
92. 7.974 ± 3.999   59.6 %  Gly.c -> Gly.ext     ( 0.18, 15.77)  
93. 0.973 ± 0.499   61.2 %  Pro.c -> Pro.ext     ( 0.00, 1.95)  
95. 380.000 ± 37.990   10.4 %  Lact.c -> Lact.ext    ( 303.17, 451.33)  
96. 60.113 ± 11.222   19.9 %  Lact.tr -> Lact.c     ( 37.97, 81.74)  
97. 31.218 ± 4.080   13.6 % Ru5P.c <=> X5P.c (net)    ( 23.34, 39.25)  
98. ( 0.0, >1e4) ± >10000  >100 %  Ru5P.c <=> X5P.c (exch)    ( 0.00, >10000)  
99. 26.695 ± 8.159   31.3 % Biomass equation (v72)    ( 10.49, 42.31)  
100. 31.289 ± 12.826   48.0 %  FA.c -> Lipids     ( 12.83, 62.85)  
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